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ABSTRACT
OLFACTORY RECEPTOR ANTAGONISM
IN THE OR-I7 ALDEHYDE RECEPTOR
AND THE MAMMALIAN OLFACTORY SYSTEM
by
Min Ting Liu
Advisor: Kevin Ryan
The detection of smell is initiated when an odorant binds and activates olfactory receptors
(ORs) within the nose. Chapter 1 studies the structural requirements for activation of the OR-I7
aldehyde receptor. Octanal is an agonist of the OR-I7 receptor.1, 2 4-Ethylcyclohexylacetaldehyde
(1.1), with a cyclohexyl ring that locks the C4-C5 bond of octanal in the gauche conformation,
was previously found to have higher potency than octanal, suggesting that the OR-I7 receptor
prefers the gauche conformation of octanal during activation.3 However, 1.1 had only been
previously tested as a mixture of cis- and trans-isomers, and therefore, it was not possible to
determine whether the response of 1.1 was stimulated by either or both of the isomers. In order
to distinguish the response of each isomer, the cis and trans compounds were individually
synthesized and tested on olfactory sensory neurons (OSNs) that co-express the OR-I7 receptor
via calcium imaging. Through this study, we gained insight into the preferred conformation of
the C6-C7 bond of octanal for activation of the OR-I7 receptor.
Removing

the

ethyl

group

of

4-ethylcyclohexylacetaldehyde

(1.1)

to

form

cyclohexylacetaldehyde (2.2), transforms the molecule from an activator to an inhibitor of ORI7.3 Chapter 2 focuses on antagonism of the rodent OR-I7 aldehyde receptor. Besides 2.2, the
response of octanal can be antagonized by several short aliphatic linear and cyclic aldehydes at
micromolar concentrations.3 It was proposed that these antagonists compete with octanal for the
iv

binding site via their aldehyde moiety, but fail to activate the receptor due to their shorter chain
lengths. The strength of antagonism for this receptor appeared to correlate with the number of
aliphatic carbons within 7 Å of the aldehyde when it was modeled in the most extended
conformation, but the data set was too small to firmly support this. To further test the possibility,
a structure-activity relationship (SAR) study was carried out in which additional carbons were
systematically substituted onto the structures of OR-I7 antagonists without exceeding 7 Å. The
synthesized analogues were tested for their ability to inhibit activation by octanal in OR-I7
receptors expressed in HEK293 cells using a cyclic AMP detection assay. This work led to more
precise information on what makes a good OR-I7 antagonist.
Currently, there is limited data on the determinants of antagonism, but several olfactory
receptors, such as OR-I7 and mOR-EG, have been reported to be antagonized by odorants which
are structurally similar to the agonist(s) of the receptor.3, 4 Structural similarities may point to
similar, orthosteric binding sites within the receptor, as opposed to allosteric binding sites.
Chapter 3 looks at determinants of antagonism in the mammalian olfactory system as a whole.
For the OR-I7 receptor, the main difference between the structure of the agonist, octanal, and the
antagonists is their chain lengths, whereas the agonist of the mOR-EG receptor, eugenol, differs
from the antagonists by the functional group on the phenyl ring and the position of the double
bond. For these two receptors, these structural variants may be directing the shift from agonist to
antagonist. A study was devised to look at the extent of OR antagonism that can be stimulated by
pairs of structurally similar odorants, differing only in their carbon chain length or their oxygen
containing functional group. The response of endogenous ORs to these odorants was acquired in
live olfactory sensory neurons via calcium imaging. The response pattern of over 11,000 cells
was analyzed. Based on this study, both the chain type and functional group type can be the
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determinant of OR antagonism, but the carboxyl group inhibited the highest percentage of cells
out of the three functional groups tested, and cells activated by aldehydes were the most
susceptible to antagonism.
In addition to the olfactory studies, which constitute the main part of this thesis, I also did
some projects involving the study of pre-mRNA and DNA. Chapter 4 describes small molecule
activators of the pre-mRNA 3’ cleavage reaction. The cleavage and polyadenylation of the 3’
end of pre-mRNA is an important process that occurs during the transcription of DNA to RNA.
It was previously believed that besides a series of cleavage factors, ATP was also required for
the cleavage step, but in an in vitro study, it was found that even without ATP, creatine
phosphate was able to initiate cleavage between 10-60 mM concentrations.5 Aside from having a
structure similar to that of an amino acid, creatine phosphate also contains a phosphate group, so
it was possible that at high concentration creatine phosphate activated cleavage by inhibiting a
phosphatase that normally suppresses cleavage,6 but the actual mechanism by which it acts is
still unclear. Through structure-activity relationship (SAR) studies, we have found a variety of
new small molecule activators of the in vitro pre-mRNA 3’ cleavage reaction. New activators
included cp38 (a cyclic peptide PPM1D inhibitor), dipeptide 4.12, abscisic acid, and an arginine
-naphthylamide analog. The minimal concentration required for in vitro cleavage stimulation
has been improved from 200 M to the 200 nM-100 M range.
Chapter 5 describes a preliminary attempt to target the molecular recognition of the DNA
double helix at a DNA nick, which is a break in one of the two strands of the double helix where
the phosphate group has been removed. This feature, which occurs thousands of times at any
given instant in the genome of a mammalian cell due to damage, may provide an opportunity for
other molecules to bind with the 3’ and 5’ hydroxyl-groups at the DNA nicks. Boronic acids are

vi

known to reversibly bind with diols at high affinity to form boronic esters.7 The close proximity
of the hydroxyl groups at a DNA nick resembles a diol, and could possibly bind with boronic
acids in a similar, equilibrium-based manner. Boronic acids have been used for the molecular
recognition of diols and polyols, and could potentially be used in the same way for DNA nicks.
We tested this possibility on two model studies, one with DNA and one using a surrogate diol,
polyvinyl alcohol (PVA).
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Chapter 1: Preference of the OR-I7 receptor for a particular C6-C7 conformation of
octanal
1.1. Introduction:
1.1.1. Octanal conformation preferred by the OR-I7 receptor
Olfaction, or the sense of
smell, is one of the major senses
used for analyzing the physical
environment. The detection of
Figure 1.1: Signal transduction pathway of the olfactory system during
the activation of the olfactory receptor.
(OR=Olfactory receptor and AC=Adenylyl cyclase)

smell is initiated when odorants
interact with olfactory receptors

(a.k.a. odorant receptors) (ORs) expressed in the cell membranes of olfactory sensory neurons
(OSNs) located within the olfactory epithelium of the nose. ORs belong to the family of Gprotein coupled receptors (GPCRs).1 As depicted on Figure 1.1, when an odorant binds and
activates an olfactory receptor, a series of intracellular events will occur resulting in the
sensation of smell.2 The G-protein (Golf) activates adenylyl cyclase to convert ATP to cAMP,
and the rise in cAMP level leads to the opening of ion channels allowing calcium and sodium
ions to enter the cell. This change in the cell’s polarity results in an action potential and a signal
being sent to the main olfactory bulb and then the brain. While ORs make up the largest group of
GPCRs in the mammalian genome, the OR machinery remains largely unexplored due to the
difficulty in stabilizing the protein for obtaining a crystal structure.
Octanal is one of the best natural product agonists of the OR-I7 receptor, a receptor
specific for aliphatic aldehydes.3,

4

Due to the flexibility of its aliphatic chain, octanal could

theoretically adopt hundreds of different conformations with similar energies. In an effort to

1

learn about the conformation(s) of octanal that activates the OR-I7 receptor, the Ryan lab
previously compared the response of octanal to that of 4-ethylcyclohexylacetaldehyde (1.1),
which has a cyclohexyl ring that locks the C4-C5 bond of octanal in the gauche conformation
(Fig. 1.2).5 (We make the assumption that only the chair conformation is accessible.)

1

2
Line
structures

4

3

5

6
7

8
1 2
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C4-C5
bond

EC50 (µM)

3
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8
7
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1.8
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?

?

Figure 1.2: The gauche conformation of octanal. Line structures (top) and Newman projections (bottom, front
carbon: C5, back carbon: C4) of octanal, 1.1, 1.2 and 1.3 in the gauche conformation. The EC50 values were
obtained from calcium imaging of the rat OR-I7 receptor.5

Compound 1.1 (EC50=1.0 µM) was found to have approximately equal potency compared to
octanal (EC50=1.8 µM), suggesting that the OR-I7 receptor prefers or at least tolerates the gauche
conformation of octanal during activation.5 However, 1.1 was tested as a mixture of cis and trans
isomers (1:2.4), so that it was ambiguous as to whether the response of the receptor was due to
activation by both or only one of the isomers. Knowing the individual response of the two
isomers would not only reveal the source of the response coming from the mixture, 1.1, but also
the preference of the OR-I7 receptor for the conformation of the C6-C7 bond on octanal.
The cis- (1.2) and trans-isomer (1.3) are conformationally restricted isomers of octanal.
The cyclohexyl ring of 1.1 (1.2 and 1.3) locks the C4-C5 bond of octanal in the gauche
2

conformation, which is present in only ~10 closely related isomers of octanal. The cis- (1.2) and
trans-isomer (1.3) restrict the conformation of octanal differently by locking the C5-C6 bond at
two of the possible positions adopted by octanal while in the gauche conformation at C4-C5. A
greater potency in either one of the isomer would indicate a conformational preference by the
OR-I7 receptor for the corresponding octanal conformation simulated by the analog.
1.2. Experimental Design:
1.2.1. Synthesis of 1.2 and 1.3
To determine the response of the individual isomers, the cis-isomer (1.2) and the transisomer (1.3) of 1.1 were each synthesized. (The synthetic route to 1.2 and 1.3 was initially
suggested by Prof. Mark Biscoe, and optimized by my colleague, Yadi Li.) The cis-isomer (1.2)
was synthesized from 4-ethylcyclohexanone (Scheme 1.1A). 4-Ethylcyclohexanone was
subjected to a Horner-Wadsworth-Emmons reaction to form the α,β-unsaturated ester, 1.2a. The
cis-intermediate was achieved through selective reduction of 1.2a with L-selectride6, 7 to obtain
the cis-ester, 1.2b. The bulkiness of L-selectride directed the reaction on the less hindered side
resulting in the cis-ester. The ester, 1.2b, was then LAH reduced to the alcohol, 1.2c, which was
PCC oxidized to the cis-aldehyde, 1.2.
The trans-isomer, 1.3, was synthesized from the commercially available trans-4ethylcyclohexylcarboxylic acid (Scheme 1.1B). Since the starting compound already contains the
1,4-trans structure, the trans-aldehyde, 1.3, was obtained after homologation of the
functionalized chain. The carboxylic acid was LAH reduced to the alcohol, 1.3a, which was then
PCC oxidized to the aldehyde 1.3b. Aldehyde 1.3b was homologated by an extra carbon via a
Wittig reaction to form the alkene 1.3c. The alkene, 1.3c, was subjected to a hydroborationoxidation reaction to form the alcohol, 1.3d, which was then PCC oxidized to form the trans-
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aldehyde, 1.3. (For this study, 1.2 was synthesized from 4-ethylcyclohexanone following the
procedures of Yadi Li and 1.3 was prepared from 1.3d, which was synthesized from trans-4ethylcyclohexylcarboxylic acid by Yadi Li.8)
A

B

Scheme 1.1: Synthesis of 1.2 and 1.3.

1.2.2. Systems for testing 1.2 and 1.3
4-Ethylcyclohexylacetaldehyde (1.1) was originally tested by the Firestein lab (Zita
Peterlin, Columbia University) through calcium imaging of rat olfactory sensory neurons that
were infected with an adenovirus encoding the rat OR-I7 and green fluorescent protein (GFP) to
mark which cells were infected and expressing OR-I7,5 but this system was no longer available
for testing 1.2 and 1.3. The cis- (1.2) and trans-isomer (1.3) were thus tested first by the
Matsunami lab (Jianghai Ho, Duke University) using a luciferase assay9 on modified HEK293
cells (called Hana3A cells) transfected with the OR-I7 receptor. The Matsunami lab found that
the mouse I7 receptor (which differs by 15 amino acid residues compared to the homologous rat
receptor, but which retains the aliphatic aldehyde pharmacology of the rat receptor10) is more
highly and more reproducibly expressed in HEK293 cells, and so we switched to the mouse OR-
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I7. The luciferase technique developed in the Matsunami lab was implemented at elevated
temperature (37°C) during which differential evaporation of odorants may occur (further
explained in Section 2.2.1). Therefore, the cis- (1.2) and trans-isomer (1.3) of 4ethylcyclohexylacetaldehyde (1.1) were re-tested in our lab through calcium imaging on OSNs
of a transgenic UBI7 mouse11, 12 (provided by Dr. Leonardo Belluscio at NIH). The UBI7 mice
have a copy of the OR-I7 transgene (two copies in homozygous mice, which we used) “knocked
in” at the olfactory marker protein (OMP) genomic loci. The OMP, and hence OR-I7, is
expressed in all OSNs but expression starts when the cell attains maturity, while endogenous
ORs begin expression earlier in development. The concentration level of OR-I7 expressed in this
recombinant way is thus lower than the normal OR expression level.
1.2.3. Limitations of the UBI7 mouse
In rodents, each mature OSN chooses only one of the ~1100 olfactory receptors for
expression.13-15 However, for the transgenic UBI7 mouse (i.e. the homozygous mice that we use;
there are two copies of the transgene in each OSN), mature olfactory sensory neurons very likely
express an endogenous receptor chosen earlier in development by the cell in addition to the ORI7 receptor (Figure 1.3).11,

12

(Here, expression means that the receptor’s messenger RNA,

mRNA, is made by transcription of the transgene and then translated into protein that is
transported to the cell membrane of the OSN in the cilia, the tip of the OSN’s dendrite.) At first,
we expected octanal, an agonist of OR-I7, to activate 100% of the OSNs of the homozygous
UBI7 mouse, instead of the ~6% OSNs (at 100 µM, Figure 1.4A) that are normally activated by
octanal in wild-type (WT) mice. However, in UBI7 cells, the OR-I7 receptor is known to be
expressed at a lower level compared to that of the endogenous receptors (possibly as low as <1%
of the expression level of endogenous receptors12) due to the nature of the transgenic mouse
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construction. While every cell should be expressing the OR-I7 receptor to some extent, the
expression level may not be high enough to be detected by calcium imaging, which is less
sensitive than the OR-I7 mRNA detection assay shown in Figure 1.3. Additionally, the
expression level of the OR-I7 receptor may vary from cell to cell, due to differences in the
development state of each neuron, preventing direct comparison of each cell’s absolute response.
This is because the OR-I7 transgene is “knocked in” to the genomic location of both copies of
the olfactory marker protein (OMP), which is turned on late during OSN development. At the
time of a given experiment, some OSNs may not have very much OR-I7 on their cell surface,
and may respond weakly or not at all, and the response in those cells may be dominated by the
endogenous receptor, whose expression begins earlier in the development of the cell and whose
identity cannot be determined in our experiments. Furthermore, the OR-I7 receptor is primarily
transported to the cilia, but we lose the cilia during cell preparation (during dissociation of the
olfactory epithelium tissue into individual cells), and consequently we lose a lot of the OR-I7
receptor. For these reasons, before comparing the conformationally restricted octanal analogs in
UBI7 OSNs, we attempted to estimate the percentage of UBI7 OSNs that actually respond to
octanal through the OR-I7 receptor versus the endogenous receptors (that, again, we have no way
of identifying).
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A. Expression of OR-I7 in a wild-type (WT) mouse (a slice of olfactory epithelium)

B. Expression of OR-I7 in a UBI7 mouse

Figure 1.3: Expression of OR-I7 in a wild-type mouse (top, A) and a UBI7 mouse (bottom, B) (Data is provided by
Dr. Leonardo Belluscio at NIH). Expression of the OR-I7 receptor is highlighted in purple. The red arrowheads
point to presumed OSNs that express the endogenous OR-I7 receptor. This experiment detects the mRNA of the
receptor. Darker color indicates higher amount of OR-I7 mRNA.

1.2.4. Testing 1.2 and 1.3 on a UBI7 mouse
To our knowledge, the calcium imaging method of detecting OR-I7 OSN activation has
never been tested on UBI7 mice, and therefore it was crucial to determine if the response of the
expressed OR-I7 receptors could actually be detected by calcium imaging. Octanal, a natural
product agonist of the OR-I7 receptor, was tested on the OSNs of the UBI7 mouse to check for
the OR-I7 response. The EC50 (concentration at which 50% of the maximal response is obtained)
of octanal in OR-I7 receptor, expressed in rat neurons, is 1.8 µM, and by 10 µM octanal the
receptor response is saturated.5 However, we do not know if this value holds for the mouse OR7

I7 in the context of the UBI7 mouse, so we tested three concentrations, 3 µM, 10 µM, and 100
µM.
Moreover, OR-I7 is known not to be activated by the corresponding alcohol, 1-octanol.4
Thus, 1-octanol (at 100 µM) was also tested as a control. Activation by octanal and 1-octanol
could indicate that the response is coming from an endogenous receptor that also happens to
respond to octanal, and not from transgenic OR-I7. Out of the ~1100 endogenous rodent
olfactory receptors, there are about 55 octanal receptors16 and in one experiment, 68% of
receptors activated by octanal were also activated by 1-octanol,17 so there is a high percentage of
octanal-responding cells that also respond to 1-octanol. We want to ignore these cells because
they have a high chance of not responding solely through OR-I7, the receptor we intend to study.
Another consideration we must keep in mind in our calcium imaging experiments is that
odorants that are applied to the cells earlier in the experiment tend to have slightly higher
response than odorants applied later, and application of odorants at high concentrations could
weaken or eliminate the response of odorants applied afterwards at lower concentrations,
possibly due to desensitization of the receptor. (Desensitization occurs as a feedback mechanism
to protect the cell from overstimulation.18) To minimize the effects of desensitization, the
odorants were applied at the lower concentrations first, and the sample of cells was divided into
four dishes, with the odorants tested at different orders in each dish.
The solvent, DMSO, was applied to the cell as a negative control. Cells that respond to
the solvent were not considered odorant-responding cells. Forskolin (10 µM), a molecule that
generates a cellular response through bypassing the olfactory receptor to activate adenylyl
cyclase in the signal transduction pathway, was applied at the end of the calcium imaging
experiment to determine if the signal transduction pathway was still functioning at the end of the
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experiment and estimate the cell’s maximum response range or full efficacy. (Efficacy describes
the effect of a ligand on the functional properties of the receptor.19 In the absence of a ligand,
most receptors exhibit some basal (i.e. ligand-independent) activation of its G-protein. The
response of a receptor could change depending on the ligand which binds to it. An inverse
agonist inhibits the basal activity, whereas an antagonist does not change the basal activity but
prevent other ligands from binding. A full agonist fully activates the receptor (in vitro, for
example, to the strength of response similar to a saturating amount of forskolin), while a partial
agonist only activates the receptor at partial efficacy even at saturating concentration (i.e. it
reaches a plateau below the full response of forskolin).) Cells that did not respond to forskolin
were excluded from the analysis (regardless of whether these cells responded to the tested
compounds). The calcium imaging responses of the tested compounds were all normalized to the
response of 10 µM forskolin and all cells that responded to forskolin were considered viable
cells. Odorant responses that were lower than 10% of the response of forskolin were excluded.
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1.3. Results and Discussion:
1.3.1. Comparison of the UBI7 mouse to wild-type (WT) mice
1.3.1.1. OR-I7 activation by octanal is detectable in UBI7 OSNs by calcium imaging
A
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Figure 1.4: Comparison of the calcium imaging response of OSNs from the UBI7 mouse and WT mice. (A) The
chart compares the percentage of cells that respond to octanal (in general) at 3 µM, 10 µM, and 100 µM for WT
mice and a UBI7 mouse (Data for the WT mice was supplied by my colleague, Mihwa Na. The response of 1octanol was not tested in these experiments.). (B) The chart compares the percentage of cells that respond to 1octanol and/or octanal for WT mice and a UBI7 mouse. (The data for the WT cells on Chart A were obtained from
different experiments than Chart B. The data for the UBI7 cells on Chart A and Chart B were from the same
experiment.)
***Note: On Chart A, the percentages were determined from experiments done on 3 WT mice and one UBI7 mouse.
The percentages were calculated relative to the number of forskolin-responding cells (WT: 9446, UBI7: 1852). On
Chart B, the sample of cells for the WT mice was collected from a total of 7 mice (11707 viable cells, results given
in chapter 3), whereas the UBI7 cells were obtained from one mouse (1852 viable cells). (More WT mice were used
for the experiments to obtain additional odorant-responding cells for analysis. Since a high percentage of UBI7 cells
responded to octanal, only one UBI7 mouse was needed.)

Transgenic OR-I7 expression in the UBI7 OSNs caused a ~8-fold increase in octanalresponding cells at 3 µM (WT-1.4%, UBI7-10.8%), a ~6-fold increase in octanal-responding
cells at 10 µM (WT-2.2%, UBI7-13%), and a ~2.5-fold increase in octanal-responding cells at
100 µM (WT-5.8%, UBI7-14.6%) compared to wild-type OSNs (Figure 1.4A). UBI7 cells that
express the OR-I7 receptor should respond to octanal, but so would some small percentage of
cells via their endogenous receptors. The percentage of UBI7 cells expressing endogenous
receptors that normally respond to octanal (in addition to the OR-I7 receptor) should be similar
to, and could therefore be estimated by, the percentage of WT cells that respond to octanal,
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which only express the endogenous receptors. The excess of UBI7 cells responding to octanal
are therefore likely responding because they express the OR-I7 receptor at a sufficient expression
level in addition to endogenous receptors that do not respond to octanal (at the given
concentrations). Based on the difference in percentages between the WT cells and the UBI7
cells, we could estimate that 87% (10.8%-1.4%/10.8% × 100%) of the octanal-responding UBI7
cells at 3 µM, 83% (13%-2.2%/13% × 100%) at 10 µM, and 60% (14.6%-5.8%/14.6% × 100%)
at 100 µM, owe their response to the expression of the OR-I7 receptor and an endogenous
receptor that does not respond to octanal.
We obtained similar results when comparing the 1-octanol-positive and 1-octanolnegative responses in WT and UBI7 cells. As shown on Figure 1.4B, there was a ~6-fold
increase in UBI7 cells that respond to octanal but not 1-octanol (WT: 1.6%, UBI7: 9.9%). From
the difference in percentages, we could estimate that 84% (9.9%-1.6%/9.9% × 100%) of the
octanal-responding cells that do not respond to 1-octanol owe their response to the expression of
the OR-I7 receptor. There was a ~2.6-fold increase in UBI7 cells that respond to both 1-octanol
and octanal (WT: 1.8%, UBI7: 4.7%), and a ~2.8-fold decrease in UBI7 cells that respond to 1octanol but not octanal (WT: 1.4%, UBI7: 0.5%) compared to WT cells. The increase in cells
that respond to both 1-octanol and octanal coupled with the decrease in cells that respond to 1octanol (and not octanal) suggest that ~62% (4.7%-1.8%/4.7% × 100%) to ~64% (1.4%0.5%/1.4% × 100%) of the UBI7 cells which express endogenous receptors that normally
respond to 1-octanol but not octanal were also expressing OR-I7. (Note: For experiments on WT
cells in which 1-octanol and octanal were both tested, the concentration used was 60 µM,
whereas 100 µM was used for UBI7 cells. Figure 1.4B provides a crude comparison between the
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WT and UBI7 cells, but there would probably be some deviation in the actual percentage
differences if the same concentrations were compared.)
The percentage of UBI7 cells estimated to express the OR-I7 receptor and an endogenous
receptor that do not respond to octanal (at the tested concentration) decreased as the
concentration of octanal increased (87% at 3 µM, 83% at 10 µM, and 60% at 100 µM). As noted
above, in rat neurons, the EC50 of octanal is about 1.8 µM and OR-I7 is saturated (reached
maximum response) by 10 µM.5 Thus, the lowest concentration of octanal tested, 3 µM, may
possibly already be sufficient to activate most of the mouse UBI7 cells that expressed an
adequate level of the OR-I7 receptor. Assuming that the OR-I7 receptor was close to saturation
at 3 µM, higher concentrations of octanal would only activate the same cells that were activated
at 3 µM. But, as the concentration of octanal increased, various endogenous receptors (some
broadly tuned perhaps) that do not respond to octanal at low concentration may start responding
at the higher concentrations, and consequently the percentage of UBI7 cells estimated to respond
to OR-I7 and an endogenous receptor that do not respond to octanal would drop as the
concentration of octanal increased above the saturating concentration of 10 µM. Nevertheless,
the increase in cells that respond to octanal for the UBI7 mouse indicates that OR-I7 was
expressed at a sufficient level in at least ~60% (at 100 µM) to ~87% (at 3 µM) of the cells that
respond to octanal, but the UBI7 cells’ responses at the lower concentration are probably more
representative of the response of OR-I7.
1.3.1.2. Removal of 1-octanol-responding cells
UBI7 cells responding to octanal and 1-octanol are suspected to be responding to an
endogenous octanal receptor that is not OR-I7 or to an endogenous receptor that responds to 1octanol co-expressed with the OR-I7 receptor. (As OR-I7 does not respond to 1-octanol,4 the
12

response to 1-octanol unquestionably arise from the endogenous receptor.) For the UBI7 OSNs,
a total of 96 cells responded to 1-octanol (@ 100 µM). Usually, over half (56% @ 60 µM
(1.8%/(1.4%+1.8%) × 100%, Figure 1.4B)) of the endogenous 1-octanol-responding cells are
cells that respond to both 1-octanol and octanal. Thus, out of the 96 cells that responded to 1octanol, we could assume that around half of them were expressing endogenous receptors that
responded to both octanal and 1-octanol based on the data for WT cells. These UBI7 cells may
also be expressing a detectable level of the OR-I7 receptor, but the response of octanal that was
stimulated by the OR-I7 receptor would likely be overlapping with the response that was
produced by the endogenous receptor (that could also respond to octanal in addition to 1octanol). We decided to remove these cells from the analysis because the response of the
endogenous receptor interferes with the OR-I7 response.
All of the 1-octanol-responding UBI7 cells were excluded from the analysis to enrich for
cells responding solely through OR-I7 (96 cells excluded, 213 cells remaining). In the process,
we also removed the other half of the 96 1-octanol-responding cells that express endogenous
receptors responding only to 1-octanol in addition to a sufficient level of the OR-I7 receptor.
(Note: There were 9 cells that express endogenous receptors responding only to 1-octanol, but
the expression of OR-I7 was evidently not sufficient to stimulate a calcium imaging response.
These cells were removed from the analysis.) While the octanal response of the co-expressed
OR-I7 receptor would not be affected in these cells, the UBI7 cells that express these
endogenous receptors were still seen as cells that respond to both 1-octanol and octanal (same as
the cells that express endogenous receptors that respond to both 1-octanol and octanal). We
could not distinguish the response of the endogenous receptor and the response of OR-I7 for
UBI7 cells that responded to both 1-octanol and octanal. By removing all of the 1-octanol-
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responding UBI7 cells, we are in effect removing half of all the octanal responses that are
produced by endogenous receptors (overlapped with the octanal response produced by detectable
levels of OR-I7) and increasing the signal from OR-I7. Thus, only the forskolin-responding cells
that do not respond to 1-octanol were used to analyze the response of the cis- (1.2) and transisomer (1.3). The number of cells that responded to each odorant at 3 µM, 10 µM, and 100 µM
for each dish of cells tested are given in Figure 1.5. The calcium imaging response of a
representative cell that responded to forskolin but not 1-octanol is shown on Figure 1.5A. This
cell responded to octanal and the trans-isomer (1.3) but not to the cis-isomer (1.2) at 3 µM, 10
µM, and 100 µM.
1.3.2. Activation of OR-I7 by octanal, 1.2, and 1.3
1.3.2.1. Trans-isomer is preferred by OR-I7 according to the number of cells activated
The trans-isomer (1.3) had a similar amount of responding UBI7 cells compared to
octanal at all three concentrations for Dish 1 and 3 (Figure 1.5). The trans-isomer (1.3) gave
slightly more responding cells than octanal in Dish 2 and 4, but in these two dishes the transisomer (1.3) was applied before octanal, and since there was a chance that the odorant applied
later would give a weaker or no response due to desensitization,20 the difference may not be
significant.
1.3.2.2. Cis-isomer has weaker response than trans-isomer and octanal
For all four dishes, the cis-isomer (1.2) activated fewer UBI7 cells compared to both the
trans-isomer (1.3) and octanal at all three concentrations regardless of the order in which it was
applied. We concluded that the cis-isomer (1.2) is a less potent OR-I7 agonist compared to
octanal and the trans-isomer (1.3). Each cell may be expressing the OR-I7 receptor at different
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levels, so it was not possible to obtain the EC50 value for each odorant, but apparently fewer cells
responded to the cis-isomer (1.2) than the trans-isomer (1.3) and octanal (Figure 1.5).
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Figure 1.5: Response of cells to octanal, 1.2 (cis-isomer), and 1.3 (trans-isomer). (A) The calcium imaging response
of a representative cell that responded to forskolin, octanal and the trans-isomer (1.3), but not the cis-isomer (1.2)
nor 1-octanol. (B) Graphs representing the response of all the UBI7 cells that do not respond to 1-octanol (the total
number of cells analyzed is given in the title of each graph). The odorants are shown in the order in which they were
applied in the calcium imaging experiment.
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1.3.3. Response strength of octanal, 1.2, and 1.3
1.3.3.1. Trans-isomer is preferred by OR-I7 according to response strength (agonist
efficacy)
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All of the UBI7 cells were assumed to express the OR-I7 receptor, but the expression
level in some cells (at least 9%, as evident from the cells that respond to only 1-octanol
(9/(9+87)) ×100%, Figure 1.4B) may not be high enough to be detected by calcium imaging. For
such cells, only the response of the endogenous receptor would be detected. From comparison of
the octanal responses for the WT cells and the UBI7 cells, we were also aware that ~13% of the
UBI7 cells at 3 µM (1.4%/10.8% × 100%, Figure 1.4A), ~17% at 10 µM (2.2%/13% × 100%,
Figure 1.4A), and ~40% at 100 µM (5.8%/14.6% × 100%, Figure 1.4A) may have responses
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stimulated by the endogenous receptors. When we categorized the responses of the UBI7 cells at
3 µM, 10 µM, and 100 µM, a minority of cell types were activated as the concentration increased
from 3 µM to 100 µM (Figure 1.6), which we believe to be the response of the endogenous
receptor only. Since the OR-I7 receptor was expressed in a majority of the UBI7 cells (~60-87%,
based on comparison of WT and UBI7 cells, Figure 1.4A), the responses from the categories of
cells that made up less than 10% of the total cell population (i.e. the cells that respond to 1) the
cis-isomer (1.2) and octanal only, 2) the cis-isomer (1.2) and the trans-isomer (1.3) only, 3) the
cis-isomer (1.2) only, and 4) octanal only) were most likely not the response of OR-I7. However,
the response of all these cells was included in the analysis on Figure 1.5.
To reduce the chance of including the response of endogenous receptors in the analysis,
only the cells in the most common categories, the cells that respond to 1) octanal, the cis-isomer
1.2, and the trans-isomer 1.3 (47.40%-58.22%, Figure 1.6), 2) the trans-isomer 1.3 and octanal
(17.84%-34.10%, Figure 1.6), and 3) the trans-isomer 1.3 only (8.92%-16.76%, Figure 1.6) were
now considered. Cells that respond only to the trans-isomer (1.3) and octanal (17.84%-34.10%)
apparently indicate that the trans-isomer (1.3) and octanal are both more potent OR-I7 agonists
than the cis-isomer (1.2), and cells that respond only to the trans-isomer (1.3) (8.92%-16.76%)
suggest that the trans-isomer (1.3) is more potent than both the cis-isomer (1.2) and octanal.
(Note: The trans-isomer (1.3) was applied before octanal in 3 out of the 4 dishes of cells tested,
and that may cause the octanal response to be desensitized.) The only category in which the
relative potency of the three odorants (in relation to each other) remains ambiguous is the cells
that respond to the cis-isomer (1.2), the trans-isomer (1.3), and octanal (47.40%-58.22%). To
compare the response strength of the cis-isomer (1.2), the trans-isomer (1.3) and octanal, we first
looked at the overall average response levels (the response levels, normalized to the response of
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forskolin, for these cells were averaged; forskolin is considered to activate the cell at 100%), and
then at the responses of the individual cells in this category.
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Figure 1.7: Response level of cells (124 total cells by 100 µM) that respond to octanal, the cis-isomer 1.2, and the
trans-isomer 1.3. The graphs show the average response for all the cells in each dish (total cells on the title of the
graph) that respond to all three odorants. (Average reponse were normalized to the response of forskolin calculated
by ‘response of odorant’/ ‘response of forskolin’ × 100%. The calcium imaging response is the ratio of the
flourescence emission at 340 nm and 380 nm, F340/F380.)

Although these UBI7 cells (82 cells @ 3 µM, 104 cells @ 10 µM, and 124 cells @ 100
µM) responded to all three odorants, the average response (agonist efficacy) of the cis-isomer
(1.2) is on average much lower (~2X lower) than the response of the trans-isomer (1.3) and
octanal for all four dishes regardless of the order of application (Figure 1.7). This evidence
further supports the idea that the OR-I7 receptor prefers the trans-isomer (1.3) over the cisisomer (1.2) of 4-ethylcyclohexylacetaldehyde (1.1) and hence prefers the specific octanal
conformation between C6-C7 that is mimicked by the trans-isomer (1.3) over the conformation
mimicked by the cis-isomer (1.2).
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1.3.3.2. The cis-isomer is a partial agonist of OR-I7
As an agonist of OR-I7, octanal should be able to fully activate the OR-I7 receptor, but
since the expression level of OR-I7 varied from cell to cell (coupled with the possibility of
desensitization), octanal may not reach the maximum response level of forskolin in every cell.
However, the average response of the cis-isomer (1.2) was clearly lower than that of the transisomer (1.3) and octanal (regardless of the order in which it was applied) even at the highest
concentration, 100 µM (Figure 1.7). Out of the cells that responded to all three odorants (the cisisomer (1.2), the trans-isomer (1.3), and octanal), the cis-isomer (1.2) had the lowest response in
51 out of 82 cells at 3 µM (62.2%, Figure 1.8A, cell #1-51), 73 out of 104 cells at 10 µM
(70.2%, Figure 1.8B, cell #1-73), and 75 out of 124 cells at 100 µM (60.5%, Figure 1.8C, cell
#1-75). There exist a minority of cells in which the cis-isomer (1.2) has a 1) similar response
level to the trans-isomer (1.3) and octanal (14 cells @ 3 µM (17.1%), Figure 1.8A, cell #52-65;
13 cells @ 10 µM (12.5%), Figure 1.8B, cell #74-86; 13 cells @ 100 µM (10.5%), Figure 1.8C,
cell #100-112), 2) similar response level as either the trans-isomer (1.3) or octanal (17 cells @ 3
µM (20.7%), Figure 1.8A, cell #74-82; 17 cells @ 10 µM (16.3%), Figure 1.8B, cell #87-103; 32
cells @ 100 µM (26%), Figure 1.8C, cell #76-99, 113-120), or 3) higher response than both the
trans-isomer (1.3) and octanal (0 cell @ 3 µM; 1 cell @ 10 µM (1%), Figure 1.8B, cell #104; 4
cells @ 100 µM (3%), Figure 1.8C, cell #121-124). However, we point out that any trend
involving such small minority of cells is likely due not to OR-I7 but to an endogenous receptor,
which will vary from cell to cell while OR-I7 remains constant. That is, a few endogenous
receptors may be present that are selective for the cis-isomer (1.2) (and/or the trans-isomer (1.3)
and/or octanal). Since the OR-I7 receptor was expressed in a majority of the UBI7 cells (at least
60% of the octanal-responding cells at 100 µM and up to ~87% at 3 µM), we attributed the
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response of the most general group, the cells in which the cis-isomer (1.2) had the lowest
response (which constitute 60.5%-70.2% of the total population of cells that respond to 1.2, 1.3,
and octanal between 3 µM and 100 µM), to be the response of OR-I7. As the response of the cisisomer (1.2) was systematically lower than that of octanal and the trans-isomer (1.3), we
conclude that the cis-isomer (1.2) is a partial agonist of OR-I7: it activates the receptor at partial
efficacy, but even at high concentration fails to achieve the maximum response. As observed for
the calcium imaging response of cell C66 (Figure 1.8D), the cis-isomer (1.2) was unable to
activate the cell at the same efficacy as the trans-isomer (1.3) and octanal even as its
concentration increased.
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Figure 1.8: Calcium imaging response of cells that respond to the cis-isomer (1.2), the trans-isomer (1.3) and
octanal. (A) Relative response of the 82 cells to the cis-isomer (1.2), the trans-isomer (1.3), and octanal at 3 µM. (B)
Relative response of the 104 cells to the cis-isomer (1.2), the trans-isomer (1.3), and octanal at 10 µM. (C) Relative
response of the 124 cells to the cis-isomer (1.2), the trans-isomer (1.3), and octanal at 100 µM. Each row represents
the relative response (normalized to the response of forskolin calculated by ‘response of odorant’/ ‘response of
forskolin’ × 100%) of one cell to the odorants. The cell was tested in the dish, denoted by D and the dish number,
designated on the column to the right of the odorants’ responses. (The odorants’ responses were arranged in the
same order for clarity, but the order of odorant application was different for each dish (Refer to Figure 1.5 or 1.7 for
the order of application in each dish.), and the order in which the odorants were applied may affect the response
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level.) The response of the corresponding cell at each concentration can be identified by the cell ID number given in
parentheses. Cells that do not respond to all three odorants (1.2, 1.3, and octanal) at the lower concentrations were
not included in Panel A and B. (D) The calcium imaging response of a representative cell (C66) displaying partial
activation by the cis-isomer (1.2).
(Note: Responses lower than 10% of the response of forskolin were usually not considered activating, but for cell
C74 and C75, the cis-isomer (1.2) did elicit a response higher than 10% at the lower concentrations, but the signal
probably was desensitized to be under 10% by 100 µM. For these two cells, there was a cis-isomer (1.2) response at
100 µM, but the response level was lower than 10%. Therefore, these cells were categorized as cells that respond to
octanal, the cis-isomer (1.2), and the trans-isomer (1.3), instead of as cells that respond only to octanal and the
trans-isomer (1.3).)

The cis- (1.2) and trans-isomers (1.3) were also tested using the luciferase assay on
HEK293 cells transfected with the OR-I7 receptor gene.8 The relative ranking of potency (data
not shown) was in agreement with our data (although the receptor did not reach saturation at the
concentrations tested). The cis-isomer (1.2) was found to have a weaker response than the transisomer (1.3).
Lastly, we note that in a majority of the cells, the response of the trans-isomer (1.3) is the
same as if not stronger than the response of octanal. As previously mentioned, one of the most
common group of cells in this experiment are the cells that respond only to the trans-isomer (1.3)
(Figure 1.6). Response to solely the trans-isomer (1.3) signifies that the trans-isomer (1.3) is
more potent than both octanal and the cis-isomer (1.2) in these cells. From Figure 1.8A, it could
already be seen that not only is the response of the trans-isomer (1.3) higher than that of the cisisomer (1.2), but it is also higher than the response of octanal in a majority of the cells.
Comparing the response level of the trans-isomer (1.3) with that of octanal in the second most
common cell category (the cells that respond to the trans-isomer (1.3) and octanal, but not the
cis-isomer (1.2)), the trans-isomer (1.3) gave a higher response than octanal in 71% (42 out of 59
cells) of the cells at 3 µM, 58% (28 out of 48 cells) of the cells at 10 µM, and 42% of the cells
(16 out of 38 cells) at 100 µM (Figure 1.9). Only in a low percentage of the cells (3% @ 3 µM (1
cell); 10% @ 10 µM (5 cells); 18% @ 100 µM (7 cells)) were the response of octanal higher
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A. 3 µM

B. 10 µM C. 100 µM

Figure 1.9: Calcium imaging response of cells that respond to the transisomer (1.3) and octanal. (A) Relative response of the 59 cells to the
trans-isomer (1.3) and octanal at 3 µM. (B) Relative response of the 48
cells to the trans-isomer (1.3) and octanal at 10 µM. (C) Relative
response of the 38 cells to the trans-isomer (1.3) and octanal at 100 µM.
Each row represents the relative response (normalized to the response of
forskolin calculated by ‘response of odorant’/ ‘response of forskolin’ ×
100%) of one cell to the odorants. The cell was tested in the dish,
denoted by D and the dish number, designated on the column to the right
of the odorants’ responses. (The odorants’ responses were arranged in
the same order for clarity, but the order of odorant application was
different for each dish (Refer to Figure 1.5 or 1.7 for the order of
application in each dish.), and the order in which the odorants were
applied may affect the response level.)
(Note: Responses lower than 10% of the response of forskolin were
usually not considered activating, but for one cell (row 31) on Panel C
(@ 100 µM), octanal did elicit a response higher than 10% at the lower
concentrations, but the signal probably was desensitized to be under
10% by 100 µM. For this cell, there was an octanal response at 100 µM,
but the response level was lower than 10%. Therefore, this cell was
categorized as a cell that responds to octanal and the trans-isomer (1.3),
instead of a cell that respond only to the trans-isomer (1.3).)

than that of the trans-isomer (1.3). (The rest of the cells (2539% from 3-100 µM) gave similar responses to the transisomer (1.3) and octanal (Figure 1.7).) These data support
the conclusion that the trans-isomer (1.3) is more potent
than octanal and the geometric relationship between the
aldehyde group and the last two carbons on the chain of
octanal is favorably mimicked by the trans-isomer (1.3)
without the loss of entropy during binding. In other words,
the conformation of the trans-isomer (1.3) may be favorably
pre-organized, and resemble the bound conformation of
octanal in complex with rodent OR-I7.
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1.3.4. A molecular explanation for our data: The OR-I7 receptor has carbon chain
conformational sensing ability
Besides having a shorter chain length when in the chair conformation (cis: 6.9 Å, trans:
7.8 Å) than the trans-isomer (1.3), the ethyl group on the cis-isomer (1.2) is also at a different
position from the ethyl group on the trans-isomer (1.3) in relation to the aldehyde group (Figure
1.10, Figure 1.11A). The trans-isomer (1.3) has higher potency and efficacy than the cis-isomer
(1.2), so the position of the ethyl group (i.e. the orientation of the C6-C7 bond) on the transisomer (1.3) should be more favorable for activation of the OR-I7 receptor.
A Line Structures and length

1.2 (chair)
6.9 Å

1.2 (twist-boat)
7.5 Å

1.3 (chair)
7.8 Å

1.3 (twist-boat)
6.6 Å

B 3D Ball and stick model and minimized energy

1.2 (chair)
46.0 kJ/mol

1.2 (twist-boat)
68.5 kJ/mol

1.3 (chair)
39.8 kJ/mol

1.3 (twist-boat)
76.6 kJ/mol

Figure 1.10: Conformations of 1.2 and 1.3. (A) Line structures and lengths of 1.2 and 1.3 in the chair and twistboat conformation (the distance from the carbonyl carbon to the carbon on the ethyl group, indicated by the red
dashed line, was calculated on Avogadro21). (B) 3D Ball and stick model and the minimized energy for 1.2 and 1.3
in the chair and twist-boat conformation. Energy minimization/optimization was done on Avogadro21 using a
MMFF94 force field with the cyclohexyl ring fixed in the chair or twist-boat conformation.

However, we noticed that if the cis-isomer (1.2) flips into the higher energy twist-boat
conformation, the length of the cis-isomer (1.2) (7.5 Å) comes close to the length of the transisomer (1.3) (7.8 Å), and the ethyl group becomes oriented in a similar position as the ethyl
group of the trans-isomer (1.3) (in the chair conformation) (Figure 1.10A and Figure 1.11B).

25

Our data support the idea that the cis-isomer (1.2) activates the OR-I7 receptor when in the
twist-boat conformation, but the energy cost required to switch from the chair conformation
(46.0 kJ/mol, calculated in Avogadro21) to the twist-boat conformation (68.5 kJ/mol, calculated
in Avogadro21) lowers the potency of the cis-isomer (1.2) and prevents it from achieving full
efficacy, hence it is a partial agonist of OR-I7.
A

B

Front View
1.2 (chair conformation)
overlapping with 1.3 (chair
conformation)

Side View

1.2 (twist-boat conformation)
overlapping with 1.3 (chair
conformation)

Figure 1.11: Overlapping 3D models. (A)
3D model of the cis-isomer 1.2 in the chair
conformation (carbons: yellow; oxygen:
blue) overlapping with the trans-isomer 1.3
in the chair conformation (carbons: gray;
oxygen: red). (B) 3D model of the cis-isomer
1.2 in the twist-boat conformation (carbons:
yellow; oxygen: blue) overlapping with the
trans-isomer 1.3 in the chair conformation
(carbons: gray; oxygen: red).
***Molecular
modeling
and
energy
minimization/optimization were done on
Avogadro21 using a MMFF94 force field
with the cyclohexyl ring of the cis-isomer 1.2
fixed in the twist-boat conformation and the
cyclohexyl ring of the trans-isomer 1.3 fixed
in the chair conformation.

1.4. Conclusions:
4-Ethylcyclohexylacetaldehyde

(1.1)

(EC50=1.0 µM, as a cis-trans mixture) was
previously found to have approximately equal
Conformation of
octanal mimicked by
the cis-isomer (1.2)

Conformation of
octanal mimicked by
the trans-isomer (1.3)

potency compared to octanal (EC50=1.8 µM),
suggesting that the OR-I7 receptor tolerates the

gauche conformation of octanal during activation.5 The cis- (1.2) and trans- (1.3) isomers of 1.1
mimicked two of the possible conformations that could be adopted by octanal while in the
gauche conformation. Analog 1.2 and 1.3 have been synthesized and tested on the olfactory
sensory neurons of a UBI7 mouse that express the OR-I7 receptor in addition to the endogenous
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receptors through calcium imaging. Based on the increase in the percentage of cells that respond
to octanal, we concluded that most of the UBI7 cells (~60% at 100 µM to ~87% at 3 µM)
expressed a functional level of the OR-I7 receptor. The potency of the trans-isomer (1.3) is
comparable to (but consistently higher than) that of octanal, whereas the cis-isomer (1.2) was
found to be a less potent OR-I7 agonist than the trans-isomer (1.3) and octanal. Thus, the
conformation of the C6-C7 bond of the trans-isomer (1.3) is a better mimic of octanal’s
conformation during activation of the OR-I7 receptor. The cis-isomer (1.2) could orient its ethyl
group into a similar position as the trans-isomer (1.3) after converting from the chair to the twistboat conformation, but the energy cost for adopting this conformation probably lowers the
efficacy of the cis-isomer (1.2), making it a partial agonist of the OR-I7 receptor.
Since octanal may adopt hundreds of different conformations, its most stable (lowest
energy) conformation, may not be its actual activating conformation, and thus there may be an
entropy penalty when octanal binds OR-I7 in a preferred conformation, and this penalty may in
part explain octanal’s relatively weak potency (EC50: 1.8 µM5). If octanal’s structure could be
constrained into its activating conformation, the efficacy would most likely rise as the entropy
loss is reduced, leading to a more favorable ∆G and a more potent OR-I7 agonist. It’s not
possible to test all of the conformations of octanal to find its optimal activating conformation, but
the cis- (1.2) and trans-isomer (1.3) represent two of the conformations that could be adopted by
octanal, and from this study, we can conclude that the conformation of octanal mimicked by the
trans-isomer (1.3) is more preferable compared to that of the cis-isomer (1.2). While the transisomer (1.3) may not be the actual conformation of octanal when activating OR-I7, it is at least a
conformation that is acceptable by the OR-I7 receptor and favorable (i.e. a closer to the actual
bound, activating conformation).
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The difference in potency between the cis-isomer (1.2) and the trans-isomer (1.3)
indicates that the OR-I7 receptor has a preference for the conformation of its ligand during
activation. As with the OR-I7 receptor, other ORs may exist with preferences for their ligands’
conformations. These results are significant because there is no structural biology information
enlightening how the mammalian odorant receptors bind their ligands. Many odorants have
flexible carbon chains, while protein-small molecule crystal structures, including the many
GPCR X-ray structures now available, teach us that attractions like H-bonds fix small molecule
conformations upon binding. But how can this apply to odorants, which in order to become
volatile must have few or no H-bonds available for binding? Our results provide experimental
data supporting the idea that even a flexible hydrophobic carbon chain can adopt a preferred
conformation upon binding and activating an odorant receptor. It is possible that many other
odorant receptors function as conformational sensors of odorant carbon chain, and this allows
them to contribute to the olfactory code and through this, natural selection during evolution.
Many natural fragrances, such as the santalols, ionones, and the patchoulenes contain
elaborate carbon ring systems and/or double bonds that place a degree of restriction on the
conformation of the odorant. Such odorants may be conformationally restricted versions of linear
compounds that activate the receptors with lower potency and efficacy.
1.5. Experimental Procedures
1.5.1. Materials and reagents
Unless otherwise stated, chemical reagents and solvents were purchased from VWR
International, Fisher Scientific, or Sigma Aldrich and used without further purification. UBI7
mouse11, 12 was provided by Dr. Leonardo Belluscio (NIH/NINDS). Octanal was distilled before
use. Aldehydes were stored at 4°C under vacuum prior to testing. Analytical TLC was performed
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on silica gel 60 F254 plates. Flash chromatography22 was performed on Teledyne Isco
CombiFlash Rf-200 flash chromatography system or manually in glass columns with 230-400
mesh silica gel. 1H and 13C NMR spectra were recorded on a Varian Mercury 300 spectrometer
or a Bruker Ultrashield 500 spectrometer. HRMS was performed by Dr. Lijia Yang (CCNY
Chemistry Department staff) on a Waters LCT XE (TOF) mass spectrometer using electrospray
ionization (ESI). Infrared (IR) spectra were recorded using Thermo Nicolet 6700 FT-IR
spectrometer. GC analyses were performed on a Shimadzu GC-2010 gas chromatograph with an
FID detector using a 15 m × 0.25 mm capillary column with dimethyl polysiloxane as the
stationary phase. Compound 1.2 and 1.3 were first synthesized and characterized by Yadi Li8
with helpful advice from Dr. Mark Biscoe on the synthetic routes to the two isomers. Compound
1.2 was synthesized for this study following his procedures, and compound 1.3 was synthesized
from 1.3d, provided by Yadi Li. (Note: The literature procedure that was applied for each
reaction is cited. The procedure may not necessarily be used for the synthesis of the same
compound as in the literature.)
General Procedure for Lithium Aluminum Hydride (LAH) reduction5
The acid or ester (1 equiv.) in diethyl ether was added slowly to lithium aluminum hydride (1.1
equiv.) in diethyl ether at 0°C. The suspension was stirred at room temperature for 2-3 h and then
cooled to 0°C. Water (1 mL per g of LAH) was added, followed by 15% sodium hydroxide (1
mL per g of LAH) and water (3 mL per g of LAH). The solution was stirred for a few minutes at
room temperature, filtered through a celite pad, washed with diethyl ether, dried, and
concentrated to give the alcohol. Flash chromatography was sometimes required to purify the
product.
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General Procedure for Pyridinium chlorochromate (PCC) oxidation5
The alcohol (1 equiv.) was added to pyridinium chlorochromate (1.1 equiv.) and silica gel (1 g/g
of PCC) in dry dichloromethane under inert atmosphere. The suspension was stirred for 2 h and
then passed through a silica gel pad. The solution was concentrated to give the aldehyde. Flash
chromatography or distillation was sometimes required to purify the product.
Ethyl 2-(4-ethylcyclohexylidene)acetate (1.2a). Compound 1.2a was synthesized
following a literature procedure.5 Ethyl 2-(diethoxyphosphoryl)acetate (8.88 g,
39.6 mmol) in THF (15 mL) was slowly added to sodium hydride, 57-63% in oil,
(1.6 g, 40 mmol) in THF (50 mL). The mixture was stirred at room temperature
for 1 hour and 4-ethylcyclohexanone (5 g, 39.6 mmol) in THF (10 mL) was slowly added so that
the temperature of the mixture was below 30°C. The solution was stirred for 15 minutes and then
quenched with water. The aqueous layer was extracted with diethyl ether. The organic layer was
dried, concentrated, and purified by flash chromatography eluting with hexanes/ethyl acetate
(19:1) to give 1.2a (2.7 g, 13.8 mmol) as a clear liquid in 35% yield. . 1H NMR (CDCl3) : 5.62
(s, 1H), 4.16 (q, J = 7.2 Hz, 2H), 3.82 - 3.70 (m, 1H), 2.35 - 2.11 (m, 2H), 2.03 - 1.86 (m, 3H),
1.50 - 1.21 (m, 6H), 1.18 - 1.01 (m, 2H), 0.99 - 0.84 (m, 3H).

13

C NMR (CDCl3) δ: 166.87,

163.56, 113.00, 59.46, 38.93, 37.31, 34.18, 33.46, 29.00, 28.95, 14.33, 11.60. IR (thin film, KBr
plates), ν (cm-1): 2932, 2855, 1715, 1649, 1380, 1235, 1186, 1150. Spectral data agree with those
reported previously.5, 23
Ethyl 2-(cis-4-ethylcyclohexyl)acetate (1.2b). Compound 1.2a (2 g, 10.2 mmol) in
THF (10 mL) was slowly added to 1 M L-selectride6,

7

in THF (30.5 mL, 30.5

mmol) so that the temperature of the mixture was below -70°C. The mixture was
stirred at -75°C for 1 hour and at -40°C for 4 hours. Ethanol (4.8 mL) was added
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followed by ethyl acetate (14.4 mL), pH=7 phosphate buffer (0.1 M, 6.4 mL), and 30% hydrogen
peroxide solution (8.8 mL). The mixture was stirred overnight. The aqueous and organic layers
were partitioned and the aqueous layer was extracted with ethyl acetate. The combined organic
layer was extracted with brine, dried, concentrated and purified by chromatography eluting with
hexanes/ethyl acetate (49:1) to give 1.2b (0.2 g, 1 mmol) as a clear liquid in 10% yield. 1H NMR
(CDCl3) : 4.20 - 4.09 (m, 2H), 2.29 (d, J = 7.5 Hz, 2H), 2.05 (m, 1H), 1.60 - 1.20 (m, 14H),
0.98 - 0.81 (m, 3H).

13

C NMR (CDCl3) δ: 173.45, 60.08, 39.30, 37.03, 32.54, 28.76, 28.24,

26.96, 14.30, 11.84. IR (thin film, KBr plates), ν (cm-1): 2960, 2921, 2855, 1736, 1451, 1297,
1219, 1171, 1123, 1035. HRMS (ESI) [M+Na]+: Calcd for C12H22O2 m/z = 221.1512, found m/z
= 221.1511.
2-(cis-4-Ethylcyclohexyl)ethanol (1.2c). Compound 1.2b (0.2 g, 1 mmol) was LAH
reduced according to the general procedure to obtain 1.2c (0.085 g, 0.54 mmol) as a
clear liquid in 54% yield. 1H NMR (CDCl3) : 3.75 - 3.66 (m, 2H), 1.69 - 1.42 (m,
7H), 1.42 - 1.17 (m, 8H), 1.02 - 0.83 (m, 3H).

13

C NMR (CDCl3) δ: 61.39, 37.25,

37.15, 31.76, 28.97, 28.42, 27.01, 11.88. IR (thin film, KBr plates), ν (cm-1): 3331 (broad), 2959,
2919, 2873, 2853, 1450, 1378, 1062, 1011, 978. HRMS (ESI) [M+Na]+: Calcd for C10H20O m/z
= 179.1406, found m/z = 179.1432.
2-(cis-4-Ethylcyclohexyl)acetaldehyde (1.2). Compound 1.2c (0.04 g, 0.26 mmol) was
PCC oxidized according to the general procedure to obtain 1.2 (0.03 g, 0.19 mmol) as a
clear liquid in 76% yield. The product contains 95.6% of the cis-isomer 1.2 and 4.4%
of the trans-isomer 1.3 according to GC analysis. 1H NMR (CDCl3) : 9.78 (t, J = 2.4
Hz, 1H), 2.41 (dd, J = 2.4, 7.2 Hz, 2H), 2.24 - 2.12 (m, 1H), 1.63 - 1.48 (m, 4H), 1.46 - 1.21 (m,
7H), 0.94 - 0.84 (m, 3H). 13C NMR (CDCl3) δ: 203.16, 48.38, 36.96, 30.08, 28.97, 28.20, 27.03,
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11.81. IR (thin film, KBr plates), ν (cm-1): 2960, 2921, 2855, 2711, 1726, 1451, 1378. HRMS
(ESI) [M+Na]+: Calcd for C10H18O m/z = 177.1250, found m/z = 177.1251.
(trans-4-Ethylcyclohexyl)methanol (1.3a). (trans-4-Ethylcyclohexyl)carboxylic acid
(5.7 g, 36 mmol) (purchased from OChem Incorporation) was LAH reduced
according to the general procedure to obtain 1.3a (5 g, 35 mmol) as a clear liquid in
97% yield. 1H NMR (CDCl3) δ: 1H NMR (CDCl3) : 3.47 (d, J = 6.2 Hz, 2H), 1.90 - 1.71 (m,
4H), 1.54 - 1.36 (m, 1H), 1.29 - 0.83 (m, 11H). 13C NMR (CDCl3) δ: 68.83, 40.70, 39.59, 32.26,
29.96, 29.49, 11.51. IR (thin film, KBr plates), ν (cm-1): 3330 (broad), 2960, 2915, 2852, 1448,
1379, 1100, 1072, 1036, 1003, 964, 896.
(trans-4-Ethylcyclohexyl)carbaldehyde (1.3b). Compound 1.3a (3 g, 21 mmol) was
PCC oxidized according to the general procedure to obtain 1.3b (2.7 g, 19 mmol) as a
clear liquid in 91% yield. The aldehyde is prone to oxidation in air so it was used
immediately for the next step without further purification.
trans-1-Ethyl-4-vinylcyclohexane (1.3c). Compound 1.3c was synthesized based on a
literature procedure.5 To an ice-cooled mixture of methyl triphenylphosphonium
bromide (10.33 g, 29 mmol) in dry THF (75 mL) was added 1.6 M n-BuLi solution
(16.9 mL, 27 mmol). The mixture was stirred at 0°C for 30 minutes, and then cooled to -75°C.
Compound 1.3b (2.7 g, 19 mmol) in THF (25 mL) was added dropwise. The mixture was stirred
at -75°C for 3 hours. Ammonium chloride solution was added and the layers were separated. The
organic layer was extracted with water, brine, and dried. The crude was purified by
chromatography eluting with pentane to give 1.3c (2.5 g, 18 mmol) as a clear liquid in 95%
yield. 1H NMR (CDCl3) : 5.78 (ddd, J = 6.6, 10.5, 17.2 Hz, 1H), 5.05 - 4.77 (m, 2H), 2.05 -
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1.65 (m, 3H), 1.39 - 1.01 (m, 6H), 1.01 - 0.70 (m, 6H).

13

C NMR (CDCl3) δ: 145.09, 111.79,

42.15, 39.31, 32.73, 31.84, 30.23, 22.91, 14.39, 11.76.
2-(trans-4-Ethylcyclohexyl)ethanol (1.3d). Compound 1.3d was synthesized based
on a literature procedure.5 1 M Borane tetrahydrofuran complex solution in THF (9
mL, 9 mmol) was added dropwise to a solution of 1.3c (2.5 g, 18 mmol) in THF (50
mL). After 15 minutes, saturated sodium carbonate solution (6.2 mL) and 30%
hydrogen peroxide solution (3.68 mL, 36 mmol) were added. The mixture was stirred for 2
hours. Water (50 mL) was added and the layers were separated. The aqueous layer was extracted
with diethyl ether. The combined organic layers were washed with brine, dried, and
concentrated.

The

crude

product

was

purified

by

chromatography

eluting

with

acetonitrile/dichloromethane/cyclohexane (1:9:10) to give 1.3d (1.2 g, 7.8 mmol) as a clear
liquid in 43% yield. 1H NMR (CDCl3) : 3.70 (t, J = 6.8 Hz, 2H), 1.86 - 1.65 (m, 4H), 1.57 - 1.44
(m, 3H), 1.41 - 1.29 (m, 1H), 1.27 - 0.81 (m, 10H).

13

C NMR (CDCl3) δ: 60.99, 40.36, 39.49,

34.46, 33.30, 32.77, 30.00, 11.51. IR (thin film, KBr plates), ν (cm-1): 3323 (broad), 2960, 2916,
2851, 1448, 1378, 1046. HRMS (ESI) [M+Na]+: Calcd for C10H20O m/z = 179.1406, found m/z =
179.1431.
2-(trans-4-Ethylcyclohexyl)acetaldehyde (1.3). Compound 1.3d (0.3 g, 1.92 mmol)
was PCC oxidized according to the general procedure to give 1.3 (0.17 g, 1.1 mmol) as
a clear liquid in 57% yield. 1H NMR (CDCl3) : 9.78 (t, J = 2.4 Hz, 1H), 2.31 (dd, J =
2.3, 6.7 Hz, 2H), 1.93 - 1.72 (m, 5H), 1.29 - 1.18 (m, 2H), 1.16 - 0.85 (m, 8H).

13

C

NMR (CDCl3) δ: 203.07, 51.37, 39.04, 33.17, 32.95, 32.52, 29.87, 11.46. IR (thin film, KBr
plates), ν (cm-1): 2960, 2919, 2852, 2711, 1726, 1448, 1378. HRMS (ESI) [M+Na]+: Calcd for
C10H18O m/z = 177.1250, found m/z = 177.1255.
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1.5.2. Calcium imaging of mouse olfactory sensory neuron
Calcium imaging was performed as described previously.5 All animal procedures were approved
by the City College of New York Institutional Animal Care and Use Committee (IACUC) and
performed at the City College of New York in compliance with relevant national guidelines and
regulations. Olfactory epithelium tissues were obtained from a 16 week old UBI7 mouse by my
colleague, Mihwa Na. The tissues were placed into a conical tube containing an enzyme solution
made with BSA (0.015 g), collagenase (0.0025 g), and 3 mL of DICAT-free Ringer solution
containing sodium chloride (145 mM), potassium chloride (5.6 mM), HEPES at pH 7.4 (10
mM), glucose (10 mM), and EGTA (4 mM). The cells were incubated at 37°C for 1 h in the
enzyme solution. The tissues were then allowed to settle to the bottle of the conical tube and the
enzyme solution was replaced with a media containing DMEM/F12-HAM, 10% FBS (Gibco),
1% Pen/Strep (Gibco), and 1X Insulin-Transferrin-Selenium-X (Gibco). Most of the media was
removed and the tissues were gently vortexed to dissociate the cells. The cells were applied onto
four coverslips pre-coated with concanavalin A. The cells were allowed to recover in the media
containing 0.02 M vitamin C (ascorbic acid) at 37°C for 45 minutes. The media was then
replaced with 1 mL of Ringer solution (sodium chloride (138 mM), potassium chloride (5 mM),
HEPES at pH 7.4 (10 mM), calcium chloride (1 mM), magnesium chloride (1.5 mM), and
glucose (10 mM)) containing Fura-2 (6.25 µL) and pluronic acid (1 µL), and incubated for
another 45 minutes at room temperature in the dark. The cells were placed in new Ringer
solution and left at room temperature for 10 minutes. The coverslip containing the cells were
viewed under a fluorescence microscope and the response was obtained using Metamorph.
Odorants (400 µL)) were applied for 8 seconds at 2 minutes intervals via syringe in a stream of
Ringer solution flowing at a rate of 1 mL/min. (The odorants were dissolved in DMSO and then
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diluted (1000X) with Ringer solution to the desired concentration.) Recordings were made at 340
nm and 380 nm. The ratio of the fluorescence reading at these two wavelengths (F340/F380)
corresponds to the amount of intracellular calcium. Forskolin (10 µM) was applied at the end of
the experiment to activate adenylyl cyclase. The calcium imaging response of the odorants were
normalized to the response of forskolin (10 µM).
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Chapter 2: Olfactory Receptor Antagonism of the OR-I7 Aldehyde Receptor
2.1. Introduction:
2.1.1. Role of antagonism in the
olfactory code
According to the olfactory
code,
Figure 2.1: Signal transduction pathway of the olfactory system
during antagonism of the olfactory receptor.
(OR=Olfactory receptor and AC=Adenylyl cyclase)

each

receptor

can

be

activated by multiple odorants, and
different odorants can activate a

different set of odorant receptors.1 Hence, the olfactory system identifies odors using a
combinatorial receptor coding scheme, and each odorant would have a unique olfactory code for
generating the smell that we experience.1 Most studies have focused on identifying the olfactory
receptors that could be activated by a specific odorant or the odorants that could activate specific
receptors, but odorants are also capable of antagonizing ORs that they do not activate.
Antagonists bind to receptors without activating them and this competitively inhibits agonists
from binding (Figure 2.1). Therefore, instead of activating all the receptors that can be activated
by the individual odorants, some receptors would lose their response in a mixture, or have it
lessened, perhaps to partial agonist levels, due to antagonism. Antagonism may play an
important role in the olfactory code, but the extent of that role and the structural criteria of
antagonism are unclear.
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2.1.2. Molecular receptive range and antagonism of OR-I7 receptor
Octanal

Pentanal (2.1)

Hexanal

2.2

1.1

Binding Site

Mid-Region

< 6.5 Å

Activation
Pocket
Length (Å)
EC50 (µM)
IC50 (µM)

~6.5-6.9 Å

8.9
1.8
-

5.1
460

6.4
1736
124

5.4
45

7.3-7.9
1.0
-

Figure 2.2: Agonists and antagonists of the rat OR-I7 receptor. EC50 and IC50 values were obtained from calcium
imaging of rat OSNs.2

In a previous study, evidence of antagonism was observed in the rat olfactory receptor,
OR-I7.2 OR-I7 is a receptor specific for aliphatic aldehydes, with octanal, an eight carbon
aliphatic aldehyde, currently as one of its most potent ligand.3,

4

Only aldehydes capable of

adopting chain lengths longer than 6.5-6.9 Å could activate OR-I7 at micromolar
concentrations.2 Removal of the ethyl group on 1.1 (to form 2.2), so that the chain length
becomes shorter than 6.5 Å, converts the molecule from an agonist to an antagonist of the OR-I7
receptor. Aldehydes with chain lengths shorter than 6.5 Å inhibited the response of octanal in a
dose-dependent manner with micromolar potency (IC50 values from 45 to 460 µM when tested
by calcium imaging, Figure 2.2). Since these antagonists all have chain lengths shorter than 6.5
Å in their most extended conformation, it was proposed that these odorants bind to the receptor
via their aldehyde moiety, but were not long enough to reach a hydrophobic pocket needed to
trigger activation of the OR-I7 receptor. The antagonists’ potencies appear to be improving as
the number of carbons in the mid-region (region in the receptor between the aldehyde binding
site and the proposed hydrophobic activation pocket) increases. Hexanal (IC50 = 124 µM), with
one more carbon than pentanal (2.1) (IC50 = 460 µM), is approximately four times more potent
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than pentanal (2.1). Cyclohexylethanal (2.2) (IC50 = 45 µM), with two extra carbons compared to
hexanal, was approximately three times as potent.
2.2.

Design and synthesis of OR-I7 antagonists

Figure 2.3: Structures of designed OR-I7 antagonists tested in Structure-Activity Relationship (SAR) study.

The predicted binding free energies in a homology model for OR-I7 suggest that
saturated aldehydes with five to eleven carbons may be partially stabilized by hydrophobic
interactions with amino acid residues.5 Increasing the carbons in the mid-region of the receptor
may promote additional van der Waal interactions as more hydrophobic surface area from the
ligand is buried in the binding site, and consequently, the affinity and potency of the antagonists
may improve. To further test this idea, a structure-activity relationship (SAR) study was
conducted in which the number of carbons in the mid-region of OR-I7 antagonists, 2.1 and 2.2,
was gradually increased (Figure 2.3). Analogues 2.3, 2.4, 2.5, 2.6, and 2.7 have increasing
numbers of carbons, compared to 2.1, by one to five carbons, respectively. Analogues 2.7, 2.8,
2.9, 2.10, 2.11, and 2.12 have one to four more carbons compared to compound 2.2. While
increasing the number of carbons, the analogues were designed to maintain chain lengths shorter
than 6.5 Å to prevent the compounds from reaching the putative hydrophobic activation pocket.
The described analogues were synthesized and tested in HEK293 cells transfected with the
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mouse OR-I7 receptor to determine if there is any correlation between the number of carbons
occupying the mid-region and the antagonist’s potency.
The target compounds were synthesized from commercially available starting materials.
Compounds 2.3 and 2.12 were synthesized in one step from the alcohols through PCC oxidation.
Compounds 2.2 and 2.10 were synthesized in two steps from the ester and carboxylic acid,
respectively, through LAH reduction followed by PCC oxidation (Scheme 2.1).

Scheme 2.1: Synthesis of 2.2, 2.3, 2.10, and 2.12.

Compound 2.4 was synthesized in four steps from 3-pentanone as previously reported
(Scheme 2.2).6 3-Pentanone was subjected to a Horner-Wadsworth-Emmons reaction to afford
the α,β-unsaturated ester 2.4a, which was then hydrogenated to give the saturated ester 2.4b. The
ester was reduced to the alcohol 2.4c and oxidized into the aldehyde 2.4.

Scheme 2.2: Synthesis of 2.4.

Compound 2.5 was also synthesized from 3-pentanone according to an established
route.7,

8

3-Pentanone reacted with ethyl cyanoacetate to form the α,β-unsaturated cyanoester

2.5a, which served as the Michael acceptor in the following 1,4 addition reaction with a Grignard
reagent, formed from magnesium and iodomethane, as the Michael donor, to obtain 2.5b. The
ester 2.5b was hydrolyzed and decarboxylated to form the nitrile 2.5c, which was then
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hydrolyzed and reduced to the alcohol 2.5d. The alcohol 2.5d was oxidized to form the aldehyde
2.5. Compound 2.6 was synthesized in a similar manner but using bromoethane instead of
iodomethane to form the Grignard reagent. Compound 2.8 and 2.9 were also synthesized through
the same route but starting with cyclohexanone instead of pentanone (Scheme 2.3).

Scheme 2.3: Synthetic route of 2.5, 2.6, 2.8, and 2.9.

Compound 2.7 was synthesized (Scheme 2.4) starting from crotonaldehyde.9,

10

The

bicyclic ring of 2.7 was obtained through two Diels-Alder reaction. First, crotonaldehyde was
subjected to a nucleophilic addition reaction to form 2.7a, which was used as the diene in the
following Diels-Alder reaction with ethyl acrylate as the dienophile to form 2.7b. Compound
2.7b was subjected to an elimination reaction to form the ester 2.7c, which would serve as the
diene in another Diels-Alder reaction with maleic anhydride as the dienophile to form 2.7d. The
alkene 2.7d was hydrogenated to the alkane 2.7e, which was then hydrolyzed to cleave the
anhydride into carboxylates 2.7f. The carboxylate groups were decarboxylated to form 2.7g. The
alkene 2.7g was hydrogenated to reduce the double bond on the ring to form 2.7h. The ester 2.7h
was LAH reduced to the alcohol 2.7i. The alcohol 2.7i was homologated by an extra carbon via a
PCC oxidation reaction, followed by a Wittig reaction and a hydroboration-oxidation reaction to
form the aldehyde 2.7j, the alkene 2.7k, and the alcohol 2.7l, respectively. The alcohol 2.7l was
then oxidized, as usual just before biological testing, to the aldehyde 2.7.
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Scheme 2.4: Synthesis of 2.7.

Compound 2.11 (Scheme 2.5) was synthesized from (-)-b-pinene. (-)-b-Pinene was
homologated by an extra carbon via a hydroboration-oxidation reaction followed by a PCC
oxidation and a Wittig reaction, to form the alcohol 2.11a, aldehyde 2.11b, and alkene 2.11c,
respectively. The elongated alkene 2.11c was then subjected to another hydroboration-oxidation
reaction to form the alcohol 2.11d, which was oxidized to the aldehyde 2.11. (It is also possible
to synthesize compound 2.11 from (-)-b-pinene in one step via a hydroformylation reaction.35, 36)

Scheme 2.5: Synthesis of 2.11.
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2.2.1. Evaporation problem associated with luciferase assay
The initial luciferase assay that our collaborator used (Hiroaki Matsunami lab, Duke
University) is a protocol that has been employed to measure the activation of specific ORs based
on the cells’ cAMP level.11 In this assay, odorants are tested in genetically modified HEK293
cells (Hana3A cells) transfected with the OR-I7 receptor gene. Transfected ORs could not easily
be expressed on the cell membrane, but RTP1S, a receptor-transporting protein, appears to help
promote cell surface expression. In the transfected cells, activation of the olfactory receptor
results in the production of cAMP, which in turn activates a protein kinase A. Protein kinase A
then activates CREB, cAMP response element binding protein, to induce the expression of the
luciferase gene, causing an increase in light output so that the response of the receptor can be
quantified from the luminescence reading. Since gene expression occurs slowly, several hours
were usually required to see a response. As such, the odorant had to be incubated at 37°C with
the transfected cell in a 75 µM buffer solution for 2-4 hours. Since the OR-I7 agonist, octanal, is
an aldehyde that is prone to oxidation in air, the production of octanoic acid over time was
monitored by GC/MS.
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Figure 2.4: Disappearance of octanal in
water. Octanal (75 µL, 0.1 mM) in a
water solution was incubated at 37 °C for
2 hours in a 96-well plate. Percentage of
octanal remaining in the solution was
monitored by GC/MS. The water sample
was directly injected into the GC/MS
without further treatment. The expected
retention time for oxidized octanal
(octanoic acid) is approximately 8.5
minutes. (A) Overlapping GC/MS
spectrum for octanal after 0 h (black), 1 h
(blue), and 2 h (red) of incubation. (B)
Percentage of octanal remaining as a
function of time. Results were obtained
from the average of 3 trials. Percentages
were calculated from the peak area for
octanal.

Octanal was incubated for 2 hours at 37°C in a water solution to test for oxidation. No
octanoic acid formed during this time span, but there was an apparent loss of octanal from the
solution (Figure 2.4A). By the end of two hours, there was less than 20% of the original amount
of octanal remaining in the water solution (Figure 2.4B). Octanal is volatile and has low
solubility in water, so we speculated that octanal was evaporating from the water solution during
the incubation. This was a potential problem because the luciferase assay requires incubation at
37°C in an aqueous solution for several hours to promote gene expression. However, if octanal
was evaporating throughout this period, we would not be testing the concentration that was
initially applied before the incubation, and different odorants undergoing comparison might
evaporate at different rates.
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To verify if evaporation occurs during the luciferase assay carried out by our
collaborators at Duke University, the amount of octanal was monitored in a mock luciferase
experiment, which was identical to an actual experiment except that the transfected cells were
not present. Octanal was incubated for 2 hours at 37°C in a CD293 buffer solution (the medium
used in the actual luciferase experiment for promoting cell growth) with 2,2-difluorooctanal. 2,2Difluorooctanal is an OR-I7 agonist that converts to the gem-diol form when hydrated in water,
and our collaborators were testing this compound in another project. The two hydroxyl groups on
the gem-diol were expected to boost the odorant’s hydrophilicity, and consequently its solubility
in water. In the case of octanal, roughly 40% converts to the gem-diol form in water.12 After two
hours of incubation at 37°C, the percentage of octanal went down by approximately 70%, while
the percentage of 2,2-difluorooctanal in the solution remained essentially the same (Figure 2.5A
and 2.5B). Thus, differential evaporation was occurring over the course of the experiment.
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Figure 2.5: Disappearance rate of 2,2-difluorooctanal and octanal in CD293 buffer in a mock luciferase reaction.
2,2-Difluorooctanal and octanal (75 µL, 0.1 mM) in a CD293 buffer solution was incubated at 37 °C for 2 hours in a
96-well plate. Percentage of odorant remaining in the solution was monitored by GC/MS. The odorants were
extracted from the CD293 buffer with chloroform as described in the procedure. (A) Overlapping GC/MS spectrum
at 0 h (black), 1 h (blue), and 2 h (red) of incubation. (B) Percentage of odorant remaining as a function of time.
Results were obtained from a single trial. Percentages were calculated from the peak area for each odorant.

To prevent octanal from escaping the 96-well plate within the two hours of incubation,
several different 96-well plate covers designed to seal the plate’s opening were used, including a
plastic lid with parafilm, crystallization tape, sealing mat, and a silicone mat. However, after
incubation at 37°C, there was still a decrease in the percentage of octanal remaining in the buffer
compared to 2,2-difluorooctanal (Figure 2.6).
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Figure 2.6: Disappearance rate of 2,2-difluorooctanal and octanal in sealed 96-well plates. 2,2-Difluorooctanal and
octanal (0.1 mM) were incubated at 37 °C for 4 hours in a CD293 buffer solution (300 µL, 200 µL used for sealing
mat). Results were obtained from a single trial. Percentages were normalized to 2,2-difluorooctanal.

Since the covers were all ineffective in maintaining the percentage of octanal in the
solution, the odorant may be interacting with the material (polystyrene with poly-D-lysine
surface) of the 96-well plate in some way, possibly getting attached onto the bottom of the plate,
designed to adhere to cells. Prior to the incubation with octanal and 2,2-difluorooctanal,
individual 96-well plates were pre-exposed to one of the following odorants at concentrations of
either 0.1 or 1 mM: 1) octanal, 2) 2,2-difluorooctanal, and 3) 1-octanol. The 96-well plates
containing these odorants were incubated at 37°C for four hours and then rinsed with water and
air-dried prior to the assay. Despite being pre-exposed to the odorants and covered with a sealing
mat during the incubation, the percentage of octanal was still appreciably reduced by the end of
two hours (Figure 2.7).
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Figure 2.7: Disappearance rate of 2,2-difluorooctanal and octanal after pre-exposure. 2,2-Difluorooctanal and
octanal (0.1 mM) were incubated at 37 °C for 2 hours in a CD293 buffer solution (200 µL). Results were obtained
from a single trial. Percentages were calculated from the peak area.

The cover should prevent octanal from escaping into the air and the odorants do not
appear to be adsorbing onto the plate. Octanal, being hydrophobic, may be vaporizing and
condensing onto the walls of the 96-well plate despite being locked inside a closed chamber. To
reduce the surface area inside the 96-well plate for the octanal to condense onto, the volume of
the buffer solution was increased while maintaining the same concentration. With the higher
volume, there was an approximately 20% increase in the amount of octanal remaining in the
solution (Figure 2.8), so that was at least part of the problem.
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Figure 2.8: Disappearance rate of 2,2-difluorooctanal and octanal at higher volume. 2,2-Difluorooctanal and octanal
(0.1 mM) were incubated at 37 °C for 30-45 minutes in a CD293 buffer solution (75 or 225 µL). Results were
obtained from a single trial. Percentages were normalized to an internal standard, bromooctane.

Although there would be less evaporation if the temperature was reduced, cooler
temperature would slow gene expression too much. Instead, we decided to look at whether the
evaporation rate was the same for other aldehydes besides octanal. While 2,2-difluorooctanal is
an aldehyde, its ability to almost completely convert to the gem-diol form in water result in
properties that are exceptionally different to other aldehydes. The evaporation rate of several
other experimental aldehydes under study in our lab (A1-A11, structures shown on Figure 2.9A)
with similar lengths as octanal were tested at 37 °C using 75 µL volumes. Overall, all the
aldehydes have similar disappearance/evaporation rate, with around 30-50% remaining after 30
minutes (Figure 2.9B).
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Figure 2.9: Disappearance rate of other aldehydes. Odorants (0.1 mM) were incubated at 37 °C for 30 minutes in
CD293 buffer solution (75 µL). (A) Structures of odorants. (B) Results were obtained from a single trial. Results
were obtained from the peak area. (Aldehydes were provided by Yadi Li.)

Next, we compared the evaporation rate of a few structural analogs of octanal and 2,2difluorooctanal. 2,2-Dimethyloctanal is an aldehyde with opposing electronic properties
(electron-donating) to that of 2,2-difluorooctanal (fluorine is electron-withdrawing). Whereas the
electron-withdrawing fluoro groups on 2,2-difluorooctanal shift the equilibrium towards the
gem-diol form, the electron-releasing methyl groups on 2,2-dimethyloctanal shift the equilibrium
towards the aldehyde form. If there is a direct correlation between the percentage of compounds
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that was converted to the gem-diol form and the disappearance of the odorants from the solution,
we should see a difference in the disappearance rate of 2,2-dimethyloctanal and octanal.
However, 2,2-dimethyloctanal and octanal appeared to have similar disappearance rate (Figure
2.10). Moreover, even the disappearance rate of alcohols, 2,2-difluorooctanol and 1-octanol,
were similar to that of octanal (Figure 2.10). With the exception of 2,2-difluorooctanal, the other
structural analogs that were tested have similar disappearance rates. Whereas the concentration
of odorants in the solution may be changing over time, the ratio of the odorants to each other
should be fairly similar at all time. In this sense, the disappearance of the odorants through time
would not be such a significant problem for the purpose of comparing the activity of odorants
within the same experiment.
A

B

Octanal

140

% Odorant Remaining

120
Difluorooctanal

100
Octanal
80

Difluorooctanal

60

Dimethyloctanal

40

Difluorooctanol

Dimethyloctanal

Octanol
20

Difluorooctanol

0
0

2

4

Octanol

Time (hours)

Figure 2.10: Disappearance rate of structural analogs. Odorants (0.1 mM) were incubated at 37 °C for 4 hours in
CD293 buffer solution (300 µL). (A) Results were obtained from the average of 3 trials. Bromooctane was used as
an internal standard. (B) Structures of odorants. (Odorants were provided by Yadi Li.)

While structurally analogous compounds are expected to leave the solution at similar
rates, the response of the OR would probably not be stimulated by the applied concentration.
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Expression of the luciferase gene required incubation of the odorant solutions at 37 °C for
several hours. However, it did not appear possible to prevent volatile odorants from escaping the
solution during this timeframe, and using cooler temperatures and volumes close to the capacity
of the 96-well plate chambers were impractical. To limit the disappearance of the odorants, the
time of the experiment need to be lowered.
2.2.2. Glosensor cAMP assay
To shorten the reaction time, our collaborators adopted the Glosensor assay to determine
the cAMP level in real time without the need for any reporter gene expression. In this assay,
HEK293 cells were transfected with the OR-I7 receptor and a mutated form of the firefly
luciferase gene fused with a cAMP binding region. Binding with cAMP promotes an immediate
increase in light output so that the response of the receptor can be quantified from the
luminescence reading in less than 15 minutes and as early as 5 minutes. Additionally, the
odorants do not need to be incubated at elevated temperature.
When an agonist binds to the receptor, activation of the signal transduction pathway leads
to an increase in the cAMP level and subsequently a boost in the light output by the GloSensor
reporter. To test for antagonism, the agonist (i.e. octanal) was co-applied with various
concentrations of each of the designed OR-I7 antagonists. The luminescence reading of the
binary mixture should be lower than the reading of octanal alone if the co-applied compound is
actually an antagonist that is competing with octanal for the binding site.
Selected odorants (octanal, 2.1, and 2.2) have been tested using this assay with HEK293
cells transfected with the rat OR-I7 receptor and the mouse OR-I7 receptor (results not shown).
The mouse OR-I7 receptor was better expressed in the cells and the Glosensor assay gave more
consistent response using the mouse ortholog. For that reason, the synthesized compounds were
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tested in the mouse OR-I7 receptor although prior testing using calcium imaging was done using
the rat OR-I7 receptor.2 There are 15 amino acid differences between the rat and mouse OR-I7
receptor, but both are aliphatic aldehyde receptors that behave similarly.13
2.3.

Results and Discussion

2.3.1. Activation of OR-I7
A

B

Figure 2.11: Relative cAMP response of agonist and
antagonist of OR-I7. HEK293 cells transfected with the
mouse OR-I7 receptor were exposed to varying
concentrations of odorant. The cAMP-induced response
was monitored for 24 minutes after odorant(s) addition.
(A) Time course plot for increasing concentration of
octanal, an agonist of the OR-I7 receptor. (B) Time
course plot for increasing concentration of
cyclohexylethanal (2.2), an antagonist of OR-I7. (C)
Time course plot for 5 µM octanal co-applied with
increasing concentration of 2.2. The average response
between 3.5 min and 7 min (between dashed lines) was
used to create a dose-response curve, shown on Figure
2.12 and 2.13. (Data was provided by Jianghai Ho,
Matsunami lab.)

C

The compounds were tested individually for agonist activity. If the compound is an
agonist of the OR-I7 receptor, such as octanal, there would be an increase in response as the
concentration of the odorant increased (Figure 2.11A). If the compound is not an agonist of ORI7, such as 2.2, which is an antagonist of the receptor, there would be no change in the relative
response as a function of concentration (Figure 2.11B). However, when an agonist is co-applied
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with an antagonist, the response of the agonist is suppressed as the concentration of the
antagonist increase (Figure 2.11C).
2.3.2. Inhibition of OR-I7
A

B

C
Structures

Compound

Relative
IC50 (µM)

2.1

150

2.3

32

2.4

94

2.5

150

2.6

140

2.7

6.5

Figure 2.12: Response of analogues 2.1, 2.3, 2.4, 2.5,
2.6 and 2.7. (A) Activation Dose-Response Curves.
Each compound was applied to HEK293 cells
expressing mouse OR-I7. The cAMP production was
monitored and the average response between 3 and 7.5
min is shown versus the compound’s concentration.
The responses were compared to that of octanal, a
known agonist of OR-I7. (B) Inhibition Dose-Response
Curves. Each set of compounds was tested for the
ability to antagonize mouse OR-I7. Cells were treated
with varying concentrations of the synthesized
compounds co-applied with 5 µM of octanal. (C) IC50
values generated from the dose-response curves. (Data
was provided by Jianghai Ho, Matsunami lab.)

Aside from octanal, and consistent with previous findings on aliphatic aldehyde shorter
than 7 Å,2 none of the compounds showed any activity as an agonist up to 100 µM (Figures
2.12A, 2.13A, and 2.14A). Since the compounds are all shorter than 6.5-6.9 Å, they should not
be long enough to reach the proposed binding pocket required for activation.
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A

B

C
Structures

Compound

Relative
IC50 (µM)

2.2

0.82

2.7

0.37

2.8

9.1

2.9

13

2.12

1.0

Figure 2.13: Response of analogues 2.2, 2.7, 2.8, 2.9,
and 2.12. (A) Activation Dose-Response Curves. Each
compound was applied to HEK293 cells expressing
mouse OR-I7. The cAMP production was monitored
and the average response between 3 and 7.5 min is
shown versus the compound’s concentration. The
responses were compared to that of octanal, a known
agonist of OR-I7. (B) Inhibition Dose-Response
Curves. Each set of compounds was tested for the
ability to antagonize mouse OR-I7. Cells were treated
with varying concentrations of the synthesized
compounds co-applied with 5 µM of octanal. (C) IC50
values generated from the dose-response curves. (Data
was provided by Jianghai Ho, Matsunami lab.)

2.3.3. Effect of carbon numbers on antagonism
All of the tested odorants antagonized the response of octanal to some extent (Figure
2.12, 2.13, & 2.14), but there does not appear to be any apparent correlation between the number
of carbons in the mid-region and the antagonist’s potency. In Set A (i.e. compounds on Figure
2.12), there was an improvement in potency after adding one carbon from 2.1 (IC50=150 µM) to
2.3 (IC50=32 µM), but the potency decreased as more carbons were added onto 2.4, 2.5, and 2.6.
In Set B (i.e. compounds on Figure 2.13), the activities of 2.7 (IC50=0.37 µM) and 2.12 (IC50=1.0
µM) were comparable to that of 2.2 (IC50=0.82 µM), but the additional carbons on the rings of
2.7 and 2.12 did not significantly improve the activity compared to 2.2. Analogues 2.8 and 2.9,
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with 1 and 2 extra carbons on the ring, were weaker antagonists than 2.2. Similarly, the
analogues (2.10 and 2.11) in Set C (i.e. compounds on Figure 2.14), which contained 1 or 3 more
carbons on the ring compared to 2.2, have weaker antagonist potency than 2.2.
A

B

C

Figure 2.14: Response of analogues 2.2, 2.10, and 2.11.
(A) Activation Dose-Response Curves. Each compound
was applied to HEK293 cells expressing mouse OR-I7.
The cAMP production was monitored and the average
response between 3 and 7.5 min is shown versus the
compound’s concentration. The responses were
compared to that of octanal, a known agonist of OR-I7.
(B) Inhibition Dose-Response Curves. Each set of
compounds was tested for the ability to antagonize
mouse OR-I7. Cells were treated with varying
concentrations of the synthesized compounds co-applied
with 5 µM of octanal. (C) IC50 values generated from the
dose-response curves. (Data was provided by Jianghai
Ho, Matsunami lab.)

Structures

Compound

Relative
IC50 (µM)

2.2

0.41

2.10

7.9

2.11

13

2.3.4. Effect of cyclic ring on strength of antagonism
Adding more carbons to the mid-region did not improve the antagonists’ activity, but the
cyclic aldehydes appeared to have higher potency than the acyclic aldehydes. The acyclic
aldehydes (2.1, 2.3, 2.4, 2.5, and 2.6) in Set A, showed weaker antagonist activity than the 2.2.2bicyclic aldehyde, 2.7. The improvement in activity from 2.1 (IC50=460 µM) to 2.2 (IC50=45
µM) for the rat OR-I7 in the previous study2 might also result from this change from a linear to a
cyclic system.
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2.3.5. Effect of protruding groups on antagonism
The reintroduction of acyclic groups onto the cyclohexyl ring system, such as the methyl
group on 2.8 and the ethyl group on 2.9, resulted in lower activity compared to 2.2, which
contains no groups on its ring. The acyclic groups, which aren’t long enough to reach the
activation pocket, might be clashing sterically with amino acid residues lining the binding site of
the receptor, and thus interfere with binding or interactions within the mid-region. In Set B
(Figure 2.13), 2.7 and 2.9 both contain the same number of carbons, but having the ethyl group
of 2.9 “tied back” onto the bicyclic ring of 2.7, may possibly prevent it from sterically clashing
with amino acid residues. In Set C, 2.11 (IC50=13 µM), containing the two methyl groups on the
ring system, have weaker activities compared to the other compounds tested in this set, 2.10
(IC50=7.9 µM) and 2.2 (IC50=0.41 µM). Ring systems that contain a globular shape, such as 2.2
(IC50=0.82 µM), 2.7 (IC50=0.37 µM) and 2.12 (IC50=1.0 µM), have the highest antagonist
potency in this experiment, followed by 2.10 (IC50=7.9 µM).
2.3.6. Effect of orientation
Out of the four aldehydes containing rigid, cyclic systems (2.2, 2.7, 2.10, and 2.12), 2.10
was the least potent antagonist of OR-I7. Compound 2.10 was ~8 to 20 times less potent than the
other aldehydes containing a globular structure and no protruding groups. To search for a
possible explanation for this difference, the four globular aldehydes were each modeled in their
most stable conformation (Figure 2.15). The orientations of the aldehydes in the receptor pocket
may have some influence on the potency of the antagonists. Comparing the orientations of the
four aldehydes, the ring systems for 2.2, 2.7, and 2.12 are all situated downwards from the
aldehyde group, whereas the ring for 2.10 is projected out of the page, sideways to the aldehyde
group. In effect, the cyclohexyl rings of 2.2, 2.7, and 2.12, may all be seen as a full hexagonal
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shape on the model (Figure 2.15) with the aldehyde group placed at the same position, whereas
the cyclohexyl ring of 2.10 is contracted by the 2.2.1-bridgehead to form the cyclopentyl rings.
The ring system of 2.10 contained a mix of cyclohexyl and cyclopentyl rings, while 2.2, 2.7, and
2.12, all consisted only of cyclohexyl ring(s). The cyclopentyl ring on 2.10 may be less
preferable for the OR-I7 receptor or the particular orientations resulting from the different ring
systems led to interactions with different residues on the receptor modulating the antagonists’
stability. The smaller ring system in compound 2.11 may also share this problem.

Length (Å)
IC50 (µM)

2.2

2.7

2.10

2.12

5.4
0.82

5.0
0.37

4.9
7.9

5.4
1.0

Figure 2.15: 3D Structural models of 2.2, 2.7, 2.10, and 2.12. The structures of the aldehydes were drawn in their
most extended conformation. The energy was minimized using MM2 on ChemBio3D Ultra 12.0. The length was
measured from the carbonyl carbon to the furthest carbon (highlighted in yellow). The structures were oriented with
the aldehyde group at the same position.

2.3.7. Effect of antagonist’s size
The size of the antagonist occupying the mid-region of the receptor appears to have
minimal effect on the potency of the compound. The switch from the small cyclohexyl ring of
2.2 to the larger adamantyl ring of 2.12 resulted in similar IC50 values (2.2: 0.82 µM; 2.12: 1.0
µM). Large groups in the mid-region may be tolerated but not necessary for antagonizing the
receptor, since 2.2 with a smaller ring system is just as potent as 2.12. Likewise, while the
protruding groups of 2.8 and 2.9 may be a source of interference, they did not entirely prevent
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Pentanal (2.1)
IC50 = 150 µM

2.6
IC50 = 140 µM

2.9
IC50 = 13 µM

2.2
IC50 = 0.82 µM

Figure 2.16: Homology model of the mouse OR-I7
receptor bound by selected antagonists. Homology
model is based on the inactive β2-adrenergic receptor.
The antagonists are colored orange (carbons) and red
(oxygen). Possible interactions with amino acid residues
are indicated by dashed lines. (Models were provided by
the Batista lab.)

2.7
IC50 = 0.37 µM
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the molecules from binding to and antagonizing the response of the receptor. The mid-region
seems able to accommodate a wide variety of compact organic ring systems, and as long as they
do not extend beyond 7 Å, they remain antagonists and do not activate the receptor.
2.3.8. Homology model of the mouse OR-I7 receptor bound by selected antagonists
To better evaluate the interactions between the designed antagonists and the OR-I7
receptor, homology models were constructed with the antagonists bound to the receptor. (Models
were constructed by another collaborator, Victor Batista, at Yale University.) Correlating the
antagonist’s IC50 value with its optimal position in the receptor pocket may aid in explaining the
observed differences between the potency of the tested antagonists. As shown on Figure 2.16, the
two weaker OR-I7 antagonists, pentanal (2.1) and 2.6 are predicted to form a H-bond with the
Tyr257 residue, whereas the stronger antagonists, 2.9 (~10X as potent) and 2.2 (>100X as
potent), are predicted to form a H-bond with the Lys164 residue. Thus, interaction with the
Lys164 residue appears to improve the antagonists’ potency. In previous homology models,
agonists of the OR-I7 receptor, including octanal, were also found to interact with the Lys164
residue.5 However, in another model, the gem-diol form of octanal, which was expected to form
when octanal becomes hydrated in water, prefers to interact with the Tyr257 residue possibly
through hydrogen bonding, and based on interaction energy calculations, the gem-diol is better
accommodated (by 2-6 kcal/mol) in the OR-I7 receptor than the aldehyde.12 As a result, the
agonist, octanal, could potentially H-bond with either the Lys164 residue or the Tyr257 residue
via the gem-diol form.
In order to antagonize the response of octanal, the antagonist needs to compete with
octanal for the binding site. When comparing the IC50 values of the weaker antagonists (2.1 and
2.6) and the stronger antagonists (2.2 and 2.9) with the residues to which they are interacting
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with in the homology model (Figure 2.16), binding with the Lys164 residue appears more
effective in inhibiting the response of octanal than binding with the Tyr257 residue. But
conversely, the most potent antagonist, 2.7, interacts with the Tyr257 residue instead of the
Lys164 residue. If interaction with the Tyr257 residue is indeed less favorable compared to the
Lys164 residue, then the 2.2.2-bicyclic ring of 2.7 may possibly be stabilizing the molecule
through additional van der Waals interactions, or the extra interaction with the Ser260 residue,
not seen for the other modeled antagonists, may be further strengthening the binding. Otherwise,
binding to either residue may be just as effective in antagonizing the response of the OR-I7
receptor, since the agonist, octanal, could bind at either residue.12,

13

The results may also

indicate that ligands can tumble in the orthosteric binding pocket.
Based on the homology models (Figure 2.16), by increasing the carbons in the midregion, not only the size of the molecules differs, but the orientations of the molecule in the
receptor pocket also shifted to accommodate the extra carbons. For instance, 2.2, 2.7, and 2.9 all
contain a cyclohexyl ring within their structure, but the ring is oriented at different positions for
the three molecules. Thus, while the aldehyde group on the antagonists were only seen to bind
onto one of two residues, the hydrophobic portion of the molecule are all involved in fairly
diverse interactions due to the differences in their orientations, which may affect the stability of
the antagonists in the receptor.
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2.3.9. Attempt to synthesize 2.13
A

2.2

1.1

2.7

2.13

B

Binding Site

Mid-Region

< 6.5 Å

Activation
Pocket
Length (Å)
EC50 (µM)
IC50 (µM)

~6.5-6.9 Å

5.4
0.82

7.3-7.9
(1.0)
-

5.0
0.37

Front View
Side View
3D model of 2.13 overlapping with 1.1
(as the trans-isomer in the chair
conformation)

7.5
?
?

Figure 2.17: Agonists and antagonists of the OR-I7 receptor. (A) Structures of agonists and antagonists of the ORI7 receptor. Chain lengths are calculated on ChemBio3D Ultra 12.0. EC50 values were obtained from calcium
imaging of rat OR-I7.2 IC50 values were obtained from cAMP detection assay of mouse OR-I7. (B) 3D model of
2.13 (carbons: purple, oxygen: blue) overlapping with the trans-isomer of 1.1 (carbons: gray, oxygen: red) in the
chair conformation.

The 2.2.2-bicyclo aldehyde 2.7 was the only antagonist found to be slightly more potent
than the original cyclohexyl aldehyde 2.2. Attaching an ethyl group onto 2.2, so that the chain
length exceeds 7 Å (forming 1.1 in chapter 1), transforms 2.2 from an antagonist to an agonist of
OR-I7.2 Similarly, attachment of an ethyl group onto the ring of 2.7 (forming 2.13, Figure
2.17A) may switch antagonist 2.7 into an agonist. Since 2.7 is a better antagonist than 2.2, 2.13
may also be a better agonist than 1.1.
As speculated in chapter 1, the cis-isomer 1.2 may be activating the OR-I7 receptor in the
twist-boat conformation. In this conformation, the position of the ethyl group on the cis-isomer
1.2 is closer to the position of the ethyl group on the trans-isomer 1.3. However, there would be
an energy barrier to convert the cis-isomer 1.2 from the chair conformation to the less favorable
twist-boat conformation. One way to reduce the energy barrier is to pay the cost during synthesis
by locking the cis-isomer (1.2) in the boat conformation using a 2.2.2-bicyclic ring, resulting in
2.13. The position of the ethyl group on 2.13 is closer to the position of the ethyl group on the
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trans-isomer (1.3) (Figure 2.17B). There will be no conformational flexibility in the mid-region,
and the aldehyde and ethyl groups should be locked in what we speculate would be a favorable
geometric relationship for OR-I7 binding.
As an extension to this study, we attempted to synthesize compound 2.13 for analysis.
Compound 2.13 would test for whether the extension of the length of 2.7 would transform the
molecule from an inhibitor to an activator of the OR-I7 receptor, and the potency of 2.13 would
give us feedback as to whether the cis-isomer 1.2 (in chapter 1) activates the OR-I7 receptor in
the boat conformation. Our prediction is that despite the boat conformation in this ring system,
the compound should be just as potent as the trans-isomer (1.3). Compound 2.13 is not
commercially available and has never been synthesized before, but there are literature procedures
for the synthesis of similar molecules, such as 2.13a (Scheme 2.6).14, 15 The alkene 2.13a, had
been synthesized from the dialdehyde 2.13b via a Wittig reaction, and 2.13b had been
synthesized from the alcohol 2.13c through oxidation (Scheme 2.6A and 2.6B).
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A

Once

2.13a

synthesized,

is

there

are

various ways to transform
2.13a

to

2.13.

For

instance, 2.13a could be

B

subjected

to

a

hydroboration-oxidation
to functionalize both or
either one of the alkenes

C

into hydroxyl group(s)
resulting in 2.13d and/or
2.13e

(Scheme

2.6C).

The remaining alkene on
2.13e could be reduced to
form 2.13g, and oxidation
of the hydroxyl group of
2.13g would give the
product
Scheme 2.6: Synthesis of 2.13. (A) Retrosynthesis of 2.13. (B) Synthesis route
for 2.13a. (C) Synthesis route for 2.13 from 2.13a. Reactions that are found in the
literature are indicated by solid arrows and proposed reactions are indicated by
dashed arrows.

2.13d,

2.13.
one

From
of

the

hydroxyl groups could be
reacted to an alkyl group

through a deoxygenation reaction or by reduction of the tosylate 2.13f to arrive at 2.13g, which
could then be oxidized to the aldehyde 2.13.
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A. Route 1

B. Route 2

C. Route 3

Scheme 2.7: Synthetic routes to arrive at 2.13c. Reactions that are found in the literature are indicated by solid
arrows and proposed reactions are indicated by dashed arrows.
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Before arriving at 2.13a, it is necessary to first synthesize 2.13c (available from
commercial sources at ~$1000/5g). Once compound 2.13c is obtained, it could be used to
synthesize 2.13a, and from 2.13a, the desired product 2.13 could be synthesized. A few possible
routes have been found in the literature to synthesize 2.13c (Scheme 2.7). The first route
(Scheme 2.7A) is the scheme originated by Holtz et. al. to synthesize 2.13c from diethyl
succinate.16 The second route (Scheme 2.7B) follows the scheme used by Della et. al. to
synthesize 2.13o from dimethyl cyclohexane-1,4-dicarboxylate.17 This route can also be used to
synthesize compound 2.14 (this structure was first suggested by Dr. Ryan Murelli) from 2.14a,
which would also be effective in locking the cis-isomer (1.2) in the boat conformation via the
2.2.1-bicyclo ring.

Retrosynthesis of compound 2.14 from 2.14a

The third route (Scheme 2.7C) is based on the scheme used by Chapman et. al. to synthesize
2.13o from cyclohexane-1,4-dicarboxylic acid.18 The ester 2.13o could afterwards be reduced to
the alcohol 2.13c.
At present, routes 1 and 2 have been attempted to synthesize 2.13c at reduced scale in our
lab. For both routes, difficulties occurred during the step to produce the 2.2.2-bicyclic ring
(Route 1: 2.13i, Route 2: 2.13o). Following both procedures (at reduced scale), multiple products
formed from the reaction (based on TLC and 1H NMR).
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Scheme 2.8: Possible transition state from 2.13n to 2.13o.

The challenge in forming the 2.2.2-bicyclic ring may mainly arise from a slow intramolecular
substitution reaction. To form the 2.2.2-bicyclic ring, the intermediate would need to shift from
the chair conformation to the sterically hindered, less stable, boat conformation (Scheme 2.8).
Meanwhile, the elimination side-products could form and intermolecular reactions could occur
between the intermediates/side products.
The scale of the reaction may also be affecting the yield. Literature procedures16, 17, 19
usually perform these reactions at multi-gram scale, whereas these reactions have only been
attempted in our lab at small scale. Some steps in the reactions involve keeping the temperature
of the reaction stabilized and crystallization of the product. At the larger scale it would be easier
to maintain the temperature of the reaction as well as promote the formation of crystals.
2.4.

Conclusions
Several aldehyde analogues with chain lengths shorter than 6.5 Å were synthesized. None

of these aldehydes can activate the OR-I7 receptor. This was in accordance with previous
studies2 suggesting that the distance from the aldehyde group to the most distant carbon needs to
be more than 6.9 Å in order to bridge two important contact points or pockets. The synthesized
short aldehydes all inhibited the response of octanal, demonstrating that the aldehydes could
compete with octanal for the binding site. The tested acyclic odorants (2.1, 2.3, 2.4, 2.5, and 2.6)
have weaker antagonist potency than the compact, unbranched cyclic odorants (specifically 2.7),
and cyclic odorants that contained acyclic, protruding groups (2.8, 2.9, and 2.11) were weaker
antagonist than the rigid, cyclic odorants (2.2, 2.7, and/or 2.12). The OR-I7 receptor appears to
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prefer rigid, cyclic groups in the mid-region, but all twelve of the synthesized odorants could
antagonize the response of octanal to some extent (IC50=0.37 µM to 150 µM), suggesting that the
mid-region accommodates aldehydes of different shapes and sizes. To summarize, the response
of the OR-I7 receptor could be inhibited by odorants containing an aldehyde functional group,
with an extended conformation of less than 6.9 Å, and preferably a rigid, cyclic structure.
Although the tested odorants were all aldehydes with chain lengths shorter than 6.5 Å, they differ
in many aspects, such as structural conformation, size, and flexibility. Yet, they were all able to
antagonize the OR-I7 receptor. It has been established that each olfactory receptor can be
activated by multiple odorants, and each odorant activates multiple receptors, but it’s noteworthy
that as with OR-I7, each receptor may also be antagonized by multiple odorants. Similarly, since
each odorant could activate multiple olfactory receptors, they may also be antagonizing multiple
olfactory receptors, as part of their contribution to the olfactory code.
2.5.

Experimental Procedures

Unless otherwise stated, chemical reagents and solvents were purchased from VWR
International, Fisher Scientific, or Sigma Aldrich and used without further purification. CD293
medium was purchased from Life Technologies. Tetrahydrofuran (THF) was dried prior to use.
Octanal and pentanal (2.1) were freshly distilled. Aldehydes were stored as a DMSO solution at
4°C in flame-sealed ampules under vacuum prior to testing. Analytical TLC was performed on
silica gel 60 F254 plates. Flash chromatography20 was performed on Teledyne Isco CombiFlash
Rf-200 flash chromatography system. Melting points were measured on a Laboratory Devices
Mel-Temp apparatus. 1H and

13

C NMR spectra were recorded on a Varian Mercury 300

spectrometer or a Bruker Ultrashield 500 spectrometer. HRMS was performed by Dr. Lijia Yang
(CCNY Chemistry Department staff) on a Waters LCT XE (TOF) mass spectrometer using
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electrospray ionization (ESI). Infrared (IR) spectra were recorded using Thermo Nicolet 6700
FT-IR spectrometer. GC/MS analysis was performed on Shimadzu GCMS QP-2010. (Note: The
literature procedure that was applied for each reaction is cited. The procedure may not
necessarily be used for the synthesis of the same compound as in the literature.)
General Procedure for Lithium Aluminum Hydride (LAH) reduction2
The acid or ester (1 equiv.) in diethyl ether was added slowly to lithium aluminum hydride (1.1
equiv.) in diethyl ether at 0°C. The suspension was stirred at room temperature for 2-3 h and then
cooled to 0°C. Water (1 mL per g of LAH) was added, followed by 15% sodium hydroxide (1
mL per g of LAH) and water (3 mL per g of LAH). The solution was stirred for a few minutes at
room temperature, filtered through a celite pad, washed with diethyl ether, dried, and
concentrated to give the alcohol. Flash chromatography was sometimes required to purify the
product.
General Procedure for Pyridinium chlorochromate (PCC) oxidation2
The alcohol (1 equiv.) was added to pyridinium chlorochromate (1.1 equiv.) and silica gel (1 g/g
of PCC) in dry dichloromethane under inert atmosphere. The suspension was stirred for 2 h and
then passed through a silica gel pad. The solution was concentrated to give the aldehyde. Flash
chromatography or distillation was sometimes required to purify the product.
General Procedure for Hydrogenation Reaction2
The alkene was hydrogenated in ethyl acetate with a catalytic amount of Pd/C for 3 h using a
balloon filled with hydrogen gas. The solution was filtered through celite and concentrated to
give the alkane.
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2-Cyclohexylethanol (2.2a). Ethyl cyclohexylacetate (2 g, 11.7 mmol) was LAH
reduced according to the general procedure to obtain the alcohol 2.2a (1.5 g, 11.7
mmol) as a clear liquid in 99% yield. 1H NMR (CDCl3) δ: 3.68 (t, J = 6.7 Hz, 2H),
1.78 - 1.59 (m, 5H), 1.51 - 1.11 (m, 7H), 1.02 - 0.84 (m, 2H). 13C NMR (CDCl3) δ: 60.89, 40.39,
34.22, 33.38, 26.57, 26.29. IR (thin film, KBr plates) ν (cm-1): 3332 (broad), 2922, 2852, 1448,
1051, 1011, 978. Spectral data match those reported previously.2
Cyclohexylacetaldehyde (2.2). Compound 2.2a (200 mg, 1.56 mmol) was PCC
oxidized according to the general procedure to obtain the aldehyde 2.2 (140 mg, 1.11
mmol) as a clear liquid in 71% yield. 1H NMR (CDCl3) δ: 9.75 (s, 1H), 2.29 (dd, J =
1.9, 6.9 Hz, 2H), 1.97 - 1.57 (m, 6H), 1.40 - 0.84 (m, 5H). 13C NMR (CDCl3) δ: 203.00, 51.38,
33.22, 32.68, 26.04, 25.97. IR (thin film, KBr plates) ν (cm-1): 2925, 2853, 2712, 1725, 1449,
1408, 1297, 1193, 1020, 900. Spectral data match those reported previously.2
3-Methylpentanal (2.3). 3-Methyl-1-pentanol (2 g, 19.6 mmol) was PCC oxidized
according to the general procedure. The product was purified by distillation to give 2.3
(450 mg, 4.5 mmol) as a clear liquid in 23% yield as a mixture of stereoisomers. 1H
NMR (CDCl3) δ: 9.80 - 9.72 (m, 1H), 2.46 - 2.31 (m, 1H), 2.21 (ddd, J = 2.5, 7.8, 16.1 Hz, 1H),
1.97 (qd, J = 6.8, 13.3 Hz, 1H), 1.45 - 1.17 (m, 2H), 1.02 - 0.78 (m, 6H). 13C NMR (CDCl3) δ:
203.19, 50.69, 29.74, 29.51, 19.52, 11.30. IR (thin film, KBr plates), ν (cm-1): 2964, 2932, 2878,
2822, 2717, 1728, 1463, 1381, 1209, 1141, 1021, 946, 875, 776. Spectral data match those
reported previously.21-23
Ethyl 3-ethylpent-2-enoate (2.4a). Compound 2.4a was synthesized according
to a literature procedure.6 Triethyl phosphonoacetate (7.8 g, 34 mmol) in THF
(12.5 mL) was slowly added to sodium hydride, 57-63% in oil, (1.4 g, 34
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mmol) in THF (10 mL) at 0°C. The suspension was stirred for 1 h and then 3-pentanone (3 g, 34
mmol) in THF (12.5 mL) was slowly added. The solution was stirred for an hour and quenched
with water. The solution was extracted with diethyl ether, and the organic layer was dried and
concentrated. The crude was purified by flash chromatography eluting with hexanes/diethyl ether
(99:1) to give 2.4a (1.58 g, 10.1 mmol) as a yellowish liquid in 29% yield. 1H NMR (CDCl3) δ:
5.59 (s, 1H), 4.14 (q, J = 6.7 Hz, 2H), 2.61 (q, J = 7.4 Hz, 2H), 2.18 (q, J = 7.4 Hz, 2H), 1.27 (t,
J = 6.6 Hz, 3H), 1.06 (t, J = 7.4 Hz, 6H).

13

C NMR (CDCl3) δ: 167.30, 166.65, 113.71, 59.44,

30.74, 25.44, 14.33, 13.04, 12.02. IR (thin film, KBr plates) ν (cm-1): 2972, 2936, 2877, 1717,
1645, 1463, 1380, 1307, 1273, 1205, 1148, 1105, 1040, 868. Spectral data match those
previously reported.24
Ethyl 3-ethylpentanoate (2.4b). Compound 2.4a (1.48 g, 9.47 mmol) was
hydrogenated according to the general procedure to give 2.4b (1.35 g, 8.53
mmol) as a clear liquid in 90% yield. 1H NMR (CDCl3) δ: 4.12 (q, J = 7.1 Hz,
2H), 2.22 (d, J = 6.9 Hz, 2H), 1.74 (p, J = 6.4 Hz, 1H), 1.42 - 1.18 (m, 7H), 0.87 (t, J = 7.4 Hz,
6H).

13

C NMR (CDCl3) δ: 173.76, 60.08, 38.56, 37.93, 25.85, 14.28, 10.82. IR (thin film, KBr

plates) ν (cm-1): 2962, 2926, 2857, 1738, 1461, 1374, 1178, 1097, 1034. Spectral data match
those previously reported.25
3-Ethylpentan-1-ol (2.4c). Compound 2.4b (1.25 g, 7.9 mmol) was LAH reduced
according to the general procedure and purified by flash chromatography eluting with
hexanes/ethyl acetate (49:1) to give 2.4c (480 mg, 4.13) as a clear liquid in 52%
yield. 1H NMR (CDCl3) δ: 3.64 (t, J = 7.2 Hz, 2H), 1.93 - 1.63 (br. s., 1H), 1.63 - 1.40 (m, 2H),
1.29 (d, J = 5.5 Hz, 5H), 0.84 (t, J = 6.9 Hz, 6H).
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13

C NMR (CDCl3) δ: 61.37, 37.08, 36.11,

25.50, 10.78. IR (thin film, KBr plates), ν (cm-1): 3331 (broad), 2961, 2925, 2874, 1461, 1379,
1062.
3-Ethylpentanal (2.4). Compound 2.4c (100 mg, 0.875 mmol) was PCC oxidized
according to the general procedure to obtain 2.4 (32 mg, 0.280 mmol) as a clear liquid
in 33% yield. 1H NMR (CDCl3) δ: 9.77 (t, J = 2.3 Hz, 1H), 2.33 (dd, J = 2.5, 6.6 Hz,
2H), 1.84 (td, J = 6.5, 12.8 Hz, 1H), 1.46 - 1.25 (m, 4H), 0.88 (t, J = 7.4 Hz, 6H).

13

C NMR

(CDCl3) δ: 203.43, 47.84, 35.88, 26.15, 10.92. IR (thin film, KBr plates), ν (cm-1): 2964, 2935,
2878, 2714, 1727, 1461, 1412, 1382, 1337, 1246, 1136, 1096, 1021.
Ethyl

2-cyano-3-ethylpent-2-enoate

(2.5a).

Compound

2.5a

was

synthesized based on a literature procedure.7 Ethyl cyanoacetate (56.5 g, 0.5
mol), 3-pentanone (51.7 g, 0.6 mol), ammonium acetate (3.85 g, 0.05 mol),
and acetic acid (6 g, 0.1 mol) were added to benzene (50 mL) in a round bottom flask connected
to a Dean-Stark apparatus. The solution was refluxed for 6 h and then washed three times with
water. The organic layer was dried and concentrated. The product was purified by distillation to
give 2.5a (58.5 g, 0.32 mol) as a clear liquid in 64.6% yield. 1H NMR (CDCl3) δ: 4.26 (q, J = 7.2
Hz, 2H), 2.78 (q, J = 7.4 Hz, 2H), 2.57 (q, J = 7.4 Hz, 2H), 1.34 (t, J = 7.2 Hz, 3H), 1.13 (t, J =
7.4 Hz, 3H), 1.19 (t, J = 7.7 Hz, 3H). 13C NMR (CDCl3) δ: 184.19, 161.70, 115.62, 104.01,
61.68, 31.40, 26.51, 14.08, 12.65, 12.38. IR (thin film, KBr plates), ν (cm-1): 2981, 2941, 2879,
2223, 1731, 1602, 1465, 1368, 1245, 1270, 1211, 1099, 1022, 912, 857, 817.
Ethyl 2-cyano-3-ethyl-3-methylpentanoate (2.5b). Compound 2.5b was
synthesized based on literature procedures.8,

26

Iodomethane (11.3 g, 80

mmol) in diethyl ether (10 mL) was slowly added to magnesium turnings
(1.83 g, 76 mmol) in diethyl ether (10 mL) at 0°C and the solution was stirred for 30 minutes.
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Copper chloride (100 mg, 1 mmol) was added, and 2.5a (9.06 g, 50 mmol) in diethyl ether (10
mL) was slowly added. The solution was stirred for 30 minutes and then added to 10% sulfuric
acid (40 mL) in ice (50 g). The aqueous phase was extracted three times with diethyl ether. The
combined organic layer was dried and concentrated. The resulting residue was purified by flash
chromatography eluting with hexanes/ethyl acetate (9:1) to give 2.5b (4.3 g, 21.8 mmol) as a
clear liquid in 43.6% yield. 1H NMR (CDCl3) δ: 4.32 - 4.20 (m, 2H), 3.45 (s, 1H), 1.64 - 1.39
(m, 4H), 1.39 - 1.22 (m, 3H), 1.08 (s, 3H), 0.98 - 0.82 (m, 6H). 13C NMR (CDCl3) δ: 165.57,
116.22, 62.32, 46.26, 40.47, 29.60, 28.91, 21.79, 14.06, 7.90, 7.75. IR (thin film, KBr plates), ν
(cm-1): 2972, 2884, 2247, 1742, 1465, 1389, 1369, 1328, 1244, 1192.
3-Ethyl-3-methylpentanenitrile (2.5d). Compound 2.5d was synthesized based on a
literature procedure.8 Compound 2.5b (4 g, 20 mmol) was added to a solution
containing 85% potassium hydroxide (5.8 mL), water (25.4 mL), and ethanol (5
mL). The solution was refluxed for 6 h and then concentrated. The resulting residue was refluxed
for 4 h in 20% sulfuric acid (31 mL). The solution was cooled to room temperature and extracted
with diethyl ether. The organic layer was dried and concentrated. A catalytic amount of copper
powder (70 mg) was added to the resulting residue (2.5c) and the suspension was slowly heated
to 170°C. The suspension was then allowed to cool back to room temperature and was purified
by flash chromatography, eluting with hexanes/ethyl acetate (19:1) to give 2.5d (1.26 g, 10.1
mmol) as a yellowish liquid in 50% yield. 1H NMR (CDCl3) δ: 2.20 (s, 2H), 1.40 (q, J = 7.2 Hz,
4H), 0.98 (s, 3H), 0.84 (t, J = 7.6 Hz, 6H). 13C NMR (CDCl3) δ: 118.57, 35.68, 30.88, 27.65,
23.65, 7.95. IR (thin film, KBr plates), ν (cm-1): 2969, 2941, 2883, 2243, 1463, 1425, 1385.
3-Ethyl-3-methylpentan-1-ol (2.5f). Compound 2.5d was hydrolyzed based on a
literature procedure.27 Compound 2.5d (1.1 g, 8.8 mmol) was refluxed in a solution
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with sulfuric acid (8.1 mL) and water (9.8 mL) for 6 h. The solution was cooled to room
temperature, diluted with water, and extracted with diethyl ether. The organic layer was dried
and concentrated. The resulting residue 2.5e was LAH reduced according to the general
procedure and purified by flash chromatography eluting with hexanes/ethyl acetate (9:1) to give
2.5f (650 mg, 5 mmol) as a clear liquid in 56.8% yield. 1H NMR (CDCl3) δ: 3.77 - 3.57 (m, 2H),
1.90 (s, 1H), 1.75 - 1.38 (m, 2H), 1.38 - 1.02 (m, 4H), 1.02 - 0.66 (m, 9H). 13C NMR (CDCl3) δ:
59.50, 41.12, 34.46, 31.36, 24.23, 7.89. IR (thin film, KBr plates) ν (cm-1): 3333 (broad), 2963,
2938, 2880, 1463, 1380.
3-Ethyl-3-methylpentanal (2.5). Compound 2.5f (100 mg, 0.77 mmol) was PCC
oxidized according to the general procedure to give 2.5 (58 mg, 0.45 mmol) in 59%
yield. 1H NMR (CDCl3) δ: 9.84 (t, J = 3.3 Hz, 1H), 2.24 (d, J = 3.3 Hz, 2H), 1.38 (q, J
= 7.4 Hz, 4H), 1.00 (s, 3H), 0.85 (t, J = 7.4 Hz, 6H). 13C NMR (CDCl3) δ: 204.05, 52.00, 36.33,
31.81, 24.33, 7.91. IR (thin film, KBr plates), ν (cm-1): 2967, 2882, 2732, 1721, 1463, 1382.
HRMS (ESI) [M+H]+: Calcd for C8H16O m/z = 129.1274, found m/z = 129.1266.
Ethyl

2-cyano-3,3-diethylpentanoate

(2.6b).

synthesized based on literature procedures.8,

26

Compound

2.6b

was

Bromoethane (8.7 g, 80

mmol) in diethyl ether (10 mL) was slowly added to magnesium turnings
(1.83 g, 76 mmol) in diethyl ether (10 mL) at 0°C and the solution was stirred for 30 minutes.
Copper chloride (100 mg, 1 mmol) was added, and 2.5a (9.06 g, 50 mmol) in diethyl ether (10
mL) was slowly added. The solution was stirred for 30 minutes and then added to 10% sulfuric
acid (40 mL) in ice (50 g). The aqueous phase was extracted three times with diethyl ether. The
combined organic layer was dried and concentrated. The resulting residue was purified by flash
chromatography eluting with hexanes/ethyl acetate (9:1) to give 2.6b (4.45 g, 21.1 mmol) as a
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clear liquid in 42% yield. 1H NMR (CDCl3) δ: 4.31 - 4.20 (m, 2H), 3.49 - 3.43 (m, 1H), 1.65 1.41 (m, 6H), 1.38 - 1.25 (m, 3H), 0.99 - 0.84 (m, 9H). 13C NMR (CDCl3) δ: 165.74, 116.67,
62.32, 44.43, 43.12, 27.59, 13.98, 7.90. IR (thin film, KBr plates), ν (cm-1): 2972, 2944, 2885,
2246, 1741, 1602, 1459.
3,3-Diethylpentanenitrile (2.6d). Compound 2.6d was synthesized according to a
literature procedure.8 Compound 2.6b (4.2 g, 20 mmol) was added to a solution
containing 85% potassium hydroxide (6.1 mL), water (26.7 mL), and ethanol (5.25
mL). The solution was refluxed for 6 hours and then concentrated. The resulting residue was
refluxed for 4 h in 20% sulfuric acid (32.6 mL). The solution was cooled to room temperature
and extracted with diethyl ether. The organic layer was dried and concentrated. A catalytic
amount of copper powder (80 mg) was added to the resulting residue (2.6c) and the suspension
was slowly heated to 170°C. The suspension was then allowed to cool back to room temperature
and was purified by flash chromatography, eluting with hexanes/ethyl acetate (19:1) to give 2.6d
(1.32 g, 9.5 mmol) as a yellowish liquid in 47% yield. 1H NMR (CDCl3) δ: 2.19 (s, 2H), 1.44 1.31 (m, 6H), 0.82 (t, J = 7.4 Hz, 9H). 13C NMR (CDCl3) δ: 118.49, 38.10, 27.87, 24.80, 7.54. IR
(thin film, KBr plates), ν (cm-1): 2968, 2943, 2882, 2245, 1735, 1461, 1425, 1383.
3,3-Diethylpentan-1-ol (2.6f). Compound 2.6d was hydrolyzed according to a
literature procedure.27 Compound 2.6d (1.1 g, 7.9 mmol) was refluxed in a solution
of sulfuric acid (8.1 mL) and water (9.8 mL) for 6 h. The solution was cooled to
room temperature, diluted with water, and extracted with diethyl ether. The organic layer was
dried and concentrated. The resulting residue 2.6e was LAH reduced according to the general
procedure and purified by flash chromatography eluting with hexanes/ethyl acetate (9:1) to give
2.6f (350 mg, 2.4 mmol) as a clear liquid in 31% yield. 1H NMR (CDCl3) δ: 3.70 - 3.57 (m, 2H),
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1.56 - 1.40 (m, 3H), 1.29 - 1.13 (m, 6H), 0.83 - 0.71 (m, 9H). 13C NMR (CDCl3) δ: 59.28, 38.08,
36.79, 27.99, 7.46. IR (thin film, KBr plates) ν (cm-1): 3323 (broad), 2964, 2939, 2880, 1464,
1378, 1036.
3,3-Diethylpentanal (2.6). Compound 2.6f (100 mg, 0.69 mmol) was PCC oxidized
according to the general procedure to give 2.6 (44 mg, 0.31 mmol) in 45% yield. 1H
NMR (CDCl3) δ: 9.83 (t, J = 3.3 Hz, 1H), 2.24 (d, J = 3.0 Hz, 2H), 1.45 - 1.32 (m, 6H),
0.92 - 0.76 (m, 9H). 13C NMR (CDCl3) δ: 204.03, 49.23, 40.98, 28.55, 7.52. IR (thin film, KBr
plates), ν (cm-1): 2967, 2882, 2733, 1721, 1462, 1381, 1300, 1155, 1093, 1028.
(1E)-N,N-diethylbuta-1,3-dien-1-amine (2.7a). Compound 2.7a was synthesized
according to a literature procedure.10 Crotonaldehyde (8 g, 0.114 mol) in toluene (15
mL) was added to a solution of diethylamine and potassium carbonate at 4°C. The
solution was allowed to come to room temperature and was stirred for 4 h. The product was
purified by distillation to give 2.7a as a yellow liquid (6.5 g, 52 mmol) in 45% yield. 1H NMR
(CDCl3) δ: 6.35 - 6.17 (m, 2H), 5.03 (dd, J = 10.7, 13.2 Hz, 1H), 4.76 - 4.64 (m, 1H), 4.50 - 4.40
(m, 1H), 3.05 (q, J = 7.2 Hz, 4H), 1.19 - 0.90 (m, 6H). Spectral data match those previously
reported.10
Ethyl 2-(diethylamino)cyclohex-3-ene-1-carboxylate (2.7b). Compound
2.7b was synthesized according to a literature procedure.10 To 2.7a (6.5 g, 52
mmol) in toluene (11.2 mL) was added ethyl acrylate (5.66 g, 56.5 mmol).
The solution was stirred for 5 days in the dark under argon. The solution was diluted with diethyl
ether and extracted three times with 2 M HCl. The combined aqueous layer was extracted twice
with diethyl ether. The pH of the aqueous solution was raised to 10 by adding 6 M NaOH. The
aqueous phase was extracted with diethyl ether three times. The combined ether layer was dried
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and concentrated to give 2.7b (9.8 g, 43 mmol) as a yellowish liquid in 84% yield. 2.7b was used
for the next step without further purification. 1H NMR (CDCl3) δ: 5.90 (br. s., 1H), 5.83 - 5.55
(m, 1H), 4.13 (dd, J = 6.9, 12.4 Hz, 2H), 3.77 - 3.51 (m, 1H), 2.75 - 2.36 (m, 5H), 2.30 - 2.10 (m,
1H), 2.05 (br. s., 1H), 1.99 - 1.83 (m, 1H), 1.80 (br. s., 1H), 1.42 - 1.11 (m, 3H), 1.10 - 0.77 (m,
6H). Spectral data match those previously reported.10
Ethyl cyclohexa-1,3-diene-1-carboxylate (2.7c). Compound 2.7c was synthesized
according to a literature procedure.10 Compound 2.7b (9.8 g, 43 mmol) was added to
acetic acid (48 mL) and refluxed for 2 h. The reaction was quenched with ice water
and extracted three times with diethyl ether. The combined organic layer was washed with water,
saturated sodium bicarbonate, and brine, dried, and concentrated. The resulting residue was
purified by flash chromatography, eluting with hexanes/ethyl acetate (49:1) to give 2.7c (5 g, 33
mmol) as a yellowish liquid in 75.5% yield. 1H NMR (CDCl3) δ: 6.95 (br. s., 1H), 6.16 - 5.94 (m,
2H), 4.26 - 4.09 (m, 2H), 2.50 - 2.31 (m, 2H), 2.31 - 2.13 (m, 2H), 1.35 - 1.18 (m, 3H). Spectral
data match those previously reported.10
Ethyl

3,5-dioxo-4-oxatricyclo[5.2.2.02,6]undec-8-ene-1-carboxylate

(2.7d).

Compound 2.7d was synthesized according to a literature procedure.9 Compound
2.7c (5 g, 33 mmol) was mixed with maleic anhydride (3.3 g, 33 mmol) and
stirred for 30 minutes at 100°C and 30 minutes at 170°C. The product was
purified by flash chromatography eluting with dichloromethane to give 2.7d (7.78 g, 31 mmol)
as a white solid (m.p. 85-86°C) in 94.6% yield. 1H NMR (CDCl3) δ: 6.73 (d, J = 8.5 Hz, 1H),
6.38 - 6.30 (m, 1H), 4.40 - 4.28 (m, 2H), 3.68 (d, J = 8.5 Hz, 1H), 3.29 (br. s., 1H), 3.20 (d, J =
9.4 Hz, 1H), 1.98 - 1.70 (m, 2H), 1.48 (br. s., 2H), 1.35 (t, J = 7.2 Hz, 3H). 13C NMR (CDCl3) δ:
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171.92, 171.89, 170.67, 132.23, 132.08, 61.84, 46.99, 45.84, 44.69, 32.34, 28.18, 23.76, 14.13.
Analytical data match those previously reported.9
Ethyl

3,5-dioxo-4-oxatricyclo[5.2.2.02,6]undecane-1-carboxylate

(2.7e).

Compound 2.7d (7.78 g, 31 mmol) was hydrogenated according to the general
procedure to give 2.7e (7.4 g, 29 mmol) as a white solid (m.p. 81-83°C) in 94%
yield. Compound 2.7e was used for the next step without further purification. 1H
NMR (CDCl3) δ: 4.22 (q, J = 6.3 Hz, 2H), 3.69 (d, J = 10.2 Hz, 1H), 3.19 (d, J = 10.5 Hz, 1H),
2.30 (br. s., 1H), 1.96 - 1.71 (m, 6H), 1.71 - 1.45 (m, 2H), 1.28 (t, J = 7.0 Hz, 3H).

13

C NMR

(CDCl3) δ: 173.85, 173.03, 171.66, 61.42, 45.53, 44.42, 40.36, 29.09, 26.70, 24.16, 22.65, 21.23,
14.09. Analytical data match those previously reported.9
Ethyl

bicycle[2.2.2]oct-2-ene-1-carboxylate

(2.7g).

Compound

2.7g

was

synthesized according to a literature procedure.9 Compound 2.7e (7.4 g, 29 mmol)
and potassium carbonate (11.67 g, 65 mmol) were refluxed in water for 2 h. The
solution was acidified to pH 1 with 10% HCl. The solution was extracted with ethyl acetate. The
organic layer was dried and concentrated to give 2.7f (7 g, 26 mmol) as a white solid (m.p. 135138°C), which was used for the next step without further purification. Compound 2.7f (7 g, 26
mmol) was added to acetonitrile (233 mL). Pyridine (2.8 g, 36 mmol) was added followed by
lead acetate (11.66 g, 26 mmol). The solution was refluxed for 3 h and then filtered through a
silica pad. The product was purified by flash chromatography eluting with hexanes/ethyl acetate
(19:1) to give 2.7g (1.41 g, 7.8 mmol) as a clear liquid in 27% yield (in 2 steps from 2.7e). 1H
NMR (CDCl3) δ: 6.47 - 6.39 (m, 1H), 6.36 - 6.27 (m, 1H), 4.18 (q, J = 7.2 Hz, 2H), 2.57 (br. s.,
1H), 1.88 - 1.76 (m, 2H), 1.66 - 1.50 (m, 2H), 1.50 - 1.22 (m, 7H). 13C NMR (CDCl3) δ: 176.72,
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134.27, 132.41, 60.44, 43.95, 29.71, 29.34, 25.56, 14.26. IR (thin film, KBr plates) ν (cm-1):
2945, 2910, 2868, 1731, 1455, 1390, 1366, 1317, 1288, 1249.
Ethyl bicyclo[2.2.2]octane-1-carboxylate (2.7h). Compound 2.7g (1.41 g, 7.8
mmol) was hydrogenated according to the general procedure to give 2.7h (1.37 g,
7.5 mmol) as a clear liquid in 96% yield. Compound 2.7h was used for the next
reaction without further purification. 1H NMR (CDCl3) δ: 4.07 (q, J = 7.2 Hz, 2H), 1.78 - 1.65
(m, 6H), 1.58 (d, J = 7.4 Hz, 7H), 1.22 (t, J = 7.2 Hz, 3H). 13C NMR (CDCl3) δ: 178.25, 60.02,
38.19, 28.04, 25.41, 23.79, 14.21. IR (thin film, KBr plates) ν (cm-1): 2945, 2921, 2866, 1726,
1457, 1365, 1336, 1243.
Bicyclo[2.2.2]oct-1-ylmethanol (2.7i). Compound 2.7h (1.37 g, 7.5 mmol) was LAH
reduced according to the general procedure to give the alcohol 2.7i (1 g, 7.13 mmol)
in 95% yield as a white solid (m.p. 60-61°C). Compound 2.7i was used for the next
reaction without further purification. 1H NMR (CDCl3) δ: 3.21 (s, 2H), 1.68 - 1.46 (m, 7H), 1.46
- 1.08 (m, 7H). 13C NMR (CDCl3) δ: 72.04, 32.44, 27.72, 25.71, 24.60.
Bicyclo[2.2.2]octane-1-carbaldehyde (2.7j). Compound 2.7i (1 g, 7.13 mmol) was
PCC oxidized according to the general procedure to give aldehyde 2.7j, which was
used for the next step without further purification. 1H NMR (CDCl3) δ: 9.40 (s, 1H), 1.79 - 1.51
(m, 13H). Spectral data match those reported previously.15
1-Ethenylbicyclo[2.2.2]octane (2.7k). Compound 2.7k was synthesized based on a
literature procedure.28 To methyl triphenylphosphonium bromide (5.4 g, 15 mmol) in
THF (30 mL) at 0°C was added potassium butoxide (1.7 g, 15 mmol). The suspension was
stirred for 1 h and then aldehyde 2.7j in THF (7 mL) was slowly added. The reaction was stirred
for 2 h at room temperature and then water was added. The layers were separated and the
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aqueous phase was extracted with diethyl ether. The combined organic layer was dried,
concentrated and purified by flash chromatography eluting with hexanes to give the alkene 2.7k.
1

H NMR (CDCl3) δ: 5.72 - 5.64 (m, 1H), 4.85 - 4.77 (m, 2H), 1.63 - 1.51 (m, 7H), 1.51 - 1.40

(m, 6H). Spectral data agree with those reported previously.15
2-(Bicyclo[2.2.2]oct-1-yl)ethanol (2.7l). Compound 2.7l was subjected to a
hydroboration-oxidation reaction.29 Compound 2.7k was dissolved in THF and
cooled to 0°C. 1 M Borane tetrahydrofuran complex solution in THF (2.4 mL, 2.4
mmol) was slowly added and the solution was stirred for 1 h at room temperature. The solution
was cooled to 0°C and water (500 µL) was added followed by 3 M NaOH (750 µL) and 30%
hydrogen peroxide (750 µL). The solution was stirred at room temperature for 2 h. The reaction
was quenched with water and the layers were separated. The aqueous layer was extracted with
diethyl ether and the combined organic layer was dried and concentrated. The product was
purified by flash chromatography eluting with hexanes/ethyl acetate (9:1) to give the alcohol 2.7l
(330 mg, 2.17 mmol) in 30% yield (over 3 steps from 2.7i). 1H NMR (CDCl3) δ: 3.83 - 3.63 (m,
2H), 1.64 - 1.32 (m, 15H), 1.28 (br. s., 1H). 13C NMR (CDCl3) δ: 59.49, 44.86, 31.15, 29.24,
26.17, 24.17. IR (thin film, KBr plates) ν (cm-1): 3331 (broad), 2930, 2859, 1455, 1352, 1265.
Bicyclo[2.2.2]oct-1-ylacetaldehyde (2.7). Compound 2.7l (100 mg, 0.65 mmol) was
PCC oxidized according to the general procedure to the aldehyde 2.7 (70 mg, 0.46
mmol) as a clear liquid in 71% yield. 1H NMR (CDCl3) δ: 9.84 - 9.79 (m, 1H), 2.12 (d,
J = 3.0 Hz, 2H), 1.65 - 1.47 (m, 13H). 13C NMR (CDCl3) δ: 203.78, 55.19, 31.31, 30.70, 25.98,
24.11. IR (thin film, KBr plates), ν (cm-1): 2937, 2862, 2728, 1721, 1456, 1409, 1268. HRMS
(ESI) [M+Na]+: Calcd for C10H16O m/z = 175.1099, found m/z = 175.1098.
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Ethyl

cyano(cyclohexylidene)acetate

(2.8a).

Compound

2.8a

was

synthesized based on a literature procedure.7 Ethyl cyanoacetate (56.5 g, 0.5
mol), cyclohexanone (58.9 g, 0.6 mol), ammonium acetate (3.85 g, 0.05
mol), and acetic acid (6 g, 0.1 mol) were added to benzene (50 mL) in a round bottom flask
connected to a Dean and Stark apparatus. The solution was refluxed for 6 h and then washed
three times with water. The organic layer was dried and concentrated. The product was purified
by distillation to give 2.8a (60.6 g, 0.31 mol) as a clear liquid in 63% yield. 1H NMR (CDCl3) δ:
4.26 (q, J = 7.0 Hz, 2H), 2.97 (t, J = 5.8 Hz, 2H), 2.70 - 2.60 (m, 2H), 1.85 - 1.57 (m, 6H), 1.34
(t, J = 7.2 Hz, 3H). 13C NMR (CDCl3) δ: 180.03, 162.03, 115.63, 102.06, 61.72, 36.91, 31.59,
28.59, 28.26, 25.65, 14.09. IR (thin film, KBr plates) ν (cm-1): 2939, 2861, 2224, 1729, 1601,
1447, 1367, 1201. Spectral data agree with those previously reported.30
Ethyl cyano(1-methylcyclohexyl)acetate (2.8b). Compound 2.8b was
synthesized based on the literature procedures.8,
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Iodomethane (11 g, 77

mmol) in diethyl ether (10 mL) was slowly added to magnesium turnings
(1.83 g, 76 mmol) in diethyl ether (10 mL) at 0°C and the solution was stirred for 30 minutes.
Copper chloride (100 mg, 1 mmol) was added, and 2.8a (9.66 g, 50 mmol) in diethyl ether (10
mL) was slowly added. The solution was stirred for 30 minutes and then added to 10% sulfuric
acid (40 mL) in ice (50 g). The aqueous phase was extracted three times with diethyl ether. The
combined organic layer was dried and concentrated. The resulting residue was purified by flash
chromatography eluting with hexanes/ethyl acetate (9:1) to give 2.8b (10.4 g, 49.7 mmol) as a
yellowish liquid in 99% yield. 1H NMR (CDCl3) δ: 4.32 - 4.19 (m, 2H), 3.45 (s, 1H), 1.62 - 1.37
(m, 10H), 1.31 (t, J = 7.0 Hz, 3H), 1.14 (s, 3H).

13

C NMR (CDCl3) δ: 165.26, 115.88, 62.20,

48.21, 37.62, 36.25, 35.36, 25.45, 21.93, 21.60, 21.55, 14.04. IR (thin film, KBr plates), ν (cm-1):
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2933, 2861, 2247, 1742, 1601, 1448, 1388, 1370, 1325. Spectral data match those previously
reported.26
(1-Methylcyclohexyl)acetonitrile (2.8d). Compound 2.8d was synthesized based on
a literature procedure.8 Compound 2.8b (5.2 g, 25 mmol) was added to a solution
containing 85% potassium hydroxide (7.5 mL), water (33 mL), and ethanol (6.5
mL). The solution was refluxed for 6 hours and then concentrated. The resulting residue was
refluxed for 4 h in 20% sulfuric acid (40.3 mL). The solution was cooled to room temperature
and extracted with diethyl ether. The organic layer was dried and concentrated. A catalytic
amount of copper powder (70 mg) was added to the resulting residue (2.8c) and the suspension
was slowly heated to 170°C. The suspension was then allowed to cool back to room temperature
and was purified by flash chromatography, eluting with hexanes/ethyl acetate (19:1) to give 2.8d
(2.2 g, 16 mmol) as a yellowish liquid in 64% yield. 1H NMR (CDCl3) δ: 2.25 (s, 2H), 1.63 1.31 (m, 10H), 1.07 (s, 3H).

13

C NMR (CDCl3) δ: 118.44, 36.95, 33.01, 30.33, 25.75, 25.24,

21.88. IR (thin film, KBr plates) ν (cm-1): 2929, 2855, 2242, 1742, 1453, 1422, 1384.
2-(1-Methylcyclohexyl)ethanol (2.8f). Compound 2.8d was hydrolyzed based on a
literature procedure.27 Compound 2.8d (1.89 g, 13.8 mmol) was refluxed in a solution
with sulfuric acid (14 mL) and water (16.8 mL) for 6 h. The solution was cooled to
room temperature, diluted with water, and extracted with diethyl ether. The organic layer was
dried and concentrated. The resulting residue 2.8e was LAH reduced according to the general
procedure and purified by flash chromatography eluting with hexanes/ethyl acetate (9:1) to give
2.8f (710 mg, 5 mmol) as a yellowish liquid in 36% yield. 1H NMR (CDCl3) δ: 3.75 - 3.65 (m,
2H), 1.61 - 1.48 (m, 2H), 1.48 - 1.17 (m, 11H), 0.90 (s, 3H). 13C NMR (CDCl3) δ: 59.45, 44.49,

81

38.15, 32.16, 26.40, 25.39, 21.97. IR (thin film, KBr plates) ν (cm-1): 3330 (broad), 2925, 2851,
1453, 1043, 1019.
(1-Methylcyclohexyl)acetaldehyde (2.8). Compound 2.8d (100 mg, 0.70 mmol) was
PCC oxidized according to the general procedure to give 2.8 (62 mg, 0.44 mmol) in
63% yield. 1H NMR (CDCl3) δ: 9.86 (t, J = 3.3 Hz, 1H), 2.29 (d, J = 3.0 Hz, 2H), 1.55
- 1.31 (m, 10H), 1.08 (s, 3H).

13

C NMR (CDCl3) δ: 203.96, 54.53, 38.18, 33.69, 26.01, 25.77,

21.78. IR (thin film, KBr plates), ν (cm-1): 2928, 2853, 2729, 1721, 1453, 1380.
Ethyl cyano(1-ethylcyclohexyl)acetate (2.9b). Compound 2.9b was
synthesized based on literature procedures.8,

26

Bromoethane (8.7 g, 80

mmol) in diethyl ether (10 mL) was slowly added to magnesium turnings
(1.83 g, 76 mmol) in diethyl ether (10 mL) at 0°C and the solution was stirred for 30 minutes.
Copper chloride (50 mg, 0.5 mmol) was added, and 2.8a (9.06 g, 50 mmol) in diethyl ether (10
mL) was slowly added. The solution was stirred for 30 minutes and then added to 10% sulfuric
acid (40 mL) in ice (50 g). The aqueous phase was extracted three times with diethyl ether. The
combined organic layer was dried and concentrated. The resulting residue was purified by flash
chromatography eluting with hexanes/ethyl acetate (9:1) to give 2.9b (3.6 g, 16.2 mmol) as a
clear liquid in 32% yield. 1H NMR (CDCl3) δ: 4.25 (q, J = 7.2 Hz, 2H), 3.61 (s, 1H), 1.76 - 1.40
(m, 12H), 1.32 (t, J = 7.0 Hz, 3H), 0.89 (t, J = 7.4 Hz, 3H). 13C NMR (CDCl3) δ: 165.56, 116.26,
62.29, 45.57, 40.50, 32.54, 32.37, 26.66, 25.39, 21.31, 21.28, 14.08, 7.42. IR (thin film, KBr
plates) ν (cm-1): 2935, 2865, 2246, 1741, 1456, 1387, 1369, 1323. HRMS (ESI) [M+Na]+: Calcd
for C13H21NO2 m/z = 246.1464, found m/z = 246.1471.
(1-Ethylcyclohexyl)acetonitrile (2.9d). Compound 2.9d was synthesized based on a
literature procedure.8 Compound 2.9b (3.5 g, 15.7 mmol) was added to a solution
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containing 85% potassium hydroxide (5.1 mL), water (22.2 mL), and ethanol (4.38 mL). The
solution was refluxed for 6 h and then concentrated. The resulting residue was refluxed for 4 h in
20% sulfuric acid (27.1 mL). The solution was cooled to room temperature and extracted with
diethyl ether. The organic layer was dried and concentrated. A catalytic amount of copper
powder (60 mg) was added to the resulting residue (2.9c) and the suspension was slowly heated
to 170°C. The suspension was then allowed to cool back to room temperature and was purified
by flash chromatography, eluting with hexanes/ethyl acetate (19:1) to give 2.9d (1.4 g, 9.3
mmol) as a clear liquid in 59% yield. 1H NMR (CDCl3) δ: 2.28 (s, 2H), 1.58 - 1.36 (m, 12H),
0.92 - 0.81 (m, 3H). 13C NMR (CDCl3) δ: 118.49, 35.38, 34.65, 30.00, 26.07, 25.80, 21.52, 7.36.
IR (thin film, KBr plates) ν (cm-1): 2966, 2929, 2857, 2243. HRMS (ESI) [M+Na]+: Calcd for
C10H17N m/z = 174.1253, found m/z = 174.1266.
2-(1-Ethylcyclohexyl)ethanol (2.9f). Compound 2.9d was hydrolyzed based on a
literature procedure.27 Compound 2.9d (1.26 g, 8.3 mmol) was refluxed in a solution
of sulfuric acid (9.3 mL) and water (11.2 mL) for 6 hours. The solution was cooled to
room temperature, diluted with water, and extracted with diethyl ether. The organic layer was
dried and concentrated. The resulting residue 2.9e was LAH reduced according to the general
procedure and purified by flash chromatography eluting with hexanes/ethyl acetate (9:1) to give
2.9f (690 mg, 4.4 mmol) as a yellowish liquid in 53% yield. 1H NMR (CDCl3) δ: 3.71 - 3.60 (m,
2H), 1.61 - 1.47 (m, 2H), 1.47 - 1.20 (m, 13H), 0.79 (t, J = 7.4 Hz, 3H). 13C NMR (CDCl3) δ:
59.15, 39.20, 35.79, 34.37, 29.67, 26.47, 21.60, 7.42. IR (thin film, KBr plates) ν (cm-1): 3329
(broad), 2925, 2859, 1460, 1379.
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(1-Ethylcyclohexyl)acetaldehyde (2.9). Compound 2.9d (100 mg, 0.64 mmol) was
PCC oxidized according to the general procedure to give 2.9 (70 mg, 0.45 mmol) in
71% yield. 1H NMR (CDCl3) δ: 9.84 (t, J = 3.3 Hz, 1H), 2.31 (d, J = 3.3 Hz, 2H), 1.53 1.35 (m, 12H), 0.90 - 0.80 (m, 3H).

13

C NMR (CDCl3) δ: 204.15, 49.99, 36.47, 35.80, 30.58,

26.10, 21.48, 7.48. IR (thin film, KBr plates), ν (cm-1): 2928, 2856, 2726, 1720, 1456, 1381.
HRMS (ESI) [M+Na]+: Calcd for C10H18O m/z = 177.1255, found m/z = 177.1275.
2-(Bicyclo[2.2.1]hept-2-yl)ethanol (2.10a). 2-Norbornaneacetic acid (1 g, 6.5 mmol)
was LAH reduced according to the general procedure to the alcohol 2.10a (780 mg,
5.6 mmol) in 86% yield as the exo (cis) product. 1H NMR (CDCl3) δ: 3.61 (t, J = 6.7
Hz, 2H), 2.18 (br. s., 1H), 1.94 (br. s., 1H), 1.66 - 1.26 (m, 8H), 1.23 - 0.96 (m, 4H). 13C NMR
(CDCl3) δ: 61.66, 41.14, 39.94, 38.34, 38.10, 36.55, 35.31, 30.07, 28.76. IR (thin film, KBr
plates) ν (cm-1): 3330 (broad), 2948, 2869, 1455, 1313, 1053, 1030, 986. Spectral data match
those previously reported.31-33
Bicyclo[2.2.1]hept-2-ylacetaldehyde (2.10). Compound 2.10a (100 mg, 0.71 mmol)
was PCC oxidized according to the general procedure to the aldehyde 2.10 (72 mg,
0.52 mmol) in 73% yield as the exo (cis) product. 1H NMR (CDCl3) δ: 9.71 (t, J = 1.9
Hz, 1H), 2.45 - 2.19 (m, 3H), 2.00 - 1.89 (m, 2H), 1.61 - 1.42 (m, 3H), 1.34 - 1.01 (m, 5H). 13C
NMR (CDCl3) δ: 202.58, 51.07, 41.11, 37.93, 36.69, 35.86, 35.21, 29.77, 28.50. IR (thin film,
KBr plates), ν (cm-1): 2950, 2870, 2818, 2716, 1724.
(6,6-dimethylbicyclo[3.1.1]hept-2-yl)methanol

(2.11a).

Compound

2.11a

was

synthesized from a hydroboration-oxidation reaction.29 (-)-b-Pinene (10 g, 73.4
mmol) was dissolved in THF (160 mL) and 1M borane tetrahydrofuran complex
solution in THF (36 mL, 36 mmol) was slowly added. The solution was stirred for 1 h at room

84

temperature. The solution was cooled to 0°C and water (7.4 mL) was slowly added to quench the
reaction followed by 3M NaOH (10 mL) and 30% hydrogen peroxide (10 mL). The solution was
stirred at room temperature for 2 h and then water (100 mL) was added. The layers were
separated and the aqueous layer was extracted with diethyl ether. The combined organic layer
was dried, concentrated, and the product was purified by flash chromatography eluting with
hexanes/ethyl acetate (49:1) to give the alcohol 2.11a (6.8 g, 44 mmol) as a clear liquid in 60%
yield. 1H NMR (CDCl3) δ: 3.67 - 3.51 (m, 2H), 2.42 - 2.31 (m, 1H), 2.25 (t, J = 7.4 Hz, 1H), 2.06
- 1.82 (m, 5H), 1.56 - 1.29 (m, 2H), 1.29 - 1.14 (m, 3H), 1.01 - 0.88 (m, 4H). 13C NMR (CDCl3)
δ: 67.85, 44.49, 42.88, 41.49, 38.66, 33.15, 27.98, 26.00, 23.34, 18.77. IR (thin film, KBr plates)
ν (cm-1): 3330 (broad), 2948, 2869.
6,6-Dimethylbicyclo[3.1.1]heptanes-2-carbaldehyde (2.11b). Compound 2.11a (6.8 g,
44 mmol) was PCC oxidized according to the general procedure to the aldehyde 2.11b
which was purified by flash chromatography eluting with hexanes/ethyl acetate (19:1)
to give 2.11b (2.1 g, 13.8 mmol) as a clear oil in 31% yield. 1H NMR (CDCl3) δ: 9.76 (s, 1H),
2.79 - 2.69 (m, 1H), 2.58 - 2.50 (m, 1H), 2.44 - 2.19 (m, 2H), 1.98 - 1.79 (m, 4H), 1.30 - 1.16 (m,
4H), 0.71 (s, 3H). Spectral data match those previously reported.34
2-Ethenyl-6,6-dimethylbicyclo[3.1.1]heptanes

(2.11c).

Compound

2.11c

was

synthesized based on a literature procedure.2 1.6 M Butyllithium in hexane (16.8 mL,
26.9 mmol) was added to a solution of methyltriphenyl phosphonium bromide (12.3 g, 34.4
mmol) in THF at 0°C. After 30 minutes, the solution was cooled to -75°C and 2.11b (3.5 g, 23.0
mmol) was slowly added. The solution was stirred for 3 h at -75°C. The reaction was quenched
with ammonium chloride solution and the organic layer was dried and concentrated. The product
was purified by flash chromatography, eluting with hexanes to give 2.11c (820 mg, 5.46 mmol)
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in 24% yield. 1H NMR (CDCl3) δ: 6.05 - 5.92 (m, 1H), 4.96 - 4.82 (m, 2H), 2.71 (br. s., 1H),
2.32 (br. s., 1H), 1.97-1.88 (m, 5H), 1.65 (d, J = 9.4 Hz, 1H), 1.19 (s, 3H), 1.03 - 0.92 (m, 3H).
2-(6,6-Dimethylbicyclo[3.1.1]hept-2-yl))ethanol (2.11d). Compound 2.11c was
subjected to a hydroboration-oxidation reaction.29 Compound 2.11c (800 mg, 5.32
mmol) was dissolved in THF (12.8 mL) and 1 M borane tetrahydrofuran complex
solution in THF (5.0 mL, 5 mmol) was slowly added. The solution was stirred for 1 h at room
temperature. The solution was cooled to 0°C and water was slowly added to quench the reaction
followed by 3 M NaOH (0.8 mL) and 30% hydrogen peroxide (1 mL, 8.82 mmol). The solution
was stirred at room temperature for 2 h and then quenched with water. The layers were separated
and the aqueous layer was extracted with diethyl ether. The combined organic layer was dried,
concentrated, and the product was purified by flash chromatography eluting with hexanes/ethyl
acetate (9:1) to give the alcohol 2.11d in 67% yield. 1H NMR (CDCl3) δ: 3.65 (dt, J = 3.4, 6.8
Hz, 2H), 2.33 (d, J = 7.2 Hz, 1H), 2.11 (d, J = 7.4 Hz, 1H), 2.02 - 1.78 (m, 4H), 1.68 (q, J = 7.1
Hz, 2H), 1.59 - 1.31 (m, 2H), 1.18 (s, 3H), 1.04 - 0.80 (m, 5H). 13C NMR (CDCl3) δ: 61.71,
46.40, 41.43, 40.74, 38.71, 37.47, 33.63, 28.18, 26.44, 23.25, 22.35. IR (thin film, KBr plates) ν
(cm-1): 3325 (broad), 2935, 2907, 1468, 1383, 1366.
(6,6-dimethylbicyclo[3.1.1]hept-2-yl)acetaldehyde (2.11). Compound 2.11d (100 mg,
0.6 mmol) was PCC oxidized according to the general procedure to the aldehyde 2.11
(24 mg, 0.14 mmol) in 24% yield (95.5% cis product by GC/MS). 1H NMR (CDCl3) δ:
9.71 (t, J = 2.1 Hz, 1H), 2.70 - 2.30 (m, 4H), 2.14 - 1.79 (m, 6H), 1.52 - 1.39 (m, 1H), 1.19 (s,
3H), 1.06 - 0.85 (m, 5H). 13C NMR (CDCl3) δ: 203.39, 52.51, 46.78, 41.55, 39.16, 35.53, 33.89,
28.42, 26.62, 23.66, 22.51. IR (thin film, KBr plates), ν (cm-1): 2984, 2941, 2909, 2869, 2814,
2713, 1725, 1468, 1408, 1384, 1367. Spectral data match those previously reported.35, 36
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2-(1-Adamantyl)ethanal (2.12). 2-(1-Adamantyl)ethanol (200 mg, 1.1 mmol was
PCC oxidized according to the general procedure to the aldehyde 2.12 (140 mg, 0.79
mmol) in 71% yield. This compound was noticed to have a camphoraceous odor. 1H
NMR (CDCl3) δ: 9.87 (t, J = 3.2 Hz, 1H), 2.13 (d, J = 3.0 Hz, 2H), 1.99 (br. s., 3H), 1.78 - 1.59
(m, 12H).

13

C NMR (CDCl3) δ: 203.59, 57.25, 42.73, 36.65, 33.34, 28.49. IR (thin film, KBr

plates), ν (cm-1): 2903, 2848, 2728, 1721, 1450, 1406, 1362, 1346. Spectral data match those
previously reported.37, 38
Mouse OR-I7 HEK293 Glosensor Assay (from collaborator Jianghai Ho experiments in
Matsunami Lab, Duke University Medical Center)
The GloSensor cAMP Assay System (Promega) was used according to manufacturer’s
instructions with slight modifications as previously described.2 A plasmid encoding Rho-tagged
mouse OR-I7 (80 ng/well) was transfected into the Hana3A cell line in 96-well plate format
along with plasmids encoding the human receptor trafficking protein, RTP1S (10 ng/well), type
3 muscarinic acetylcholine receptor (M3-R) (10 ng/well), and pGloSensor TM-22F (10 ng/well).
Then, 18 to 24 h following transfection, cells were loaded with 2% GloSensor reagent for 2 h
and treated with compounds in a total volume of 74 µL. Luminescence was measured using a
Polarstar Optima plate reader (BMG) with a time interval of 90 seconds per well. Data was
analyzed and IC50s were estimated using Prism 5.0 and Microsoft Excel. Responses over t=3-7.5
minutes were summed, base-lined, normalized, and plotted versus odorant concentration (Figures
2.12, 2.13, and 2.14).
Homology Model Construction and Ligand Docking (Experiments done in the lab of Victor
Batista, Yale University, Department of Chemistry)
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General procedure for evaporation assay
These experiments were mock experiments, done without the transfected cells, but otherwise
identical to our collaborator’s lab at Duke University. The solute evaporation was monitored to
learn whether there were different odorant evaporation rates in the biological testing. The
odorant was diluted with DMSO to 1.0 M, and the 1.0 M DMSO solution was diluted with
CD293 buffer (or water) to 0.1 mM. Designated volumes of the 0.1 mM solution were
transferred into 96-well plates and incubated at 37˚C for the designated timespan. The 96-well
plate was then placed on top of ice and the odorant solutions were pooled. An aliquot of the
pooled solution was extracted with an equal volume of chloroform or a 0.1 mM 1-bromooctane
solution in chloroform as an internal standard. The layers were separated and the organic layer
was diluted with 2.0 mL of chloroform, dried with magnesium sulfate and analyzed by GC/MS.
GC/MS analyses were obtained on a Shimadzu GC/MS-QP2010 instrument. Temperature
program for GC analysis was as follows: Injection temperature = 250˚C; held at 65˚C for 1
minute, heated from 65˚C to 80˚C at 5˚C/minute, held at 80˚C for 1 minute, heated from 80˚C to
120˚C at 15˚C/minute, held at 120˚C for 1 minute, heated from 120˚C to 200˚C at 40˚C/minute,
and held at 200˚C for 3 minutes. The amount of odorant in the solution was determined relative
to the peak area or relative to 2,2-difluorooctanal or 1-bromooctane (as an internal standard). The
percentage of odorant remaining over time was compared to a sample that was extracted prior to
the incubation, designated as time = 0 minute.
Pre-exposure assay
For the experiment requiring pre-exposure to the odorants, 400 µL of the following solution in
water was separately added into the 96-well plates prior to the experiment: water, 0.1 mM
octanal, 0.1 mM 1-octanol, 0.1 mM 2,2-difluorooctanal, 1 mM octanal, 1 mM 1-octanol. The
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solutions were incubated at 37°C for 4 hours uncovered. Afterwards, the solutions were
discarded, and the well plates were rinsed three times with water and left to dry overnight.
During the experiment, 200 µL of 0.1 mM octanal and 2,2-difluorooctanal was added to the well
plates. The 96-well plates were covered with sealing mats (ThermoScientific, catalog #4411-11)
and treated as described in the general procedure.
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Chapter 3: Olfactory Receptor Antagonism in the Mammalian Olfactory System
3.1. Introduction
3.1.1. Combinatorial receptor coding
Olfaction is one of the major senses used to analyze the physical environment. Rodents
have about 1100 olfactory receptor genes and humans have about 390 olfactory receptor genes,
plus many pseudogenes.1 Each odorant can activate multiple olfactory receptors and each
olfactory receptor can be activated by multiple odorants, suggesting that each odorant has a
specific combinatorial olfactory code for generating its unique smell.1 An odor was generally
believed to be linked to the activation of a set of receptors by specific odorant(s), but mixtures
have long been noted to elicit lower response than the individual components,2 suggesting the
possibility of odorants to act as inhibitors as well as activators. Recently, odorants were
identified that antagonized olfactory receptors through binding to the receptors without
activating them.3-5 These antagonists inhibit the action of agonists. Thus, in a mixture, some
receptors may have their response modulated due to antagonism, and the original olfactory code
of the individual odorants might become much more complex, but currently, it is uncertain
whether antagonism is an important contributor to the olfactory code in natural product mixtures
and whole animals.
3.1.2. Antagonism at the receptor level
OR-I7

Octanal
Agonist

mOR-EG

Cyclohexylethanal
Antagonist

Eugenol
Agonist

Methyl isoeugenol
Antagonist

Agonist and antagonist of OR-I7 and mOR-EG.
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Octanal, an eight-carbon, aliphatic aldehyde, activates the aldehyde receptor OR-I7 when
applied alone, but its response has been shown to decrease when co-applied with citral3 and
cyclohexylethanal,5 both now considered antagonists of the OR-I7 receptor. Octanal’s olfactory
code, and consequently its smell, would presumably be modified in a mixture with these
compounds. Similarly, the response of eugenol (100 µM) in the mOR-EG receptor was
eliminated in a mixture containing high concentration (1 mM) of methyl isoeugenol.4 For each of
these rodent receptors, the antagonists were structurally similar to the agonist, which may mean
they act at the orthosteric site. Octanal differs from cyclohexylethanal by only its extended chain
length, and eugenol differs from methyl isoeugenol by the functional groups on the phenyl ring
and the position of a double bond. Antagonism had also been seen in human olfactory receptors.
The human receptor, OR1G1, could be activated by several odorants, with 9-carbons being the
optimal chain length, and the agonist-induced response was inhibited by several shorter 6carbons odorants.6 These findings demonstrated that the response of odorants can be antagonized
at the receptor, and structural variations in chain length and functional group, can change an
agonist into an antagonist. In these cases, where the structure of the antagonist is related to the
structure of the agonist (activating odorant ligand), it is assumed that the antagonist targets the
same or overlapping binding site as the activating ligand, though this does not need to be the case
as allosteric antagonists are known for other GPCRs.7
While the aforementioned receptors are one of the many receptors that are activated by
octanal and eugenol, they cannot be representative of the whole receptor set that generate the
smell of each of these odorant. Octanal at 30 µM was found to activate 144 cells (6%) out of
2301 cells from rats,3 and eugenol at 100 µM could activate 95 cells (3%) out of 3000 cells4 in
previous experiments. Since each mature olfactory sensory neuron (OSN) express only one
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olfactory receptor,8,

9

it’s possible that octanal’s and eugenol’s olfactory code involve several

olfactory receptors. However, antagonizing the response of a single receptor may be sufficient to
change the odorant’s smell. Currently, little is known about the degree at which antagonism
affects the olfactory code and there is limited information on the determinants of antagonism in
olfactory receptors. One way to study antagonism is to look at all (or a sampling of) the ORs in
the mammalian olfactory system. Activation of an OR leads to an increase in the intramolecular
calcium level, allowing a large repertoire of olfactory receptors to be screened and profiled at
once via calcium imaging. Since each olfactory sensory neuron expresses only one olfactory
receptor,8,

9

the response of an OR can be determined, with and without an antagonist, by

studying the calcium level of olfactory sensory neurons.
Designated Agonist

Tested as Antagonist
Functional Group
vs
Length/Conformation

Experiment A:
1-Octanol (3.1)

Octanal (3.2)

Octanoic acid (3.3)

Cyclohexylethanol (3.4)

Octanal (3.2)

1-Octanol (3.1)

Octanoic acid (3.3)

Cyclohexylethanal (3.5)

Octanoic acid (3.3)

1-Octanol (3.1)

Octanal (3.2)

Cyclohexylethanoic acid (3.6)

Experiment B:

Experiment C:

Table 3.1: Agonists and antagonists tested in OSNs. In Exp. A, 1-octanol (3.1) was treated as the agonist. In Exp.
B, octanal (3.2) was treated as the agonist. In Exp. C, octanoic acid (3.3) was treated as the agonist. The
individual odorants were first applied alone and then co-applied with the agonist.

3.1.3. Factors causing mixture suppression
In a mixture, reduced activation, compared to the individual components, may be
attributed to other factors besides competition with the agonist for the active site. Other than
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competing with the agonist for the orthosteric or active site, an odorant may also inhibit the
receptor through binding to an allosteric site, another site on the receptor besides the orthosteric
site. Additionally, an odorant may cause reduction in activity by activating alternative pathways.
For instance, ORs have been found to display phosphoinositide 3-kinase (PI3K)-dependent
antagonism with odorant pairs.10 Activation of PI3K would stimulate the production of
phosphatidylinositol (3,4,5) triphosphate (PIP3) which negatively regulates the sensitivity of the
ion channel and thereby reduce the signal of the receptor. However, the activation of two
functionally distinct targets is expected to require very different ligands. The orthosteric and
allosteric sites usually bind to structurally distinct molecules, and PI3K-dependent antagonism
was achieved by odorant pairs with few structural similarities. For instance, the only structural
similarity between citral and 1-octanol, which could be inhibited by citral in a PI3K-dependent
manner,10 was their extended carbon chain, whereas their degree of saturation, functional groups,
and the number of carbons are all different. In summary, very little is known about the structural
attributes that distinguish an agonist from an antagonist in the orthosteric site of a receptor. It is
expected that they will share some structural features, but it’s not clear what these features are.
3.1.4. Experimental design: Length vs. functional group
In this chapter, we aim to uncover the relative importance of the functional group
(alcohol, aldehyde, or carboxylic acid) and of the carbon chain (linear vs. cyclic 8-carbon chain)
in a presumed orthosteric antagonist. To reduce the possibility of an odorant modifying the
response of a receptor through an allosteric site or a separate pathway, there should be minimal
structural differences between the two odorants tested in the binary mixtures. The odorants in our
study were designed to only differ from each other by either their chain length or their functional
group. When the chain length is changed, the number of carbons is kept constant, but they are
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conformationally restricted in a cyclohexyl ring. Thus, any decline in activity would most likely
be linked to these structurally-related odorants competing for the same binding site on the
receptor rather than stimulating distant sites or pathways. Accordingly, these two variations,
chain length and functional group, were simultaneously evaluated as possible determinants of
antagonism. In this study, the degree of antagonism elicited by binary mixtures in olfactory
sensory neurons was analyzed (Table 3.1).
The first experiment (please refer to Table 3.1) focused on all of the receptors that can be
activated by 1-octanol (3.1). In the activated cells, 1-octanol (3.1) was applied as a binary
mixture with octanal (3.2), octanoic acid (3.3), or cyclohexylethanol (3.4). Octanal (3.2) and
octanoic acid (3.3) have the same number of carbons and unconstrained chain length as 1-octanol
(3.1), but a different functional group. These mixtures tested the functional group as a decisive
factor for antagonism. Cyclohexylethanol (3.4) has the same number of carbons and functional
group as 1-octanol (3.1) but a shorter chain length. The mixture of the two tested for chain length
as the source of antagonism. Since the structure of 1-octanol (3.1) is similar to that of octanal
(3.2), octanoic acid (3.3), and cyclohexylethanol (3.4) (with the exception of the functional group
or chain length), any antagonism seen, would most likely arise from competition for the
orthosteric site, rather than from binding to a distinct allosteric site. The second experiment was
conducted in a similar manner, except the designated agonist was switched from 1-octanol (3.1)
to octanal (3.2). Octanal (3.2) was tested in a mixture with 1-octanol (3.1) or octanoic acid (3.3)
to look at functional group and with cyclohexylethanal (3.5) to look at carbon chain length or
shape as the determinant of antagonism. The same was done with octanoic acid (3.3) as the
agonist. Octanoic acid (3.3) was tested in binary mixtures with 1-octanol (3.1) or octanal (3.2) to
study the effect of functional group and cyclohexylethanoic acid (3.6) to study the effect of chain
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length on antagonism. The response of endogenous ORs to the individual compounds and their
binary mixtures in live mouse olfactory sensory neurons was obtained through calcium imaging.
The odorant vehicle, or solvent, DMSO, was first applied to the cell as a negative control.
Cells that respond to the solvent were not considered odorant-responding cells. Individual
odorants were applied to the cells at the beginning of the experiment and again at the end of the
experiment. Cells that failed to respond at the beginning or end (possibly due to sensitization or
desensitization of the receptor) were not considered as an odorant-responding cell. Cells that
gave irregular responses (i.e. noisy responses or a response when no odorant was applied) were
not considered odorant-responding cells. Forskolin was applied at the end of the calcium imaging
experiment to determine if the signal transduction pathway was still functioning. Forskolin is a
molecule that bypasses the olfactory receptor to activate adenylyl cyclase. All cells that
responded to forskolin were considered viable cells regardless of whether they responded to the
odorants (viable cells may respond to functional groups and carbon chain other than the ones that
were tested in this experiment). During calcium imaging screens with individual organic
odorants, it is common to activate between 0 - 8% of the set of forskolin-responding cells (about
2000 cells per mouse).
Different ORs will probably be activated and antagonized at different ligand
concentrations. Since we cannot test all concentrations, 60 µM was the concentration chosen for
this study. The odorant responses were in all cases normalized to the response of forskolin.
Responses (of individual odorants) that were consistently lower than 10% of the response of
forskolin were omitted. An inhibitory, and possibly antagonistic, response was defined as a 70100% reduction in the agonist’s response (compared to when the agonist was applied alone).
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3.2. Results and Discussion:
The rodent olfactory system consists of around 1100 ORs,1 and the response profiles of
over 10,000 viable cells (forskolin responding cells) were obtained and analyzed in total.
Although the identity of the OR expressed in each cell was unknown, we aim to profile a
majority of the olfactory receptor types through analyzing 10-fold the number of receptors.
Olfactory sensory neurons were exposed to 60 µM of each odorant and then binary mixtures that
contain the designated agonist and one other odorant at 60 µM. If the odorant is not an antagonist
for the receptor expressed in an observed cell, then there should be no reduction in the response
of the binary mixtures compared to the response of the agonist, but if the odorant is antagonizing
the response of the agonist, the binary mixture will display a reduction in signal (Figure 3.1).

Figure 3.1: Calcium imaging response of cells. A baseline was drawn from the DMSO response to the forskolin
response and a line was drawn between the two peak signals of the designated agonist, applied before and after the
binary mixtures. The height of the binary mixture response, x, and the height between the binary mixture response
and the interpolated agonist response, y, were measured. To calculate the percent antagonism (signal reduction), y
was divided by ‘x+y’ and multiplied by 100%. Only cells that show at least 70% reduction from the agonist
response to the binary mixture response were considered to be inhibited. (The odorant designated as the antagonist
was applied 4 seconds before and during application of the agonist.)
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Figure 3.2: Percent activation and percent
antagonism. Each row represents the relative
response of one cell to the four odorants. The
response of the cell to the designated agonist in
each experiment is shown in the first column. The
response of the cell to the other three odorants
tested in the experiment is shown in the following
three columns. The response of the agonist in each
cell was antagonized by the odorant(s) whose
compound number is bolded in the last column. The
percentage of antagonism (% reduction of the
agonist’s response) is given in parentheses.
1-Octanol
3.1

In order to be considered an antagonist, the
molecule must not respond to the cell on
its own (partial agonists could also lower
the response of full agonists).

Octanal
3.2

3.2.1. Summary of antagonism
The response of the agonist was
reduced by at least 70% in 38 total cells
(out of 11707 viable cells tested) (Figures

Octanoic
acid
3.3

3.2, 3.3). In the first experiment with 1octanol (3.1) as the agonist, 125 cells
responded to 1-octanol (3.1) (out of 3830
viable cells). Out of these 125 cells,

3.4

antagonism was seen in 7 cells (5.6%).
Octanoic acid (3.3) was the inhibitor in 2
cells (1.6%), cyclohexylethanol (3.4) was

3.5

the inhibitor in 4 cells (3.2%), and 1 cell
(0.8%) was inhibited by both octanoic acid
(3.3) and cyclohexylethanol (3.4). In the
3.6
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second experiment with octanal (3.2) as the agonist, 82 cells were activated by octanal (out of
3478 viable cells). Out of these 82 cells, inhibition was seen in 31 cells (37.8%). Two cells
(2.4%) were inhibited by 1-octanol (3.1), 12 cells (14.6%) were inhibited by octanoic acid (3.3),
12 cells (14.6%) were inhibited by 3.5, 1 cell (1.2%) was inhibited by both 3.1 and 3.5, 3 cells
(3.7%) were inhibited by both 3.3 and 3.5, and 1 cell (1.2%) was inhibited by both 3.1 and 3.3.
In the experiment with octanoic acid (3.3) as the agonist, 39 cells (out of 4399 cells) were
activated by octanoic acid (3.3), but inhibition was never seen in any of these cells. Out of the
three tested agonists, 3.1, 3.2, and 3.3, the cells activated by octanal (3.2) were the most
susceptible to inhibition by one or more of the other compounds tested, being inhibited in 37.8%
of the cells, followed by 1-octanol (3.1), which was inhibited in 5.6% of the cells, and cells
activated by octanoic acid (3.3) was the least susceptible to inhibition (These data are
summarized in Figure 3.3).
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Figure 3.3: Summary of antagonized cells. In Exp. A, there were 3830 forskolin responding cells, 125 1-octanolresponding cells, and 7 1-octanol-responding cells that were antagonized by one or more of the three other
compounds (designated antagonists). In Exp. B, there were 3478 forskolin responding cells, 82 octanal-responding
cells, and 31 octanal-responding cells that were antagonized. In Exp. C, there were 4399 forskolin responding cells,
39 octanoic acid-responding cells, and zero antagonized cell.

3.2.2. Competitive Inhibition
We limited our study to only a few structurally similar molecules, so that antagonism
would most likely arise from competitive inhibition, but there would always be the chance that
reduction in activity was due to other types of inhibition, in addition to the initiation of inhibitory
G-protein pathways. To ask if some of the cells showing a reduction in response were due to an
antagonist competitively inhibiting the active site, additional experiments were conducted to test
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for competitive inhibition.4, 11, 12 We note that in all of our experiments, the identity of the OR
expressed by the cells is unknown. Due to the nature of the experimental apparatus, we cannot
inspect the data during the experiment and change to a different type of experiment on the same
day. Consequently, after finding evidence for inhibition (Figure 3.2 and 3.3) we planned a new
experiment specifically searching for evidence of pharmacologic antagonism. To determine if the
inhibition was competitive, first the concentration of the antagonist was gradually increased, and
then the concentration of the agonist was gradually increased. We should see a reduction in the
agonist’s response as more antagonists compete with the agonist for the binding site, and we
should see the agonist’s response recovering as more agonist is applied to compete with the
antagonist for the binding site.
Thus, in a new experiment, where one odorant was kept constant and the other varied by
dose, out of 1775 forskolin responding cells, 8 cells (0.45%; compared to 0.46% in Experiment
B) were found to show dose-dependent inhibition by a compound designated as an antagonist.
As seen for one of the 8 cells in Figure 3.4A, the concentration of the agonist, octanal, was kept
constant at 60 µM, while the concentration of the antagonist, 3.5, increased from 30 to 300 µM.
The response of the agonist, octanal (3.2), was gradually reduced as higher concentrations of the
antagonist, cyclohexylethanal (3.5), were applied. Conversely, in a separate experiment, an
example of which is shown in Figure 3.4B, the concentration of the antagonist, 3.5, was kept
constant at 60 µM, while the concentration of the agonist, octanal (3.2), increased from 30 to 300
µM. Out of 1473 cells, the response of octanal was rescued in 2 cells (0.14%; compared to
0.46% in Experiment B). In these cells, the response of the agonist, octanal (3.2), was lower
when co-applied with 3.5. As the concentration of octanal (3.2) increased, the response of
octanal (3.2) was recovered.
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In comparison, the percentage of cells that were antagonized by 3.5 in these two
experiments (0.45% and 0.14%) was lower than that in Experiment B (0.46%). Since a higher
concentration (up to 300 µM compared to only 60 µM in Experiment B) of the antagonist, 3.5,
was applied, we expected a higher percentage of cells to be antagonized. Due to experimental
limitations, we have no control over the types of receptors that were sampled in each experiment,
and the cells that were collected per experiment probably account for less than 1% of the total
population of cells in the olfactory epithelium, so each of our experiment entail a stochastic
sampling, that is, we cannot be sure the same receptors show up in every sampling. Furthermore,
only a low number of cells were antagonized in each separate experiment so that the inclusion or
omission of 1 or 2 cells as an antagonized cell would lead to a significant change in the
percentages. Differences between experiments are inevitable, but we hope to converge to some
general statistics as the total number of cells profiled increase.
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A

B

Figure 3.4: Cells showing competitive inhibition. (A) Dose-dependent inhibition of octanal (3.2) by
cyclohexylethanal (3.5). (B) Response of octanal (3.2) in the absence and presence of cyclohexylethanal (3.5).

3.2.3. Trends between the ability to activate, to antagonize, and to be antagonized (Based
on analysis of data from Experiments A, B, and C)
Octanal (3.2), an aldehyde, activated the highest percentage of forskolin-positive cells
(3.323%) (in agreement with previous work3,

13

), followed by 1-octanol (3.1) (3.152%), an

alcohol, and lastly octanoic acid (3.3), a carboxylic acid (0.880%) (Figure 3.5). This ordering
holds true for their shorter cyclic counterparts as well, with 3.5, an aldehyde, activating the
highest percentage of cells (1.67%), followed by 3.4 (0.52%), an alcohol, and 3.6 (0.21%), a
carboxylic acid (Table 3.2). Although octanal (3.2) activated the most cells, it was also
antagonized in the highest number of cells (31 cells, 37.8%, compared to 5.6% for octanol and
0% for octanoic acid). Octanoic acid activated the fewest cells, but was antagonized in the least
102

number of cells (0 cells). Thus, the cells that were activated by the highest-activating odorant
(octanal) were also the most susceptible to antagonism and vice versa (i.e. the cells that were
activated by the least-activating odorant (octanoic acid) were the least susceptible to
antagonism). However, since antagonism could only be seen for cells that were activated, it’s not
entirely unexpected for the agonist that activated the highest percentage of cells to also be
inhibited the most. One might also state that odorant GPCRs appear to like to bind aldehydes
more than alcohols and acids, and binding may lead to activation or antagonism.
In the tested binary mixtures (3.1&3.2, 3.1&3.3, and 3.2&3.3), antagonism was always
observed to some extent. In the case of the binary mixtures containing 3.1 and 3.2, 3.2 never
inhibited the response of 3.1, but 3.1 could inhibit the response of 3.2 in 4 cells (4.9%). For
binary mixtures containing 3.1 and 3.3, 3.1 never inhibited the response of 3.3, whereas 3.3
inhibited the response of 3.1 in 3 cells (2.4%). For binary mixtures of 3.2 and 3.3, 3.2 never
inhibited the response of 3.3, but 3.3 inhibited the response of 3.2 in 16 cells (19.5%).
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Figure 3.5: Status of each odorant in the 11,707 cells as 1) designated agonist, 2) designated antagonist, and 3) an
agonist whose response is inhibited (susceptibility to antagonism). The percentages are all relative to the total
11,707 cells tested.

The response to octanoic acid (3.3), when it was tested as the designated agonist, was
never inhibited by any of the other odorants, but octanoic acid (3.3) was able to inhibit the
response of the other odorants in several cells. (The odorants were diluted in solutions buffered
to pH = 7.3. The odorants do not change the pH of the solution, eliminating the possibility that
inhibition occurred due to change in the pH.) With the same chain length, but a different
functional group, octanoic acid (3.3) inhibited the response of a total of 3 (out of 125) 1-octanolresponding cells and 16 (out of 82) octanal-responding cells. In comparison, octanal (3.2) did not
inhibit the response of any odorant, and antagonism by 1-octanol (3.1) was substantially lower,
comprising of only 4 (out of 82) octanal-responding cells and 0 (out of 39) octanoic acidresponding cells. In these experiments, the ability of one odorant to act as the antagonist
appeared to be the reverse of their susceptibility to be antagonized (Figure 3.5). Octanal (3.2),
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which did not inhibit the response of any cell, was antagonized in a total of 31 cells (out of 82),
whereas octanoic acid (3.3), which antagonized a total of 19 cells, was never antagonized in any
cell (out of 39). 1-Octanol (3.1) antagonized 4 cells and was antagonized in 7 cells. Hence, the
best antagonist is the worst at being antagonized and vice versa.
Although octanal (3.2) activated the most cells, it was never observed to inhibit the
response of any cell activated by the other odorants tested. As the least activating odorant of the
three functional groups tested, octanoic acid (3.3) was actually found to be the best inhibitor.
Concurrently, octanal (3.2) is known to have a strong, citrus, fruity odor, whereas octanoic acid’s
rancid smell is much fainter in comparison (though perhaps in part due to its higher boiling point
and lower vapor pressure). In regards to the olfactory code, this characteristic of octanoic acid
(3.3) suggest that weakly activating odorants might be triggering signal transduction in very few
ORs, but they could still be binding to many receptors. Odorants with a faint smell may activate
few receptors, but they may nevertheless be effective in masking the odor of highly activating,
strong odorants. This speculative statement is suggested by our data.
3.2.4. Effect of chain length and functional group on activation and antagonism
Multiple ORs were seen to be inhibited by the linear carbon chain odorants and/or the
shorter cyclic analog (Figure 3.2 and 3.3). The molecular features of chain length and functional
group probably play a role in determining antagonism in ORs other than OR-I7 and mOR-EG
(mentioned above), but overall, in our limited study, neither emerged as the clearly more
important antagonist structural feature since the number of cells antagonized by each category,
antagonists with a different chain type, linear or cyclic, (16 out of 38 antagonized cells) and
antagonists with different functional groups (17 out of antagonized 38 cells), were similar (the
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remaining 5 cells were antagonized by both antagonists with different chain length and
antagonists with different functional group).
However, cells that responded to only one odorant, and therefore only one of the three
functional groups tested, were more commonly antagonized by the cyclic odorant bearing the
same functional group (13 out of 20 antagonized cells, Figure 3.2, top: C1-C3, C4-C5, C7-C11,
C14, C19-C20) than were antagonized by the linear odorants bearing a different functional group
(5 out of 20 antagonized cells, Figure 3.2, top: C6, C12, C15, C17-C18 (the two remaining
antagonized cells, C13 and C16, were inhibited by both a cyclic odorant bearing the same
functional group and a linear odorant bearing a different functional group)). These types of cells
appear to be selective for the odorant’s functional group, with antagonism or activation being
determined by structural features of the carbon chain (in our study, the number of carbons in the
chain did not vary).
A majority of the antagonized cells that responded to more than one odorant (11 out of 18
antagonized cells, Figure 3.2, bottom: C21-C22, C25-C26, C28-C33, C35) were inhibited by
only octanoic acid (3.3). Since these cells could bind with multiple odorants, binding to these
cells conceivably relies on the odorants’ affinity to the active site. These cells may be
antagonized by octanoic acid (3.3) due to the higher affinity of octanoic acid for the binding site,
possibly through stronger hydrogen bonding with the amino acid residues on the receptor.14
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3.2.4.1. Linear vs. cyclic
A

B

Figure 3.6: Response of functional group-specific cells. (A) Response pattern of functional group-specific cells. (B)
Proposed binding pockets of linear and cyclic odorant specific receptor.

For all cells that are specific for functional groups, the response of the linear odorants
was never higher than that of their cyclic counterpart. Cells which were specific for functional
groups usually responded more strongly for the shorter, cyclic odorant. Within the group of cells
that responded to both the linear and cyclic odorant bearing the same functional group, cells
which responded more strongly for the linear odorant were never encountered though equipotent
examples were observed (Figure 3.6A). The responses of the linear odorant were either the same
as or lower than the response of the cyclic odorant. Since the linear and cyclic odorants contain
the same number of carbons and the same functional group, but differ in their size and chain
length, the cells that showed similar responses for the linear and cyclic odorants probably have
little preference for the size or chain length. Conversely, the cells showing higher responses for
the cyclic odorant probably prefer its more compact, rotationally restricted shape.
The more flexible, linear odorants can adopt a conformation with a similar size and
length as the cyclic odorants (Figure 3.6B). While the response of the linear odorant would be
weaker due to unfavorable conformational entropy loss and/or steric clashes with amino acids in
the receptor, it might still elicit a response in cells that prefer the cyclic odorant. No cells were
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observed in which the response of the linear odorant was higher (at the same concentration) than
the response of the cyclic odorant, but there should be cells that prefer the size and length of the
linear odorant. In contrast to the flexible linear odorant, the constrained cyclic odorant could not
adopt the chain length of the longer linear odorants (Figure 3.6B). As with the OR-I7 receptor,
the cyclic odorant might act as an antagonist in this type of cell, binding to the receptor but not
activating it due to failure to reach both the aldehyde and small hydrophobic activation pockets
at the same time.5 Notably, there were as many cells that responded to only the linear odorant but
were inhibited by only the cyclic odorant (3 for 1-octanol, Figure 3.2: C1-C3; 10 for octanal,
Figure 3.2: C4-C5, C7-C11, C14, C19-C20; not applicable to octanoic acid) as the number of
cells that responded to only the linear and cyclic odorants with the same functional group (2 for
1-octanol, Figure 3.6A:C39-C40; 9 for octanal, Figure 3.6A: C41-C49). These inhibited cells
may be cells that were more selective for the chain length of the linear odorant. As with the ORI7 receptor, the cyclic odorant was able to compete with the linear odorant for the binding site,
but was unable to activate the receptor, probably because of its shorter chain length.
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A

3.2.4.2. Gem-diol vs. carboxylate
Cells that responded to octanal (3.2) and
octanoic acid (3.3) displayed a similar response
pattern as the cells that responded to the linear and
cyclic odorants bearing the same functional group.

B

For all cells that responded to both octanal (3.2) and
octanoic acid (3.3), the response of octanal (3.2)
was never higher than the response of octanoic acid
(3.3) (for C55-C56, the response of octanal and
octanoic acid were both over 90% when normalized
to forskolin, but the response of octanoic acid was
noticeably higher (data not shown); the response of
octanal was less than 70% of the response of
octanoic acid in both C55 and C56) (Figure 3.7A).

Figure 3.7: Cells responding to only octanal and
octanoic acid. (A) Response pattern of all cells
that respond to octanal (3.2) and octanoic acid
(3.3). (B) Hydrolyzed form of octanal and
deprotonated form of octanoic acid.

At equilibrium in the buffer solution (pH ~ 7.3),
octanal (3.2) is partially hydrated to the gem-diol
form and octanoic acid (3.3) would be fully

deprotonated to a carboxylate. The carboxylate may be able to form stronger hydrogen bonding
or carboxylate ionic interactions15,

16

with the OR compared to the gem-diol (Figure 3.7B),

causing all the cells to produce a weaker response towards octanal (3.2).
The higher affinity that the carboxylate may have for the receptors might explain why
octanoic acid (3.3) was the best antagonist out of the three functional groups tested. Octanoic
acid (3.3) was able to inhibit the response of octanal (3.2) in 16 cells, whereas octanal (3.2) was
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never seen to inhibit the response of octanoic acid (3.3). It is worth mentioning that in several
cells that initially responded to both octanal (3.2) and octanoic acid (3.3) individually (octanal
giving the lower response), the cells stopped responding to octanal (3.2) by the end of the
experiment, but they still responded to octanoic acid (3.3) (these cells were excluded from the
final data due to their inconsistent response to octanal, which consequently lowered the actual
percentage of octanal and octanoic acid responding cells). Exposure of the receptor to a strong
ligand, octanoic acid (3.3), may possibly be desensitizing the response of the weaker ligand,
octanal (3.2).
3.2.5. Correlation between activation and inhibition

3.1
# of Activating
Odorants

Percentage of
Activated Cells

Sum of
Activated Cells
# Antagonized
Cells

3.2

3.4

3.3

3.5

3.6

1 out of 4
3.1 (1.32%)*
3.2 (1.31%)*
3.3 (0.57%)*
3.4 (0.52%)A
3.5 (1.67%)B
3.6 (0.21%)C

2 out of 4
3.1 & 3.2 (1.44%)*
3.1 & 3.3 (0.00%)*
3.1 & 3.4 (0.05%)A
3.1 & 3.5 (0.12%)B
3.1 & 3.6 (0.00%)C
3.2 & 3.3 (0.13%)*
3.2 & 3.4 (0.16%)A
3.2 & 3.5 (0.29%)B
3.2 & 3.6 (0.00%)C
3.3 & 3.4 (0.00%)A
3.3 & 3.5 (0.00%)B
3.3 & 3.6 (0.11%)C

3 out of 4
3.1, 3.2, & 3.3 (0.09%)*
3.1, 3.2, & 3.4 (0.24%)A
3.1, 3.2, & 3.5 (0.37%)B
3.1, 3.2, & 3.6 (0.00%)C
3.1, 3.3, & 3.4 (0.05%)A
3.1, 3.3, & 3.5 (0.00%)B
3.1, 3.3, & 3.6 (0.00%)C
3.2, 3.3, & 3.4 (0.00%)A
3.2, 3.3, & 3.5 (0.00%)B
3.2, 3.3, & 3.6 (0.00%)C

4 out of 4
3.1, 3.2, 3.3, & 3.4 (0.08%)A
3.1, 3.2, 3.3, & 3.5 (0.00%)B
3.1, 3.2, 3.3, & 3.6 (0.05%)C

5.60%

2.30%

0.75%

0.13%

20

11

7

0

*Tested in Experiments A, B, and C; ATested in Experiment A; BTested in Experiment B; CTested in Experiment C
Table 3.2: Percentage of cells that were activated by 60 µM of odorant(s). The responses of 11707 viable cells were
analyzed. Four odorants were tested in each experiment. The response to 1-octanol (3.1), octanal (3.2), and octanoic
acid (3.3) was tested in every cell. All responses were normalized to the response of forskolin at 10 µM. To
calculate the percentages, the number of cells activated by the indicated odorant(s) was divided by the total number
of forskolin responding cells and multiplied by 100%.
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3.2.5.1 Narrowly vs. broadly tuned cells
Cells that were specific for one odorant among the small set of related compounds tested
here (these cells will be referred to as ‘narrowly tuned’ cells) were more common than cells that
responded to more than one odorant (these cells will be referred to as ‘broadly tuned’ cells,
though in the literature broadly tune usually means capable of being activated by a wide variety
of functional groups and carbon chain shapes) (Table 3.2). Of the total 11707 viable cells tested
at 60 µM, 5.6% responded to only one of the four odorants tested, 2.3% responded to two out of
four odorants, 0.75% responded to three odorants and 0.13% responded to all four odorants. The
percentage of responding cells were similar in the individual experiments (Figure 3.8 Experiment A, with 1-octanol (3.1) tested as the agonist, Experiment B, with octanal (3.2) tested
as the agonist, and Experiment C, with octanoic acid (3.3) tested as the agonist). Over half of the
odorant-responding cells, responded to only one out of the four odorants tested, suggesting that

% Responding OSNs

most cells distinguish between these three closely related functional groups.

4
3
Experiment A
Experiment B

2

Experiment C
1
0
1

2

3

4

Number of Activating Odorants

Figure 3.8: Percentage of OSNs responding to 1, 2, 3, or 4 odorants in each experiment. In Experiment A, 1-octanol
(3.1) was tested as the agonist. There were 3830 forskolin-responding cells. In Experiment B, octanal (3.2) was
tested as the agonist. There were 3478 forskolin-responding cells. In Experiment C, octanoic acid (3.3) was tested as
the agonist. There were 4399 forskolin-responding cells.
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The highest number of antagonized cells (20 cells) came from the ‘narrowly tuned’ cells
that responded to only one of the four odorants. The number of antagonized cells gradually went
down for the less common cell types - cells responding to two odorants (11 antagonized cells)
and cells responding to three odorants (7 antagonized cells). Since the “narrowly tuned” cells
were most common, these cells should statistically have a higher chance of being antagonized
compared to the less common cell types.
In Figure 3.2, the cells showing antagonism were divided into two groups, those that are
‘narrowly tuned,’ responding to only one odorant, in this case the agonist (Fig. 3.2, top), and
those that respond to more than one odorant, including the agonist (Fig. 3.2, bottom). Among the
cells that responded to only one out of the four odorants tested, a majority of the cells were
antagonized by the cyclic odorant of the same functional group (13 out of 20 antagonized cells),
whereas among cells that responded to more than one odorant, a majority were antagonized by
octanoic acid (3.3) (11 out of 18 cells showing antagonism). The total number of cells inhibited
by antagonists with a shorter chain length than the agonist (16 cells) was similar to the number of
cells inhibited by antagonists with a different functional group from the agonist (17 cells), but
chain length appeared to be a more common determinant of antagonism among ‘narrowly tuned’
cells, whereas functional group, specifically the carboxyl group of 3.3, appeared to be a more
common determinant among ‘broadly tuned’ cells.
Of the ‘broadly tuned’ cells that showed antagonism, the odorant that was antagonized in
each cell was never the one that stimulated the highest response. Consequently, the response of
the designated agonist was never inhibited in a ‘broadly tuned’ cell wherein the agonist gave the
strongest signal. In these antagonized cells, the agonist had the same or a weaker signal than the
other odorants that could activate those cells (Figure 3.2, bottom). The agonist may possibly
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have a similar or lower efficacy and/or affinity for these receptors, and consequently its response
would be easier to antagonize in these cells, just as it was more difficult to antagonize the
response of octanoic acid (3.3), which was expected to have a higher affinity for the receptors
due to ionic interactions with charged amino acids in addition to hydrogen bonding.
3.2.5.2. 1-Octanol and octanoic acid responding cells

Figure 3.9: Cells that respond to 1-octanol (3.1) and octanoic acid (3.3), but not octanal (3.2).

Among the antagonized cells, there were no cells that could bind to 1-octanol (3.1) and
octanoic acid (3.3) (as an antagonist), without also binding to octanal (3.2). In other words, cells
responding to the alcohol and acid appeared obligated to also bind the aldehyde. This may relate
to how a receptor recognizes and distinguishes these functional groups. The cells that respond
only to 1-octanol (3.1) (Fig. 3.2, top) were only antagonized by the cyclic alcohol (3.4), and the
cells that were antagonized by octanoic acid (3.3) (Fig. 3.2, bottom) responded to octanal (3.2) in
addition to 1-octanol (3.1). Hence, none of the antagonized cells were able to bind with only 1octanol (3.1) and octanoic acid (3.3).
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compared to forskolin, the response pattern of the two cells was nearly identical. These cells
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likely expressed the same receptor, suggesting that there is at least one olfactory receptor in the
mouse genome that can bind 1-octanol (3.1) and octanoic acid (3.3) but not octanal (3.2). In this
case, it occurs in 0.017% of all viable cells (roughly 1 out of 5000 cells). Due to experimental
limitations, it was not possible to look at every single cell, and thus every receptor, in the
olfactory epithelium, but the more cells that are analyzed the closer we would be to analyzing all
the olfactory receptors.
Theoretically, given a constant carbon chain shape, distinguishing the alcohol and
carboxyl group from the aldehyde group should be difficult. A receptor that is specific for
alcohols would bind with 1-octanol (3.1) and the gem-diol form of octanal (3.2) (Figure 3.10A).
A receptor that is specific for the carbonyl group would bind with the aldehyde form of octanal
(3.2) and octanoic acid (3.3) (Figure 3.10B). A receptor that is specific for the hydroxyl group
(or hydrogen donors) would be expected to bind only 1-octanol (3.1) and octanoic acid (3.3), but
because octanal (3.2) forms a significant amount of the gem-diol form,17-19 such a receptor could
bind to all three functional groups (Figure 3.10C). For a receptor to interact with 1-octanol (3.1)
and octanoic acid (3.3) but not octanal (3.2), either the concentration of the gem-diol form
(present at equilibrium in roughly half the amount of octanal (3.2) applied) was not high enough
to activate the receptor selective for hydrogen donors (1-octanol (3.1), octanal (3.2), and octanoic
acid (3.3) were all tested at the same concentration (60 µM), so the fraction of octanal (3.2) that
became hydrated to the gem-diol would be considerably lower compared to the concentration of
1-octanol and octanoic acid present) (i.e. the receptor depicted on Figure 3.10C), or the receptor
could only accommodate one hydroxyl group, whereas there is two present on the gem-diol form
of octanal (3.2) (i.e. the receptor on Figure 3.10D).
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3.2.5.3. 1-Octanol and octanal responding cells
The percentage of cells that responded selectively to one odorant was always observed in
our experiment to be higher than the percentage of cells responding to more than one odorant,
with one exception: cells that respond to both 1-octanol (3.1) and octanal (3.2). The percentage
of cells responding to this pair of odorants (1.44%) was comparable to or even higher than the
percentage of cells that responded to single odorants, with the percentage of cells responding to a
single odorant being highest for 1-octanol (1.32%) and octanal (1.31%). Cells responding to the
other pairs of odorants were noticeably lower (Table 3.2, column 2), with the percentage of the
next most common cell type (aldehyde-specific cells responding only to 3.2 and 3.5, 0.29%)
being around 5-fold lower. Much of the cells appeared to be unable to distinguish between the
alcohol and aldehyde group.3, 13 Of all the cells that responded to octanal (390 cells), 53% (205
cells) were found to also respond to 1-octanol at 60 µM (49%3 and 68%19 of octanal-responding
cells were found to also respond to 1-octanol in rat OSNs at 30 µM). The high percentage of
cells responding to alcohol 3.1 and aldehyde 3.2 might be attributed to the gem-diol form of
aldehyde 3.2. It was previously found that 42% of cells that appear to require (i.e. specific for)
the aldehyde group for activation responded to the gem-diol form.19 The gem-diol form differs
from the aldehyde form in terms of geometry, hydrogen bonding, and dipole strength and
direction to such an extent that it could be considered a different functional group. The hydration
equilibrium constant (KH) for aliphatic aldehydes is around 0.83 at 25°C,17-19 so accordingly,
approximately 45% of the aldehyde is converted to the gem-diol in water at equilibrium. Since
aldehydes convert to the gem-diol form in approximately a one to one ratio in the presence of
water, some of the cells activated by octanal (3.2) may possibly be activated by its gem-diol
form. Cells that responded to both 1-octanol (3.1) and octanal (3.2) may express receptors that
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are specific for the hydroxyl group of alcohols (Figure 3.10A). A portion of the 1octanol/octanal-responding cells may be responding to 1-octanol (3.1) and the gem-diol form of
octanal (3.2). At the same time, for cells where octanal (3.2) was antagonized, it might actually
be the gem-diol form that was antagonized by the antagonists with the different chain length
and/or functional group.
3.3. Conclusions
In this study, limited to the main oxygen functional groups with different oxidation states
(alcohol, aldehyde, and carboxylic acid) with either an eight carbon linear chain or an eight
carbon shorter chain with a cyclohexyl ring, a few notable trends were observed regarding
antagonism. There did not appear to be a clear preference for either chain type or functional
group type as the determinant of inhibition, but octanoic acid (3.3) inhibited the highest
percentage of cells out of the three functional groups tested. Carboxylic acids may have higher
affinity for ORs compared to aldehyde and alcohol possibly due to strong hydrogen bonding and
charge-charge interactions. While octanoic acid (3.3) inhibited the response of the most cells
compared to 1-octanol (3.1) and octanal (3.2), it was also the weakest activator, activating the
lowest percentage of cells. In comparison, although octanal (3.2) did not inhibit the response of
any cells, it was the best activator, suggesting a possible inverse-correlation between the ability
of an odorant to activate versus inhibit ORs. None of the functional group-specific receptors
responded more strongly to the linear odorant compared to the cyclic odorant, suggesting that
chain length/shape may be a dominant feature of functional group-selective ORs. When an
odorant contains a chain below a certain length (number of carbons), it may bind but fail to
satisfy some distal steric requirement for activation, and becomes an antagonist. A relatively
small set of odorants were tested in this study to ensure the viability of the cells by the end of the
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experiment. In order to confirm the observed trends, a larger set of odorants would need to be
tested.
In this study, agonism appears to be more common than antagonism, but in comparison to
agonism, it’s more difficult to identify all the cells that were antagonized. Activation of a cell is
determined from the rise in the calcium level, but since there would be no change in the calcium
level when a ligand binds but not activate a receptor, it is not possible to check for antagonism
(i.e. binding) if an agonist of the receptor was not present. In this study, we only see antagonism
in the cells that were activated by one of the odorants designated as an agonist. Each odorant
might be binding a higher percentage of cells than what was observed, but evidence of
antagonism was only limited to the cells in which an agonist was applied. In addition, only one
concentration (60 µM) was used for the agonist and antagonist. Even though the response of the
agonist might not be inhibited at 60 µM by an antagonist, it may be inhibited if a higher
concentration was applied, and in designing such experiments, it is not clear what concentrations
are the most physiologically relevant. To ensure that the reduction in signal was due to
antagonism and not signal fluctuation, only cells showing over 70% reduction in activity were
considered to be antagonized (we did not want to mistake response-to-response variation for
antagonism), but there may also be cells that were antagonized, and suppressed by less than 70%
at the tested concentration. Thus, we used a stringent criterion for calling antagonism.
The percentage of antagonism in cells may be underestimated in this study, but still,
antagonism was seen in several cells and as long as antagonism occurs, the original olfactory
code of the odorant would be modified. All of the tested binary mixtures (3.1&3.2, 3.1&3.3, and
3.2&3.3; not applicable to the mixtures containing the cyclic odorants because antagonism of the
cyclic odorant by the linear odorant was not tested in all possible combinations, but signs of
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antagonism were already seen for 3.1&3.4 and 3.2&3.5) displayed some degree of antagonism.
In each pair of odorants, one of the two odorants would serve as the antagonist, while the other
acted as the agonist. Unlike rodents, humans are predicted by their genomic DNA to have only a
few hundred olfactory receptors, but we may be exposed to hundreds of different odorants at
once. As more receptors become activated, everything would be expected to eventually converge
to the same smell if antagonism, or some other kind of mixture suppression,2 were not at work in
the mixture. Mixtures clearly do not all converge to the same smell. Antagonism of the receptors
may possibly act as a fine tuning mechanism to produce the smell that we experience, with our
larger brains sorting out the greater combinatorial complexity of signals generated in the nose.
3.4. Experimental Procedures
Materials and reagents
Unless otherwise stated, chemical reagents and solvents were purchased from VWR
International, Fisher Scientific, or Sigma Aldrich and used without further purification. C57BL/6
mice were purchased from Charles River Laboratories. Octanal (3.2) was distilled before use. 1Octanol (3.1) and octanoic acid (3.3) were purified by flash chromatography prior to testing.
Aldehydes were stored at 4°C under vacuum prior to testing. Analytical TLC was performed on
silica gel 60 F254 plates. Flash chromatography20 was performed on Teledyne Isco CombiFlash
Rf-200 flash chromatography system. 1H and

13

C NMR spectra were recorded on a Varian

Mercury 300 spectrometer or a Bruker Ultrashield 500 spectrometer. Infrared (IR) spectra were
recorded using Thermo Nicolet 6700 FT-IR spectrometer. (Note: The literature procedure that
was applied for each reaction is cited. The procedure may not necessarily be used for the
synthesis of the same compound as in the literature.)
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2-Cyclohexylethanol (3.4) (Compound 2.2a in chapter 2). Compound 3.4 was
synthesized according to a literature procedure.5 Ethyl cyclohexylacetate (2 g, 11.7
mmol) in diethyl ether (10 mL) was added slowly to lithium aluminum hydride (0.49
g, 13 mmol) in diethyl ether (40 mL) at 0°C. The suspension was stirred at room temperature for
2 h and then cooled to 0°C. Water (0.5 mL) was added, followed by 15% sodium hydroxide (0.5
mL) and water (1.5 mL). The solution was stirred for a few minutes at room temperature, filtered
through a celite pad, washed with diethyl ether, dried, and concentrated. The crude was purified
by flash chromatography eluting with ethyl acetate/hexanes (1:9) to obtain the alcohol 3.4 (1.5 g,
11.7 mmol) as a clear liquid in 99% yield. 1H NMR (CDCl3) δ: 3.68 (t, J = 6.7 Hz, 2H), 1.78 1.59 (m, 5H), 1.51 - 1.11 (m, 7H), 1.02 - 0.84 (m, 2H). 13C NMR (CDCl3) δ: 60.89, 40.39, 34.22,
33.38, 26.57, 26.29. IR (thin film, KBr plates) ν (cm-1): 3332 (broad), 2922, 2852, 1448, 1051,
1011, 978. Spectral data match those reported previously.5
Cyclohexylacetaldehyde (3.5) (Compound 2.2 in chapter 2). Compound 3.5 was
synthesized according to a literature procedure.5 The alcohol 3.4 (200 mg, 1.56 mmol)
was added to pyridinium chlorochromate (370 mg, 1.7 mmol) and silica gel (370 mg)
in dry dichloromethane (10 mL) under inert atmosphere. The suspension was stirred for 2 h and
then passed through a silica gel pad. The solution was concentrated to give the aldehyde 3.5 (140
mg, 1.11 mmol) in 71% yield. 1H NMR (CDCl3) δ: 9.75 (s, 1H), 2.29 (dd, J = 1.9, 6.9 Hz, 2H),
1.97 - 1.57 (m, 6H), 1.40 - 0.84 (m, 5H).

13

C NMR (CDCl3) δ: 203.00, 51.38, 33.22, 32.68,

26.04, 25.97. IR (thin film, KBr plates) ν (cm-1): 2925, 2853, 2712, 1725, 1449, 1408, 1297,
1193, 1020, 900. Spectral data match those reported previously.5
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Cyclohexylethanoic acid (3.6). Compound 3.6 was synthesized based on a
literature procedure.21 Ethyl cyclohexylacetate (936 mg, 5.5 mmol) was placed in 1
M NaOH (90% methanol in water, 30 mL) and stirred for 3 h. The mixture was
concentrated and water (25 mL) was added. The solution was acidified with 5 M HCl (6 mL) and
extracted with ethyl acetate (3 × 20 mL). The organic layer was washed with brine, dried, and
concentrated. The crude was purified by flash chromatography eluting with ethyl acetate/hexanes
(1:9) to give the carboxylic acid 3.6 (560 mg, 3.9 mmol) in 72% yield. 1H NMR (CDCl3) δ:
11.57 (s, 1H), 2.23 (d, J = 6.3 Hz, 2H), 1.91 - 1.52 (m, 6H), 1.44 - 1.08 (m, 3H), 1.08 - 0.69 (m,
2H). 13C NMR (CDCl3) δ: 179.55, 41.90, 34.66, 32.97, 26.09, 26.00. IR (thin film, KBr plates) ν
(cm-1): 3029 (broad), 2925, 2853, 1707, 1449, 1411, 1297. Spectral data match those reported
previously.22, 23
Calcium imaging of mouse olfactory sensory neuron
Calcium imaging was performed as described previously.5 All animal procedures were approved
by the City College of New York Institutional Animal Care and Use Committee (IACUC) and
performed at the City College of New York in compliance with relevant national guidelines and
regulations. Dissociated olfactory epithelium tissue was obtained from 6-8 weeks old C57B/6
mice by my colleague, Mihwa Na. The tissues were placed into a 15 mL Corning conical
polypropylene centrifuge tube containing an enzyme solution made with BSA (0.015 g),
collagenase (0.0025 g), and 3 mL of DICAT-free Ringer solution containing sodium chloride
(145 mM), potassium chloride (5.6 mM), HEPES at pH 7.4 (10 mM), glucose (10 mM), and
EGTA (4 mM). The cells were incubated at 37°C for 1 h in the enzyme solution. The tissues
were then allowed to settle to the bottle of the conical tube and the enzyme solution was replaced
with a media containing DMEM/F12-HAM, 10% FBS (Gibco), 1% Pen/Strep (Gibco), and 1X
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Insulin-Transferrin-Selenium-X (Gibco). Most of the media was removed and the tissues were
gently vortexed to dissociate the cells. The cells were allowed to adhere to coverslips pre-coated
with the protein concanavalin A. The cells were allowed to recover in the media containing 0.02
M vitamin C (ascorbic acid) at 37°C for 45 minutes. The media was then replaced with 1 mL of
Ringer solution (sodium chloride (138 mM), potassium chloride (5 mM), HEPES at pH 7.4 (10
mM), calcium chloride (1 mM), magnesium chloride (1.5 mM), and glucose (10 mM))
containing Fura-2 (6.25 µL) and pluronic acid (1 µL), and incubated for another 45 minutes at
room temperature in the dark. The cells were placed in new Ringer solution and left at room
temperature for 10 minutes. The coverslip containing the cells were viewed under a fluorescence
microscope and the response was obtained using Metamorph. Odorants were applied via in-line
syringes hooked up to a manifold for 8 seconds at 2 minutes intervals and the antagonist was
applied 4 seconds before and during application of the agonist.
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Chapter 4: Small molecular activators of the pre-mRNA 3’ cleavage reaction
Parts of this chapter have been published in Bioorganic and Medicinal Chemistry, 22 (2), Liu,
M.; Nagre, N. N.; Ryan, K., Structurally diverse low molecular weight activators of the
mammalian pre-mRNA 3’ cleavage reaction, 834-841.
4.1. Introduction
Eukaryotic pre-messenger RNA (pre-mRNA) undergoes multiple processing steps prior
to translation, and each of these steps provides the cell with an opportunity for gene expression
regulation.1 The pre-mRNA 3’ cleavage step, a site-specific RNA hydrolysis reaction that
specifies where the polyadenylate (poly(A)) tail will be added to the mRNA, can take place at
different locations near the 3’ end of a nascent mRNA, downstream of the translation stop codon.
This variability leads in many genes to alternative mRNA isoforms with different 3’ untranslated
regions (3’UTRs) between the stop codon and the poly(A) tail.2, 3 The pre-mRNA 3’ cleavage
step can influence the stability of the mature mRNA because many 3’UTRs contain destabilizing
sequences and miRNA binding sites, the loss of which, when 3’ cleavage occurs relatively close
to the stop codon, may slow turnover and allow escape from repression.2,

4-6

Shorter 3’UTRs

resulting from alternative polyadenylation in some oncogenes have been correlated with cellular
proliferation and may contribute to oncogenesis.7,

8

The 3’ cleavage and polyadenylation

reactions are coupled in vivo but can be studied separately in vitro. Natural product inhibitors of
the pre-mRNA polyadenylation step have recently been found.9,

10

However, low molecular

weight compounds that influence the 3’ cleavage step in cells are not yet available, but would
enable new experimental inquiries into the multi-protein complex that carries out 3’ cleavage,
and might provide a chemical tool to influence alternative polyadenylation.
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We previously found in vitro evidence that a kinase-phosphatase pair may exert influence
over the 3’ cleavage reaction.11 Considering this possibility led us to propose that creatine
phosphate, long known to stimulate the in vitro reaction at high concentration,12, 13 might do so
by acting as a serendipitous inhibitor of an unknown 3’ cleavage-suppressing protein
phosphatase. This model led to experiments identifying two protein phosphatase 2C (PP2C,
a.k.a. PPM1) family inhibitors that stimulated 3’ cleavage in place of creatine phosphate.14 In
humans, the PPM1 superfamily consists of at least eighteen different Mg2+- or Mn2+-dependent
Ser/Thr phosphatases defined by shared sequence homology.15-18 In plants, the PPM1 family is
greatly expanded, with at least 80 family members in Arabidopsis.19 The in vitro 3’ cleavage
reaction is carried out in the presence of excess EDTA, where free Mg2+ and Mn2+
concentrations are very low. Thus, if a PPM1 family member is involved in vitro, it would likely
act in a manner that does not require its metal-dependent enzymatic activity, perhaps acting
allosterically or by influencing the multi-protein 3’ cleavage factor complexes.
While progress in other major protein phosphatase families has benefited from the
identification of natural product inhibitors,20 inhibitor discovery for the PPM1 family has been
slower. The inhibitors we previously identified as 3’ cleavage activators had been discovered
using the PPM1A family member.21 They had micromolar potency against PPM1A and only
modest selectivity for the PPM1 family over the other major protein phosphatase families.21 By
analogy with the toxin inhibitors of the other protein phosphatase families, we expect PPM1
inhibitors to show a measure of family-specific activity, enabling 3’ cleavage activation even if
PPM1A is not the actual family member involved in pre-mRNA 3’ cleavage. Here, we have
tested more potent PPM1 inhibitors for pre-mRNA 3’ cleavage activity, and carried out
structure-activity relationships for two previously identified 3’ cleavage activators. Though we
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are not yet able to identify the protein targeted by these small molecules, our results strengthen a
model in which a PPM1 family member or related protein acts to suppress 3’ cleavage in vitro.
4.2. Results and Discussion
4.2.1. Pre-mRNA 3’ cleavage activation by a potent PPM1D cyclopeptide inhibitor
Cyclic phosphopeptides based on substrates of the PPM1D family member, also known
as Wip1, are among the most potent inhibitors of any PPM1 family phosphatase.22, 23 We used
one of these, cyclic peptide 38 (cp38, Fig. 4.1A),22 in place of 50 mM creatine phosphate in the
in vitro pre-mRNA 3’ cleavage reaction. This peptide inhibits PPM1D with a Ki of 150 nM.22 In
the 3’ cleavage assay, a standard in vitro pre-mRNA 3’ cleavage substrate adapted from the
simian virus 40 (SV40) late poly(A) signal24 is exposed to partially purified 3’ cleavage factors
from HeLa cell nuclear extract.11, 13, 25, 26 Cleavage of the radiolabeled substrate into its 5’ and 3’
fragments can be observed and quantitated following resolution on a denaturing polyacrylamide
gel. In the absence of creatine phosphate, or other activator, this reaction is inefficient. In all
experiments presented here, the amount of cleavage brought about by an activator (5’
fragment/(5’ fragment+uncleaved SV40L RNA)) is normalized to that brought about by 50 mM
creatine phosphate (R.C., or relative cleavage in figures). As shown in Fig. 4.1B, at 200 nM,
cp38 activated a level of RNA cleavage comparable to that produced by 50 mM creatine
phosphate. Removal of cp38’s serine and tyrosine phosphate groups with calf intestinal alkaline
phosphatase (CIP) prior to cleavage, led to complete loss of activation, while removal of only the
tyrosine phosphate, using a tyrosine-specific phosphatase, did not reduce activity. (Residual CIP
activity was inhibited11 before cp38 was added to the in vitro reaction to prevent possible
dephosphorylation of the cleavage factor proteins.) A repeat of this experiment is shown on
Figure 4.1D. Cyclopeptide cp38 is therefore 1000-fold more potent than the most potent 3’
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cleavage activator previously identified,14 and phosphorylation of its serine, which is required for
PPM1 inhibition,23 is required to activate pre-mRNA 3’ cleavage. PPM1D is present at very low
levels in HeLa cells,27 an observation that lead us to suppose that cp38 is likely not working
through this PPM1 family member, but may instead be a family-specific inhibitor that activates
3’ cleavage through another family member, or homologous protein.
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Figure 4.1: Pre-mRNA in vitro 3’ cleavage activation by PP2C inhibitors. (A) Structure of cyclic peptide cp38 and
(S)-(+)-abscisic acid (ABA). (B) Denaturing gel analysis of SV40L pre-mRNA 3’ in vitro cleavage reactions
activated by cp38. Creatine phosphate (CP) or cp38 was added, with or without pre-treatment with CIP (calf
intestinal alkaline phosphatase), mock CIP (CIP buffer only) or tyrosine phosphatase (YOP). Residual CIP activity
was completely removed before mixing cp38 with cleavage factor proteins.11 Relative cleavage (R.C. = [5’
fragment/(5’ fragment + uncleaved RNA)]X100) was normalized to CP, which is set to R.C. = 1.00. (C) Denaturing
gel analysis of in vitro cleavage using ABA in place of CP. DMSO lane corresponds to reaction without ABA. (D)
Repeat of pre-mRNA 3’ cleavage reaction using cp38 as activator. (E and F) Repeat of pre-mRNA 3’ cleavage
reaction using ABA as activator.
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4.2.2. Pre-mRNA 3’ cleavage activation by abscisic acid
To further test the hypothesis that a PPM1 family member acts to suppress 3’ cleavage,
we used the isoprenoid plant hormone (S)-(+)-abscisic acid (ABA). This natural product is a
potent inhibitor of the group A plant PPM1 enzymes.28 It works by forming a ternary complex
with the PPM1 enzyme and a co-receptor from the PYR/PYL/RCAR family of ABA receptors.28,
29

For example, ABA inhibits the plant PPM1s ABI1 and ABI2 with IC50 values of 60 nM and 70

nM, respectively, when RCAR1 is present.29 ABA is bound mainly by the PYR/PYL/RCAR
receptor, but also makes contact with the PPM1.30, 31 In the absence of a PYR/PYL/RCAR coreceptor, ABA can directly inhibit some plant PP2C/PPM1 enzymes in vitro, though with much
lower potency. For example, ABA reduces ABI2 phosphatase activity in vitro by about 15% at
ABA concentrations above 3 M.29 We found no pre-mRNA 3’ cleavage activation when
nanomolar concentrations of ABA were used in place of creatine phosphate (not shown).
However, at and above 100 M ABA, approximately 10%-15% of the normal 3’ cleavage
activity was observed (cf. 50 mM creatine phosphate) (Fig. 4.1C). Two repeats of this
experiment are shown on Figures 4.1E and 4.1F. We consider two possible interpretations of this
result. First, the absence of activation at nanomolar ABA concentration may indicate that there
are no conserved mammalian proteins that can act in the manner of the plant PYR/PYL/RCAR
co-receptors, though ABA is found in animal cells.32 A BLAST search did not reveal any human
RCAR homologs. Second, homology between the plant and human PPM1 proteins may be
sufficient to conserve the direct but much less potent inhibition of PPM1 family members. In
either case, though its cleavage activation efficiency was low, compared to our first generation
compounds, ABA is a relatively potent 3’ cleavage activator. This result adds to the
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accumulating though circumstantial evidence that a PPM1 family member can influence premRNA processing.
4.2.3. Structure-activity study of arginine β-naphthylamide: Aryl group and side chain
Prior to the present work, compound 4.1 (Fig. 4.2A) was identified as a 3’ cleavage
activator through a limited structure-activity relationship study undertaken using commercially
available compounds related to our initial lead, leucine β-naphthylamide, a weak PPM1A
inhibitor.14 To search for a more potent activator than 4.1, we synthesized a series of analogs in
which the naphthalene ring was altered (Fig. 4.2A, 4.2-4.4) or the guanidino group was alkylated
or replaced by another positively charged group (Fig. 4.2A, 4.5-4.6).

129

A

B

C

D

E

z

Figure 4.2: Structure-activity study of compound 4.1, previously found to activate pre-mRNA 3’ cleavage in vitro.
(A) Analogs included changes to the naphthyl group and the arginine side-chain of 4.1. (B) In vitro 3’ cleavage
results for duplicate cleavage reactions using the indicated analogs in place of 4.1, all at 1 mM. R. C., relative
cleavage, defined in Fig. 4.1, normalizes all compounds to activation by 50 mM CP.
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The synthesis of compounds 4.2-4.6 (Scheme 4.1, A and B) was accomplished by coupling the
relevant aryl amine to the suitably protected arginine, ornithine or lysine, followed by
guanidinylation where necessary, and finally deprotection.
A

B

C

Scheme 4.1: (A and B) Synthesis of the arginine--naphthylamide analogs used in Fig. 4.2. (C) Synthesis of
morpholine analog 4.7 used in Fig. 4.3.
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We evaluated each of the compounds shown in Fig. 4.2A for their ability to activate in vitro 3’
cleavage at 1 mM in place of, and compared to, 50 mM creatine phosphate. The results of
duplicate reactions are shown in four independent 3’ cleavage reactions in Fig. 4.2, B-E.
Changes to the naphthalene ring and guanidino group of 4.1 led to loss of activity (compounds
4.2, 4.3, 4.4, 4.5), and the guanidino group could not be replaced by trimethylammonium
(compound 4.1 vs. 4.6), even though both groups have a positive charge.
4.2.4. Arginine β-naphthylamide modified at the -position retains potency
In previous work we found that acetylation of the -amino group of leucine naphthylamide led to some loss of that compound’s 3’ cleavage activity, as well as a significant
decrease in solubility, a point of practical importance due to the high activator concentrations
needed for activity. In view of the poor results changing the naphthyl and guanidino groups of
lead compound 4.1, we decided to modify the -amino group. To minimize a reduction in
solubility we chose the morpholine group for its high water solubility (compound 4.7, Fig. 4.3,
and Scheme 4.1C). Unlike the other changes, this modification retained activity. A representative
in vitro 3’ cleavage comparison of 4.7 with 4.1 over 25 to 200 M (as usual, in place of, and
compared to, creatine phosphate) is shown in Fig. 4.3B. Corroborating experiments are shown on
Figure 4.3C and 4.3D. Compound 4.7 proved to be slightly more potent than lead compound 4.1,
and to have a similar maximum relative cleavage (Fig. 4.3B). While only slightly more potent
than 4.1, the activity of compound 4.7 indicates that modifications of the alpha amine can be
tolerated, and that this part of the molecule merits a larger SAR study beyond the scope of the
present work.
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A

B

C

D

Figure 4.3: Structure and 3’ cleavage activity of a morpholine-modified arginine--naphthylamide analog. (A)
Structure of 4.7. (B) Side by side comparison of 4.1 and 4.7 in an SV40L pre-mRNA 3’ in vitro cleavage reaction.
R. C., relative cleavage, as defined in Fig. 4.1, with activation by 50 mM creatine phosphate (CP) set to 1.00. (C
and D) Repeats of pre-mRNA 3’ cleavage reaction.

4.2.5. Structure-activity study on phosphocholine
We previously identified phosphocholine as a pre-mRNA 3’ cleavage activator. Like
creatine phosphate, it activates 3’ cleavage over the 10-50 mM range.14 Its ability to inhibit
PPM1 family proteins is unknown. Phosphocholine is an intermediate in the biosynthesis of
phosphatidylcholines, and it is unlikely to be a physiological cofactor in 3’ cleavage.14 However,
understanding the determinants of 3’ cleavage activity of this very simple structure might help us
to design more potent activators. To learn whether all three methyl groups are necessary for
activity, we synthesized the mono- and dimethyl phosphocholine analogs, 4.9 and 4.10 (Scheme
4.2A). Their synthesis is shown in Scheme 4.2B. We also made an analog of phosphocholine
with an extra carbon between the charged groups (compound 4.11, Scheme 4.2A, C). None of
these compounds showed detectable in vitro 3’ pre-mRNA cleavage activity (not shown). The
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lack of activity in these analogs showed that all three methyls of the trimethylammonium group
are required, and the two-carbon spacing between this group and the phosphate is critical.
A

B

C

Scheme 4.2: Phosphocholine (PhC) analogs. (A) Structures of the analogs. (B) Synthesis of analogs 4.9 and 4.10.
(C) Synthesis of analog 4.11.

4.2.6. Phosphocholine as a possible modified histone protein mimic
Trimethyllysine and phosphoserine residues are commonly found among the histone
proteins of chromatin,33 where in vivo transcription takes place. Since several of the 3’ cleavage
factor proteins associate with transcribing RNA polymerase II34, 35 and the 3’ cleavage reaction is
coupled to transcription and begins co-transcriptionally,36,

37

it is conceivable that a histone

protein could, within the chromatin, locally interact with RNA polymerase II-associated cleavage
factor proteins to play a role in 3’ cleavage. In trying to understand how phosphocholine
activates 3’ cleavage in vitro, we have considered the possibility that it may mimic a modified
histone protein having closely situated trimethyllysine and phosphoserine (or threonine) residues
(Fig. 4.4A). In an initial test of this idea, we replaced 50 mM creatine phosphate in a 3’ cleavage
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reaction with dipeptide 4.12, Ac-Lys(Me)3-Ser(PO4)-CO2H (Fig. 4.4B). Peptide 4.12 may also be
viewed as a derivative of phosphoserine which, like creatine phosphate, activates 3’ cleavage in
the 10 to 50 mM range.38 Peptide 4.12 activated in vitro 3’ cleavage at 1 mM (Fig. 4.4C), while
phosphoserine and phosphocholine14 have no effect at this concentration. A repeat of this
experiment is shown on Figure 4.4D. This result shows that placing the two functional groups of
phosphocholine in the structural context of a dipeptide, where they can approach each other as
closely as they do in phosphocholine, reduced the concentration necessary for them to activate 3’
cleavage. Viewed differently, placing phosphoserine in a dipeptide coupled to N(acetyl)trimethyllysine (to create 4.12) led to increased potency. While far from directly
implicating a histone protein in the 3’ cleavage reaction, this result indirectly supports the
possibility that phosphocholine works by mimicking such a cleavage-promoting modified
histone variant. We note that the partially purified protein 3’ cleavage factors used in our assay
are fractionated from soluble nuclear proteins, and not from the chromatin-rich insoluble nuclear
pellet, so a cleavage-enhancing chromatin protein would be depleted or lost during cleavage
factor preparation. Interestingly, the PPM1G family member plays a role in histone H2A-H2B
exchange into chromatin.39 PPM1G is also involved in splicesomal splicing,40 a pre-mRNA
processing step that can be coupled to 3’ cleavage.41 In view of this context, this result justifies
additional study of suitably modified lysine, serine and threonine-containing peptide sequences
taken from the heavily modified histone protein tails.
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A

B

C

D
Figure 4.4: Phosphocholine (PhC) as a mimic of a modified histone
protein tail. (A) Phosphocholine holds a trimethyl ammonium group
close to a phosphate, as a histone protein can do with trimethylated
lysine and phosphoserine (or phosphothreonine). (B) Structure of
dipeptide 4.12. (C) SV40L pre-mRNA 3’ cleavage activation by
peptide 4.12 compared to phosphocholine (PhC), creatine phosphate
(CP) and phosphoserine (PS). R.C., relative cleavage, as defined in
Fig. 4.1. (D) Repeat of pre-mRNA 3’ cleavage reaction.

4.2.7. Inhibitory activity of pre-mRNA 3’ cleavage activators
The small molecules that we have found to activate pre-mRNA cleavage were either
inhibitors of a protein phosphate or analogs of inhibitors. Therefore, it is of interest to determine
whether the small molecules were activating cleavage through inhibition of a protein
phosphatase. While we speculate that a protein phosphatase may be involved in the cleavage
reaction, we are uncertain as to which protein is actually involved. As a preliminary test, PPM1A
was used as a representative enzyme. PPM1A may not be the exact protein phosphatase involved
in the cleavage reaction, but it should be structurally homologous to the other protein
phosphatase in the family and possibly share some family-specific activity.
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1.2
1
0.8
0.6
0.4
0.2
0

Compounds

Figure 4.5: Inhibitory activity of small molecule activators. The ability of the small molecule cleavage activators
(creatine phosphate (CP), phosphocholine (PhC), arginine β-naphthylamide (4.1), 4.2 (an analog that is not a
cleavage activator at the tested concentration), 4.7, dipeptide 4.12, abscisic acid (ABA), and cyclic peptide 38
(cp38)) to inhibit PPM1A was tested using para-nitrophenylphosphate (pNPP) as the substrate.

The inhibitory activities for a selected group of small molecules were tested at the
concentration at which they activate cleavage using p-nitrophenylphosphate as the substrate.
Unfortunately, besides creatine phosphate and phosphocholine, which stimulated over 40%
reduction in activity, the other cleavage activators were not able to significantly inhibit PPM1A
at the concentration in which they activate pre-mRNA 3’ cleavage. This result signifies that
either the compounds were not activating cleavage through inhibiting a protein phosphatase or
that the compounds were suppressing a protein phosphatase which was not PPM1A.
4.3.

Conclusions
Guided by a model proposing that a PPM1 phosphatase acts to suppress or negatively

regulate the pre-mRNA 3’ cleavage reaction, an obligatory step in the maturation of nearly all
eukaryotic mRNAs, we have assayed a group of structurally diverse PPM1 inhibitors and new
synthetic small molecules for their ability to activate this reaction in vitro. Our results lend
further, though circumstantial, support to this model. The minimal concentration required for in
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vitro cleavage has been improved from 200 M to the 200 nM-100 M range. In addition, our
results point to future experiments aiming to further the goal of developing membrane-permeable
small molecule activators of 3’ cleavage sufficiently potent for use in tissue culture experiments.
4.4. Experimental procedures
4.4.1. Materials and methods
Unless otherwise stated, commercial reagents and solvents were used without additional
purification. Solvents were purchased from VWR. Cyclic peptide 38 (cp38) was provided by E.
Appella and R. Hayashi and made as previously described.22 (S)-(+)-Abscisic acid (ABA),
phosphocholine (PhC), and phosphoserine (PS) were purchased from TCI America. Creatine
phosphate (CP) was purchased from Calbiochem. Compound 4.1 was purchased from Bachem.
Compound 4.8 was purchased from Fluka. Compound 4.12 was purchased from Shanghai
Apeptide Co., Ltd. Unless otherwise stated, starting reagents were purchased from VWR.
Analytical TLC was performed on silica gel 60 F254 plates. Flash chromatography was performed
manually in glass columns on 230-400 mesh silica gel (Alfa Aesar). Analytical samples were
dried overnight in vacuo over phosphorus pentoxide prior to testing. Melting points were
measured on a Laboratory Devices Mel-Temp apparatus. 1H and 13C NMR spectra were recorded
on a Varian Mercury 300 spectrometer or Varian Inova 500 spectrometer. High-resolution mass
spectra (HRMS) were measured using electrospray ionization (ESI) on a Waters LCT XE (TOF)
mass spectrometer by Dr. L. Yang (CCNY). Infrared (IR) spectra were recorded using a Thermo
Nicolet 380 FT-IR spectrometer or Thermo Nicolet 6700 FT-IR spectrometer.
4.4.2. General Procedure for the synthesis of compounds 4.2-4.4
Z3-Arg-OH (Z, benzyloxycarbonyl) was dissolved in dichloromethane. 1.2 equiv. of the amine
was added followed by 2.5 equiv. of 1-hydroxy-7-azabenzotriazole (HOAt). 1.5 equiv. of 1-
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ethyl-3-(3-dimethyllaminopropyl)carbodiimide

hydrochloride

(EDC)

was

dissolved

in

dichloromethane and slowly added to the reaction at room temperature. Reaction progress was
monitored by TLC (ethyl acetate:dichloromethane). The solution was washed sequentially with
0.5 M HCl solution, water, brine, dried, and concentrated. The crude was purified by flash
chromatography.42 The resulting product was hydrogenated in methanol using a latex balloon
with catalytic amount (approximately a spatula tip) of palladium hydroxide (Pd 20% on carbon,
nominally 58% water) for 3 hours. The solution was then filtered through celite and concentrated
to yield the final product.
2-Amino-5-guanidino-pentanoic acid phenylamide (4.2).
White solid (yield 72%, m.p. 110°C dec.). 1H NMR (D2O) δ: 7.17 - 7.32
(m, 4H), 7.10 (m, 1H), 3.89 (t, J = 6.33 Hz, 1H), 2.95 - 3.11 (m, 2H),
1.70 - 1.87 (m, 2H), 1.43 - 1.61 (m, 2H).

13

C NMR (D2O) δ: 169.49,

156.78, 135.98, 129.51, 129.35, 126.24, 122.05, 121.83, 53.80, 53.51, 40.43, 28.65, 23.63. IR
(neat) ν (cm-1): 3175, 1655, 1596, 1546, 1442, 1360, 1309, 1253, 752, 691. HRMS (ESI)
[M+H]+: Calcd for C12H19N5O m/z = 250.1668, found m/z = 250.1655.
2-Amino-5-guanidino-pentanoic acid naphthalen-1-ylamide (4.3).
White solid (yield 62%, m.p. 166°C dec.). 1H NMR (D2O) δ: 7.57 7.75 (m, 3H), 7.21 - 7.41 (m, 4H), 4.18 (t, J = 6.33 Hz, 1H), 2.99 (t, J =
6.60 Hz, 2H), 1.79 - 1.99 (m, 2H), 1.47 - 1.73 (m, 2H). 13C NMR (D2O)
δ: 169.52, 156.62, 133.93, 130.49, 128.71, 128.46, 128.05, 127.07, 125.63, 124.10, 121.95,
121.66, 53.35, 53.11, 40.34, 28.33, 23.86. IR (neat) ν (cm-1): 3149, 1658, 1536, 1497, 1348, 793,
770. HRMS (ESI) [M+H]+: Calcd for C16H21N5O m/z = 300.1824, found m/z = 300.1816.
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2-Amino-5-guanidino-pentanoic acid quinolin-3-ylamide (4.4).
Yellow solid (yield 30%, m.p. 113°C dec.). 1H NMR (D2O) δ: 9.34
(s, 1H), 8.97 (s, 1H), 8.02 (d, J = 8.80 Hz, 1H), 8.07 (d, J = 8.53 Hz,
1H), 7.91 (t, J = 7.70 Hz, 1H), 7.72 - 7.84 (m, 1H), 4.19 (t, J = 6.46
Hz, 1H), 3.11 (t, J = 6.74 Hz, 2H), 1.97 (m, 2H), 1.51 - 1.73 (m, 2H). 13C NMR (D2O) δ: 168.80,
156.79, 138.45, 138.08, 135.98, 135.76, 135.28, 134.63, 131.59, 130.88, 129.07, 120.31, 119.94,
53.65, 53.39, 40.37, 28.01, 23.66. IR (neat) ν (cm-1): 3159, 1663, 1558, 1491, 1466, 1365, 782,
747. HRMS (ESI) [M+H]+: Calcd for C15H20N6O m/z = 301.1777, found m/z = 301.1786.
2-Amino-5-(N'-ethylguanidino)-pentanoic acid naphthalen-1-ylamide
(4.5). Boc-Ornithine(Z)-OH (500 mg, 1.36 mmol) was dissolved in
dichloromethane (25 mL). 1-Naphthylamine (234 mg, 1.64 mmol) was
added followed by HOAt (464 mg, 3.41 mmol) and EDC (392 mg, 2.05
mmol). Reaction progress was monitored by TLC. The resulting material was purified by flash
chromatography, eluting with dichloromethane/ethyl acetate (9:1) to give 4.5a (531 mg, 1.08
mmol, 79% yield). Compound 4.5a (531 mg, 1.08 mmol) was hydrogenated for 2 h in methanol
(50 mL) with a catalytic amount of palladium hydroxide as described in section 4.4.2. The
solution was filtered through celite and concentrated to give 4.5b. Compound 4.5b was dissolved
in acetonitrile (7 mL) and ethylated N, N’-bis-tert-butoxycarbonylpyrazole-1-carboxamidine
(364 mg, 1.08 mmol) was added followed by diisopropylethylamine (181 mg, 2.34 mmol). The
solution was stirred overnight, concentrated and purified by flash chromatography, eluting with
dichloromethane/ethyl acetate (4:1) to give 520 mg (0.83 mmol) of a white, sticky solid. The
resulting compound (170 mg, 0.27 mmol) was dissolved in dichloromethane (2 mL) and
deprotected with trifluoroacetic acid (2 mL) overnight. The solution was concentrated,
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suspended in fresh dichloromethane, and extracted with water. The aqueous layer was
concentrated and dried overnight in a drying pistol with phosphorus pentoxide to give 4.5 as a
sticky, white solid in 68% yield. 1H NMR (D2O) δ: 7.59 - 7.81 (m, 3H), 7.24 - 7.45 (m, 4H), 4.11
- 4.23 (m, 1H), 3.05 (m, 2H), 2.85 (q, J = 6.88 Hz, 2H), 1.85 - 2.02 (m, 2H), 1.60 (m, 2H), 0.81
(t, J = 7.01 Hz, 3H). 13C NMR (D2O) δ: 169.49, 163.23, 162.76, 155.38, 133.99, 130.53, 128.39,
127.09, 126.75, 125.64, 123.90, 122.11, 118.25, 114.38, 53.35, 53.13, 40.15, 36.20, 28.26, 23.84,
13.02. IR (neat) ν (cm-1): 3208, 3051, 1659, 1542, 1181, 1131, 798, 721. HRMS (ESI) [M+H]+:
Calcd for C18H25N5O m/z = 328.2137, found m/z = 328.2121.
[5-Amino-5-(naphthalen-2-ylcarbamoyl)-pentyl]-trimethylammonium (4.6). Boc-Lys(Z)-OH (1 g, 2.6 mmol) was dissolved in
dichloromethane (50 mL). 2-Naphthylamine44 (0.37 g, 2.6 mmol)
was added followed by HOAt (0.89 g, 6.54 mmol) and EDC (0.76 g,
3.96 mmol). After 1.5 h, the solution was concentrated and purified by flash chromatography,
eluting with chloroform/ethyl acetate (4:1) to give 4.6a (800 mg, 1.58 mmol), in 61% yield.
Compound 4.6a (288 mg, 0.57 mmol) was suspended in methanol (25 mL) and hydrogenated
with a catalytic amount of palladium hydroxide. After 1.5 h, the solution was filtered through
celite and concentrated to give 4.6b (212 mg, 0.57 mmol) in quantitative yield. Compound 4.6b
(205 mg, 0.55 mmol) was then dissolved in acetonitrile (1 mL) and potassium carbonate (191
mg, 1.38 mmol) was added followed by iodomethane (392 mg, 2.76 mmol). The solution was
stirred overnight, concentrated, suspended in dichloromethane, and filtered. The filtrate was
concentrated and the crude compound was dissolved in dichloromethane (2 mL) and
trifluoroacetic acid (2 mL) was added. The solution was stirred for 1.5 h and then concentrated,
suspended in fresh dichloromethane, and extracted with water. The aqueous layer was
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concentrated and dried overnight over phosphorus pentoxide to give 4.6 as an orange, sticky
solid in 85% yield. 1H NMR (D2O) δ: 7.88 (s, 1H), 7.66 - 7.78 (m, 3H), 7.28 - 7.40 (m, 3H), 3.99
(t, J = 6.60 Hz, 1H), 3.06 - 3.15 (m, 2H), 2.84 (s, 9H), 1.83 - 1.94 (m, 2H), 1.66 (m, 2H), 1.34
(m, 2H).

13

C NMR (D2O) δ: 168.48, 162.78, 133.88, 133.41, 131.29, 129.43, 127.94, 127.84,

127.33, 126.38, 121.10, 119.01, 66.12, 53.81, 53.05, 30.65, 22.31, 21.32. IR (neat) ν (cm-1):
3049, 1671, 1198, 1128, 832, 799, 720. HRMS (ESI) [M]+: Calcd for [C19H28N3O]+ m/z =
314.2232, found m/z = 314.2223.
5-Guanidino-2-morpholin-4-yl-pentanoic acid naphthalen-2ylamide (4.7). Boc-Orn(Z)-OH (1 g, 2.73 mmol) was dissolved in
dichloromethane (50 mL). 2-Naphthylamine44 (470 mg, 3.28
mmol) was added followed by HOAt (929 mg, 6.83 mmol) and
EDC (785 mg, 4.09 mmol). Reaction progress was monitored by TLC. The resulting material
was purified by flash chromatography, eluting with dichloromethane/ethyl acetate (9:1) to give
4.7a (570 mg, 1.56 mmol, 49% yield). Compound 4.7a (320 mg, 0.65 mmol) was dissolved in
dichloromethane (2 mL) with trifluoroacetic acid (2 mL) and stirred at room temperature
overnight. The solution was concentrated and used for the next step without further purification.
The crude compound was dissolved in acetonitrile (6 mL) and refluxed with potassium carbonate
(360 mg, 2.6 mmol) and bis(2-bromoethyl)ether (181 mg, 0.78 mmol) overnight. The next day,
the solution was filtered and purified by flash chromatography (first 1:1 ethyl
acetate/dichloromethane then 100% ethyl acetate) to give 4.7b (100 mg, 0.22 mmol) as a
yellowish solid in 33% yield. Compound 4.7b was hydrogenated in methanol (12 mL) with
catalytic amount of palladium hydroxide. After 2 h, the solution was filtered through celite and
concentrated. The resulting compound was dissolved in acetonitrile (1 mL) and N,N’-bis-tert-
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butoxycarbonylpyrazole-1-carboxamidine45 (27 mg, 0.87 mmol) was added followed by DIPEA
(15 mg, 0.113 mmol). The reaction was stirred overnight, concentrated and purified by flash
chromatography, eluting with ethyl acetate/hexanes (4:1) to give 4.7c (20 mg, 0.035 mmol) as a
sticky, white solid in 41% yield. Compound 4.7c was dissolved in dichloromethane (1 mL) and
trifluoroacetic acid (1 mL) was added. The solution was stirred overnight and then concentrated,
suspended in dichloromethane, and extracted with water. The aqueous layer was concentrated
and dried overnight over phosphorus pentoxide to give 4.7 in 85% yield. 1H NMR (D2O) δ: 7.96
(s, 1H), 7.70 - 7.85 (m, 3H), 7.34 - 7.48 (m, 3H), 3.18 - 4.05 (m, 9H), 3.11 (t, J = 6.46 Hz, 2H),
1.86 - 2.15 (m, 2H), 1.45 - 1.72 (m, 2H).

13

C NMR (D2O) δ: 166.00, 162.95, 156.95, 133.31,

131.47, 129.47, 127.91, 127.36, 126.56, 120.97, 119.33, 117.67, 115.35, 69.27, 63.74, 40.48,
24.62, 23.86. IR (neat) ν (cm-1): 3360; 2877, 2718, 1668, 1563, 1508, 1435, 1364, 1200, 800,
723, 707. HRMS (ESI) [M+H]+: Calcd for C20H27N5O2 m/z = 370.2243, found m/z = 370.2224.
Phosphoric

acid

mono-(2-methylamino-ethyl)

ester

(4.9).

2-

Methylaminoethanol (500 mg, 6.66 mmol) was stirred with sodium
bicarbonate (1.12 g, 13.31 mmol) in diethyl ether (6.6 mL). Benzyl chloroformate, 30-35% in
toluene, (3.6 g, 6.66 mmol) was slowly added at 0˚C. The solution was warmed to room
temperature after 15 minutes. After 1 h, the solution was concentrated and purified by flash
chromatography, eluting with dichloromethane/ethyl acetate (1:1) to give 4.9a in 63% yield.
Compound 4.9a (300 mg, 1.43 mmol) was dissolved in diethyl ether (5 mL) and diphenyl
chlorophosphate (578 mg, 2.15 mmol) was added followed by triethylamine (290 mg, 2.87
mmol). After 2 h, the solution was filtered and purified by flash chromatography, eluting with
dichloromethane/ethyl acetate (9:1) to give 4.9b (633 mg) in 81% yield. Compound 4.9b (500
mg, 1.13 mmol) was added to a solution containing sodium hydride, 57-63% in oil, (86 mg, 2.15
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mmol) and benzyl alcohol (368 mg, 3.42 mmol) in diethyl ether (5 mL). After 1 h, the solution
was purified by flash chromatography, eluting with dichloromethane/ethyl acetate (9:1) to give
4.9c (324 mg) in 60% yield. Compound 4.9c (324 mg, 0.69 mmol) was hydrogenated in
methanol (25 mL) with catalytic amount of Pd/C (10% Pd, 50% wet with water) for 1 h. The
solution was filtered through celite, and the celite pad was washed with water. The solution was
concentrated and dried overnight over phosphorus pentoxide to give a 4.9 (90 mg, 0.58 mmol) as
a white solid (m.p. 204 - 206°C) in 84% yield. 1H NMR (D2O) δ: 3.76 - 3.94 (m, 2H), 2.97 - 3.13
(m, 2H), 2.49 (s, 3H). 13C NMR (D2O) δ: 60.25, 49.11, 48.99, 32.77, 32.41. IR (neat) ν (cm-1):
3017, 2729, 2520, 1146, 1075, 1026, 923, 815. HRMS (ESI) [M+H]+: Calcd for C3H10NO4P m/z
= 156.0426, found m/z = 156.0424.
Phosphoric

acid

mono-(2-dimethylamino-ethyl)

ester

(4.10).

2-

Dimethylaminoethanol, 4.10a, (500 mg, 5.61 mmol) was dissolved in ether
(5.6 mL) and diphenyl chlorophosphate (1.8 g, 6.73 mmol) was added followed by triethylamine
(1.135 g, 11.22 mmol). After 1 h, the solution was concentrated and purified by flash
chromatography, eluting with dichloromethane/triethylamine (9:1) to give 4.10b (1.37 g) in 76%
yield. Compound 4.10b (540 mg, 1.68 mmol) was added to a solution containing sodium
hydride, 57-63% in oil, (121 mg, 3.03 mmol) and benzyl alcohol (545 mg, 5.04 mmol) in ether
(5.4 mL). After 1 h, the solution was concentrated and purified by flash chromatography, eluting
with ethyl acetate/methanol (19:1) to give 4.10c (340 mg) in 58% yield. Compound 4.10c (166
mg, 0.48 mmol) was hydrogenated in methanol (25 mL) with catalytic amount of palladium
hydroxide for 1 h. The solution was filtered through celite, concentrated, and dried overnight
over phosphorus pentoxide to give 4.10 (70 mg) as a white solid (m.p. 155 - 157°C) in 87%
yield. 1H NMR (D2O) δ: 3.92 (m, 2H), 3.19 (m, 2H), 2.71 (s, 6H).
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C NMR (D2O) δ: 57.87,

13

42.95, 42.43. IR (neat) ν (cm-1): 3415, 2629, 2404, 1163, 1149, 1093, 1026, 993, 951, 931, 768.
HRMS (ESI) [M+H]+: Calcd for C4H12NO4P m/z = 170.0582, found m/z = 170.0609.
Trimethyl-(3-phosphonooxypropyl)-ammonium iodide (4.11). 3,3Dimethylamino-1-propanol (500 mg, 4.846 mmol) was dissolved in
ether (4.8 mL) and diphenyl chlorophosphate (1.56 g, 5.816 mmol) was added, followed
immediately by triethylamine (1 g, 9.692 mmol). After 1 h, the solution was concentrated and
purified by flash chromatography, eluting with ethyl acetate/triethylamine (19:1) to give 4.11a
(1.45 g) in 92% yield. Compound 4.11a (1.45 g, 4.32 mmol) was added to a solution of sodium
hydride, 57-63% in oil, (519 mg, 12.97 mmol) and excess benzyl alcohol in diethyl ether (14.5
mL). After 1 h, the reaction was concentrated and the crude was purified by flash
chromatography, eluting with ethyl acetate/triethylamine (19:1) to give 4.11b (246 mg) in 15%
yield. Compound 4.11b (246 mg, 0.68 mmol) was dissolved in acetonitrile (1 mL) and
iodomethane (192 mg, 1.35 mmol) was added. After 1 h, the solution was concentrated to give
4.11c (337 mg), which was used in the next step without further purification. Compound 4.11c
(337 mg, 0.67 mmol) was first hydrogenated in 50 ml methanol:water (1:1) with a catalytic
amount of palladium hydroxide. These conditions removed only one of the two benzyl groups.
The second benzyl group was removed by latex balloon hydrogenation in 150 ml 30% (v/v)
aqueous formic acid with a catalytic amount of Pd/C. The reaction contents were filtered through
a celite pad, concentrated under reduced pressure, and washed with dichloromethane. The
aqueous layer was further evaporated under reduced pressure, and the residue was exhaustively
dried overnight over phosphorus pentoxide to give 4.11 (80 mg) as a white solid (m.p. 230°C
dec.) in 35% yield. 1H NMR (D2O) δ: 3.75 (m, 2H), 3.14 - 3.34 (m, 2H), 2.93 (s, 9H), 1.92 (m,
2H). 13C NMR (D2O) δ: 64.41, 60.60, 52.96, 24.29, 24.20. IR (neat) ν (cm-1): 3379, 3020, 2957,
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2939, 2887, 2432, 1190, 1054, 932. HRMS (ESI) [M]+: Calcd for C6H17NO4P+ m/z = 198.0890,
found m/z = 198.0879.
4.4.3. Low molecular weight activator stock solutions
Cyclic peptide 38 (cp38), kindly provided by E. Appella, was dissolved in water (1 M) and then
serially diluted with same. Dephosphorylation of cp38 with calf intestinal alkaline phosphatase
(CIP; Promega) and YOP Protein Tyrosine Phosphatase (NEB) were carried out as described for
other proteins.11 The possibility of exposure of the cleavage factors to residual CIP activity was
eliminated by using an established and validated procedure. (S)-(+)-Abscisic acid (ABA) was
dissolved in DMSO (500 mM) and then serially diluted with water. Compounds 4.1-4.7 were
placed in water and treated with 1-3 equiv. of 1.00 M HCl to dissolve the compounds.
Compound 4.1 was purchased as the HCl salt and dissolved in water directly. Compounds 4.84.11 were dissolved in water and treated with NaOH until the pH reached 6 - 7.9. (1.1 equiv. of
NaOH was added to compound 4.8 and 4.9; 1.0 equiv. of NaOH was added to compound 4.10;
1.5 equiv. of NaOH was added to compound 4.11; 0.25 equiv. of NaOH was added to compound
4.12.)
4.4.4. Cleavage factor fractionation from HeLa cell nuclear extract (Kindly carried out by
my colleague, N. Nagre)
HeLa cell pellets were purchased from the National Cell Culture Center (Biovest International).
Nuclear extract and 3’ cleavage factor DEAE-sepharose fractions (CPSF, CstF and CFm) were
prepared as described in detail elsewhere.11, 25 Active fractions from each cleavage factor were
pooled, concentrated by 70% ammonium sulfate precipitation and dialyzed 2 X 3 h at 4°C
against Buffer D50AS (20% glycerol, 20 mM Na-HEPES, pH 7.9, 0.2 mM EDTA, 0.2 mM
PMSF, 0.5 mM DTT and 50 mM ammonium sulfate). Total protein concentration of cleavage
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factor fractions was estimated by Bio-Rad Bradford protein assay with bovine serum albumin as
the standard and determined to be: CPSF (3 mg/mL): CstF (3.5 mg/mL): CFm (3 mg/mL). The
amount of 3’ cleavage factor fractions used in a 12.5 l cleavage reaction were: CPSF (0.8 L);
CstF (0.6 L); CFm (3 µL).
4.4.5. RNA substrate (Kindly made by my colleague, N. Nagre)
SV40 late pre-mRNA (233 nt) was transcribed in vitro by SP6 RNA polymerase (Promega) from
the pG3SVL-A plasmid linearized at the DraI site. Substrate RNA was uniformly labeled by
including [-32P]-UTP (Perkin-Elmer Life Sciences) and 5’ capped during transcription using the
5’Me7G(5’)ppp(5’)G-Cap analog (NEB). The transcript was purified on a 0.4 mm denaturing
polyacrylamide gel, located by shadowing on film, and extracted as previously described.
4.4.6. In vitro 3’ cleavage reactions (Kindly carried out by my colleague, N. Nagre)
Cleavage reactions were carried out as described in detail elsewhere in 12.5 µL and contained, in
addition to the cleavage activators indicated in the figures, tRNA (0.1 mg/mL), pH 8 EDTA (2
mM), 2’-dATP (2 mM), DTT (0.41 mM), BSA (Roche; 40 ng/mL), placental RNase inhibitor
(Promega, 0.32 u/mL), polyvinyl alcohol (2.5%), 10% glycerol, 10 mM HEPES-NaOH (pH 7.9),
25 mM ammonium sulfate, the cleavage factor fractions described in section 4.4, and the RNA
substrate (1–5 nM). The reactions were incubated at 30°C for 2 h and then digested with
Proteinase K, phenol-CHCl3 extracted, ethanol precipitated, and resolved on a 6% denaturing
polyacrylamide gel. After drying, the gel was exposed to a Molecular Dynamics Storm
PhosphorImager screen and the bands were quantitated using ImageQuant software. Relative
cleavage (R.C.) was calculated as [5’ fragment/ (5’ fragment + uncleaved RNA)] x 100. The total
recovered RNA varied from lane to lane due to losses during phenol-CHCl3 extraction and
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ethanol precipitation. Use of the R.C. ratio standardizes the amount cleaved and allows
comparison of gel lanes with different amounts of total recovered RNA.
4.4.7. PPM1A inhibition assay
A 16.25 µL solution containing 154 mM Tris-HCl (pH 7.9), 15% glycerol, 31 mM MgCl2, and
154 mM ammonium sulfate was placed in a microfuge tube on ice. To this was added 26.25 µL
of a mixture containing 0.95 mg/mL BSA, 0.95 mM DTT, and 38 mM pNPP (all in water). Five
µL of a 10X stock solution of the tested compound was then added. To start the reaction, 2.5 µL
of a 0.05 mg/mL (approximately 1 µM) solution of PPM1A in 152 mM Tris-HCl, 5 mM
imidazole, 3.75 mM NaCl, 30 mM MgCl2, 140 mM ammonium sulfate, and 15% glycerol was
added. Final concentration of all components were as follows: 58 mM Tris-HCl, 6% glycerol, 12
mM MgCl2, 53 mM ammonium sulfate, 0.5 mg/mL BSA, 0.5 mM DTT, 20 mM pNPP, 250 µM
imidazole, 187 µM NaCl, 50 nM PPM1A, plus the inhibitor concentration as follows: CP,
PhC: 10 and 50 mM; 4.1, 4.2: 0.2 and 1 mM; 4.7: 25, 100, 200 M; 4.12: 0.1 and 1 mM; ABA:
50, 100, 200 M; cp38: 150, 200 nM. The solution was gently mixed, centrifuged, and incubated
at 37°C for 2.5 h. 10 µL of 500 mM EDTA (pH 10) was added to stop the reaction and the
absorbance at 405 nm was taken on a NanoDrop spectrophotometer.
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Chapter 5: Use of boronic acids towards molecular recognition of DNA nicks
5.1. Introduction
Deoxyribonucleic acid (DNA) is a macromolecule that carries genetic information
essential for life. The nucleotides making up DNA are linked with phosphodiester bonds, but
some of these bonds may be broken due to damage or enzymatic activities resulting in nicks on
the DNA. Theoretically, these DNA nicks could provide a point of recognition for designed
small molecules to bind with the 3’ and 5’ hydroxyl-groups at the breaks. In this study, we aimed
to substitute the phosphate group at DNA nicks with a boronate group (Scheme 5.1).

DNA

Nicked DNA

Scheme 5.1: Representation of a DNA fragment with the phosphate group replaced with a boronate group.

Boronic acids are known to reversibly bind with diols with modest affinity to form
boronic esters, and as a result, they have been used for various applications, including the
development of saccharides sensors, nucleotide and carbohydrate transporters, affinity ligands,
and antibody mimics.1 The close proximity of the hydroxyl groups at the DNA nick resembles a
diol, and could possibly bind with boronic acids in a similar way. Indeed, a DNA assembly had
been synthesized with the phosphate linkage replaced with a boronate linkage,2 demonstrating
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that nucleotides on DNA could be bonded within a boronate linkage in a stable manner.
Although the phosphate group could potentially be replaced with a boronate group, whether
boronic acids easily bind to DNA nicks is still uncertain, due to the only modest affinity between
the boronic acid and the diol. We expect that the equilibrium shown in Scheme 5.1 (right) favors
the middle structure, i.e. nick not filled with boronate. Our long term idea is to add the boronic
acid to other DNA-recognizing structures to increase affinity and impart selectivity for the DNA
break.
5.2. Experimental design
To determine whether boronic acids readily bind onto DNA nicks, we could simply mix
the two together and observe if binding occurs. In order to replicate a DNA that contains nicks,
we used two short DNA strands, DNA 1 – 5’-GTCGCC-3’ and DNA 2 – 5’-GACGGC-3’, which
could form partial complementary pairings, leaving the OH at the ends to participate in binding
(Figure 5.1).

Figure 5.1: Expected interaction between boronic acid, 5.4, and the nicked DNA form from DNA 1 and DNA 2.
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Complementary base-pairing occurs at physiological pH (~pH 7.4). At high pH, the
guanine and thymine bases become deprotonated, leading to less hydrogen bonding and therefore
less pairing. The stability of the boronate ester is also pH-dependent.1 Boronate ester formation
only occurs near or above the pKa of the boronic acid, so it was necessary to use a boronic acid
with a lower pKa than the physiological pH of 7.4. The pKa’s of boronic acids are typically
above pH 8, but the benzoxaborole was found to have a pKa around physiological pH, ~7.2-7.3.3
Unfortunately, benzoxaborole only contains the boronic group on one end of the phenyl ring, and
thus it would not be effective in producing cross-links on DNA. To produce a boronic acid with a
pKa around physiological pH and that is able to cross-link with DNA nicks, benzoxaborole 5.4
was synthesized. Benzoxaborole 5.4, which contains two boronic acid groups, was expected to
bind onto the DNA nicks at around pH 7.4 (Figure 5.1).
One way to assess that binding has occurred was from the formation of a gel. Gels form
when polymers are linked together. An especially well-known gel formation reaction is
formulated using polyvinyl alcohol (PVA) and sodium tetraborate (borax).4, 5 The borate acts as
cross-linker for PVA, and the degree of cross-linking could be modulated by changing the
concentration of the borate or the pH of the solution.4, 5 If the benzoxaborole 5.4 is indeed linking
together chains of DNA, then it’s likely that a gel would form. However, it’s of importance to
ensure that the ratio of the linker and polymer to the water content is adequate for gel formation.
To determine the appropriate ratio of linker to polymer that would lead to gel formation,
preliminary testing was done using compounds 5.1, 5.2, and 5.3. These boronic acids were tested
for gel formation with polyvinyl alcohol (PVA), a polymer containing a multitude of hydroxyl (OH) groups (as a simple though imperfect mimic of a diol). Boric acid 5.1, 5.3, and 5.4, were
expected to form a gel with PVA through cross-linking, whereas the negative control,
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phenylboronic acid 5.2, which contains only one boronic acid group, should not be able to form a
gel (Scheme 5.2). Since the pKa of 5.1 (9.24), 5.2 (8.8), and 5.3 (~8.8) are all above 8, they need
to be tested at high pH in order for gel formation to occur. (For the purpose of this experiment,
pH 10 was used). Once a ratio was found which afford gel formation between boric acid 5.1 and
PVA, the same ratio was used to test 5.2, which should not form a gel, and 5.3 and 5.4, which
should form a gel with PVA. If gel formation was seen using 5.4 with PVA, then 5.4 would be
tested with DNA at physiological pH.

Scheme 5.2: Expected interaction of PVA with 5.1, 5.2, 5.3, and 5.4.
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5.3. Results and Discussion

Scheme 5.3: Synthesis of 5.4.

Compounds 5.1, 5.2, and 5.3 were commercially available. The diboronic acid 5.4 was
synthesized starting from tolidine. Tolidine was subjected to a Sandmeyer reaction to convert the
amino groups to bromo-groups forming 5.4a.6 A free-radical halogenation reaction using Nbromosuccinimide (NBS) and AiBN as the initiator was employed to brominate the methyl
groups on 5.4a to obtain 5.4b. The primary bromo-groups on 5.4b were reacted into acetylgroups using potassium acetate to form 5.4c. Compound 5.4c was then subjected to a Miyaura
borylation reaction to form 5.4d. The pinacol protecting groups on 5.4d was removed using
sodium periodate giving the boronic acid 5.4e. Deprotection of the acetyl-groups gave the final
product 5.4. The compounds (Table 5.1) were first tested on PVA for gel formation.
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Compounds

5.1

Boric acid

5.2

Phenylboronic acid

5.3

4,4-Biphenylbisboronic acid

5.4

Synthesized boronic acid

Structure

Table 5.1: Tested compounds.

Test #
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

Buffer
conc.
(mM)
150
47.5
60
72.5
45
72.5
85
72.5
100
72.5
45
72.5
122.5
72.5
150
150
150
150
72.5
72.5
150
72.5

PVA
conc.
(mM)
1.4
1.8
1.75
1.7
1.05
1.5
1.65
1.3
1.6
1.1
0.56
0.9
1.5
0.7
1.4
1.26
1.12
1.05
0.5
0.3
0.56
0.1

Boric acid,
5.1,
conc. (mM)
0
9.5
12
14.5
9
14.5
17
14.5
20
14.5
9
14.5
24.5
14.5
30
30
30
30
14.5
14.5
30
14.5

Mole Ratio
PVA
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

Boric acid
0
5.3
6.9
8.5
8.6
9.7
10.3
11.2
12.5
13.2
16.1
16.1
16.3
20.7
21.4
23.8
26.8
28.6
29
48.3
53.6
145

OH Ratio
PVA
53.8
41.4
33.3
33.1
29.4
27.5
25.4
22.7
21.5
17.7
17.6
17.4
13.7
13.2
11.9
10.6
9.9
9.8
5.9
5.3
2.0

Boric acid
0
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

Gel?
No
No
No
Yes
No
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No

Table 5.2: Optimized conditions for gel formation. Carbonate buffer at pH = 10 was used. Highlighted rows are
conditions that led to the formation of a strong gel. OH ratio for boric acid was determined from the assumption that
each molecule of boric acid could bind with four OH groups. The PVA used for the experiment consisted of
polymers with molecular weights ranging from 30000 to 70000 g/mol. The average molecular weight, 50000 g/mol,
was employed for the purpose of calculating the number of monomers, and therefore the number of OH units, on
each molecule of PVA. (Testing was done by MS Biochemistry student, Jane Tania.)
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Before testing the synthesized benzoxaborole, 5.4, on nicked DNA, we need to determine the
ratio of benzoxaborole to DNA that would result in the formation of a gel. Preliminary
optimization was done with commercially available polyvinyl alcohol (PVA) and boric acid, 5.1.
Various concentrations of PVA and boric acid (5.1) were tested to achieve gel formation. From
the data, gel formation was most apparent at a PVA: boric acid (5.1) mole ratio of 1:10, but gel
formation may not occur when the PVA and/or boric acid (5.1) concentration are too low, as
exemplified by test # 5 and 11 (Table 5.2), in which the mole ratio was almost the same as the
mole ratio for test # 4 and 12 (Table 5.2), but gel formation did not occur. Additionally, gel did
not form at pH = 7.4, which is below the pKa of boric acid (5.1) (results not shown). Since the
other boronic acids (5.2, 5.3, and 5.4) are less soluble in water compared to boric acid, 5.1, a few
additional tests were done to determine the lowest concentration of boric acid that could be used
to afford gel formation with PVA (Table 5.3).

Test #

Buffer
conc.
(mM)

PVA
conc.
(mM)

Boric acid,
5.1, conc.
(mM)

Mole Ratio

OH Ratio

PVA
Boric acid
PVA
Boric acid
23
50
1
5
1
5
56.8
1
24
50
1
10
1
10
28.4
1
25
50
1.5
10
1
6.7
42.6
1
26
50
1.5
7.5
1
5
56.8
1
Table 5.3: Lowering boric acid concentration for gel formation. Carbonate buffer at pH = 10 was used.

Gel?
No
Yes
Yes
No

Gel formation could not occur at a concentration lower than 10 mM of boric acid (Table 5.3), so
this concentration was used to test the other compounds (Table 5.4).
Buffer
PVA
Cpd.
Mole Ratio
OH Ratio
conc.
conc.
conc.
(mM)
(mM)
(mM)
PVA
Cpd.
PVA
Cpd.
27
50
1
20
1
20
28.4
1
5.2
28
50
1
10
1
10
56.8
1
5.2
29
50
1.5
20
1
13.3
42.6
1
5.2
30
50
1.5
10
1
6.7
85.1
1
5.2
31
50
1
10
1
10
28.4
1
5.3
32
50
1.5
10
1
6.7
42.6
1
5.3
33
50
1
10
1
10
28.4
1
5.4
34
50
1.5
10
1
6.7
42.6
1
5.4
Table 5.4: Gel formation of 5.2, 5.3, and 5.4 with PVA. Carbonate buffer at pH = 10 was used.
Test #

Cpd.
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Gel?
No
No
No
No
Yes
Yes
Yes
Yes

As expected, phenylboronic acid, 5.2, did not form a gel with PVA at any of the concentrations
tested (Table 5.4). Since phenylboronic acid (5.2) could only bond with two OH groups at a time,
it is less likely to crosslink molecules of PVA together. Boronic acid 5.3 was able to form a
partial gel with PVA. Due to the low water solubility of 5.3, it forms a gel locally before it could
homogenize with the solution. Since benzoxaborole 5.4 has a higher solubility in water, it was
able to form a strong gel with PVA (Table 5.4, test # 33 and 34), but here the pH was 10. We
wanted to eventually test the benzoxaborole 5.4 with DNA at pH 7.4, so 5.4 was tested with
PVA at pH 7.4 (Table 5.5).
Buffer
PVA conc. Cpd. conc.
Mole Ratio
OH Ratio
Test #
Cpd. conc. (mM)
(mM)
(mM)
PVA
Cpd.
PVA
Cpd.
35
50
1
10
1
10
28.4
1
5.4
36
50
1.5
10
1
6.7
42.6
1
5.4
Table 5.5: Gel formation of benzoxaborole 5.4 at pH 7.4. (ppt = precipitated out of solution)

Gel?
ppt
ppt

Instead of forming a gel at the lower pH, 5.4 precipitated out of the solution (Table 5.5). To
ensure that 5.4 fully dissolves when tested with DNA (to test for possible gel formation with
DNA nicks), various concentrations of 5.4 were tested at pH 7.4 and pH 10 with a low
concentration of DNA nicks (0.5 mM) formed from DNA 1 (5’-GTCGCC-3’) and DNA 2 (5’GACGGC-3’) (Figure 5.1).

Buffer DNA 1 DNA 2
Mole Ratio
OH Ratio
5.4
Buffer
conc.
conc.
conc.
conc.
Test #
pH
(mM)
(mM)
(mM)
(mM)
Gel?
DNA
DNA
5.4
5.4
37
7.4
5
0.5
0.5
0.1
1
0.2
5
1
No
38
10
5
0.5
0.5
0.1
1
0.2
5
1
No
39
7.4
5
0.5
0.5
0.3
1
0.6
1.7
1
No
40
10
5
0.5
0.5
0.3
1
0.6
1.7
1
No
41
7.4
5
0.5
0.5
0.5
1
1
1
1
No
42
10
5
0.5
0.5
0.5
1
1
1
1
No
43
7.4
5
0.5
0.5
2
1
4
0.25
1
No
44
10
5
0.5
0.5
2
1
4
0.25
1
No
Table 5.6: Gel formation of 5.4 with DNA1 (5’-GTCGCC-3’) and DNA 2 (5’-GACGGC-3’).

Notes
Clear
Clear
Clear
Clear
Cloudy
Clear
Precipitate
Precipitate

Benzoxaborole 5.4 could not be tested at 10 mM as planned since it was not soluble at even 2
mM in the DNA solution at either pH 7.4 or pH 10 (Table 5.6, test # 43 and 44).
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Buffer
DNA 1
DNA 2
Mole Ratio
OH Ratio
5.4
Buffer
conc.
conc.
conc.
conc.
Test #
pH
(mM)
(mM)
(mM)
(mM)
Gel?
DNA
DNA
5.4
5.4
45
7.4
50
5
5
0.1
1
0.02
50
1
No
46
10
50
5
5
0.1
1
0.02
50
1
No
47
7.4
50
5
5
0.2
1
0.04
25
1
No
48
10
50
5
5
0.2
1
0.04
25
1
No
49
7.4
50
5
5
0.3
1
0.06
16.7
1
No
50
10
50
5
5
0.3
1
0.06
16.7
1
No
51
7.4
50
5
5
0.4
1
0.08
12.5
1
No
52
10
50
5
5
0.4
1
0.08
12.5
1
No
53
7.4
50
5
5
0.5
1
0.1
10
1
No
54
10
50
5
5
0.5
1
0.1
10
1
No
Table 5.7: Gel formation of 5.4 with higher concentration of DNA 1 (5’-GTCGCC-3’) and DNA 2 (5’-GACGGC3’).

During the testing, the concentration of both 5.4 and the DNA were lowered to ensure that 5.4
remained dissolved and concurrently achieve the OH ratio to achieve gel formation from the tests
with PVA (Table 5.4, test #33 and 34). With PVA, 5.4 formed a strong gel at a ratio of ~ 3040(PVA):1(5.4) (Table 5.4, test #33 and 34). The DNA was adjusted to be ~10 – 50 times more
concentrated in OH sites than the boronic acid. Unfortunately, gel formation did not occur. The
DNA solution may be too dilute to observe gel formation.
Buffer
PVA
Cpd.
conc.
conc.
conc.
Test #
Cpd
(mM)
(mM)
(mM)
55
50
1
10
5.3
56
50
1
9
5.3
57
200
1
2
5.3
58
200
1
1
5.3
59
200
1
0.5
5.3
60
50
1
0.5
5.3
61
200
1
0.4
5.3
62
50
1
0.4
5.3
63
50
1
0.5
5.4
64
50
1
0.75
5.4
65
50
1
1
5.4
Table 5.8: Solubility at pH 7.4 (~10% DMSO).

Mole Ratio
PVA
1
1
1
1
1
1
1
1
1
1
1

Cpd.
10
9
2
1
0.5
0.5
0.4
0.4
0.5
0.75
1

OH Ratio
PVA
28.4
31.5
141.9
283.8
567.5
567.5
709.4
709.4
567.5
378.3
283.8

Cpd.
1
1
1
1
1
1
1
1
1
1
1

Gel?
No
No
No
No
No
No
No
No
No
No
No

Notes
Precipitate
Precipitate
Precipitate
Cloudy
Cloudy
Cloudy
Clear
Clear
Clear
Clear
Cloudy

Although gel formation with DNA did not occur at the tested conditions (Table 5.7), it was still
of interest to determine if 5.4 could affect gel formation at pH 7.4. Thus, 5.4 was further tested
on PVA. While 5.4 is slightly more soluble than 5.3 at pH 7.4, they both were not able to form a
gel at the concentrations in which they were soluble (Table 5.8).
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Buffer
PVA
Cpd.
Mole Ratio
conc.
conc.
conc.
Test #
Cpd
(mM)
(mM)
(mM)
PVA
Cpd.
66
50
1
0.75
1
0.75
5.4
67
50
1
1
1
1
5.4
Table 5.9: Solubility at pH 7.4 using MOPS buffer.

OH Ratio
PVA
378.3
283.8

Cpd.
1
1

Gel?
No
No

Notes
Clear
Cloudy

To ensure that the phosphate buffer is not interfering with the solubility of 5.4, the compound
was retested at pH 7.4 using another buffer, MOPS. As shown on Table 5.9, 5.4 behaved
similarly in the MOPS buffer. As with the phosphate buffer (Table 5.8, test # 64 and 65), 5.4 was
soluble at 0.75 mM but not 1 mM (Table 5.9, test # 66 and 67). Since 5.4 is soluble and could
form a gel at 10 mM in a pH 10 buffer (Table 5.4, test # 33 and 34), the lower pH of the
phosphate and MOPS buffer is likely affecting the solubility of the benzoxaborole 5.4.
Buffer
PVA
Cpd.
Mole Ratio
conc.
conc.
conc.
Test #
Cpd
(mM)
(mM)
(mM)
PVA
Cpd.
68
50
1
10
1
10
5.4
69
50
1
2
1
2
5.4
70
50
1
1.5
1
1.5
5.4
71
50
1
1.3
1
1.3
5.4
Table 5.10: Solubility at pH = 7.8 using phosphate buffer.

OH Ratio
PVA
28.4
141.9
189.2
218.3

Cpd.
1
1
1
1

Gel?
No
No
No
No

Notes
Precipitate
Cloudy
Cloudy
Clear

Since the phosphate buffer does not appear to be affecting the solubility of the compound
compared to other buffer (MOPS), 5.4 was again tested in a phosphate buffer with the pH
increased to 7.8. At pH 7.4, 5.4 could only dissolve at concentrations lower than 0.75 mM, but at
pH 7.8, 5.4 could dissolve at 1.3 mM (Table 5.10, test #71). There was an improvement in the
solubility at pH 7.8, but unfortunately there were still not enough linkers in the solution to affect
gel formation at physiological pH.
5.4. Conclusions
The synthesized benzoxaborole 5.4 was able to form a gel with PVA at pH 10, but it was
not able to form a gel with DNA at any of the tested concentrations. This does not necessarily
indicate that 5.4 was not binding with the DNA, seeing as the solution may be too diluted for a
gel to form. Although the ratio (of the OH groups) of 5.4 to DNA was similar to the ratio of 5.4
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to PVA that led to gel formation, there was a large difference in the amount of OH groups on the
DNA compared to PVA that was in the solution, and thus the hydroxyl group concentration was
much lower. The DNA was tested at a concentration of 5 mM whereas PVA was only tested at
1.0-1.5 mM, but each molecule of PVA could have at least 680 OH groups, while the two DNA
strands produce only four OH groups. Even at 1 mM, PVA has at least 34 times more OHs that
are available for binding compared to DNA at 5 mM. In order to mimic the conditions for gel
formation using PVA, the concentration of DNA may have to be over 100 mM, which is not
practical for a biopolymer. Instead, other methods such as NMR, viscometry or calorimetry
might be better to use to test for binding.
5.5. Experimental Procedures
Unless otherwise stated, chemical reagents and solvents were purchased from VWR
International, Fisher Scientific, or Sigma Aldrich and used without further purification.
Analytical TLC was performed on silica gel 60 F254 plates. Flash chromatography7 was
performed on Teledyne Isco CombiFlash Rf-200 flash chromatography system. Melting points
were measured on a Laboratory Devices Mel-Temp apparatus. 1H and

13

C NMR spectra were

recorded on a Varian Mercury 300 spectrometer or a Bruker Ultrashield 500 spectrometer. (Note:
The literature procedure that was applied for each reaction is cited. The procedure may not
necessarily be used for the synthesis of the same compound as in the literature.)
4,4’-Dibromo-3,3’-dimethyl-biphenyl (5.4a). Compound 5.4a was
synthesized based on literature procedure.6 Tolidine (5 g, 23.5
mmol) was dissolved in a solution of 50% sulfuric acid (25 mL), water (100 mL), and
acetonitrile (100 mL). The solution was cooled to 0°C and sodium nitrite (4.1 g, 60 mmol) in
water (10 mL) was added. The mixture was stirred briefly and copper bromide (7.5 g, 52 mmol)
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in 48% hydrobromic acid (100 mL) was added. The mixture was warmed to room temperature
and refluxed overnight. The crude mixture was passed through a silica pad. The filtrate was
concentrated and purified by column chromatography eluting with 100% hexanes to obtain the
product 5.4a (3.6 g, 10.6 mmol) as a white solid (m.p. 63-65°C) in 45% yield. 1H NMR (CDCl3)

: 7.57 (d, J = 8.3 Hz, 2H), 7.46 - 7.31 (m, 2H), 7.29 - 7.16 (m, 2H), 2.55 - 2.39 (s, 6H). 13C
NMR (CDCl3) 
4,4’-Dibromo-3,3’-bis-bromomethyl-biphenyl (5.4b). Compound
5.4b was synthesized based on literature procedure.8 Compound 5.4a
(2.45 g, 7.2 mmol), N-bromosuccinimide (2.56 g, 14.4 mmol), and a
catalytic amount of azobisisobutyronitrile (AiBN) were suspended in chloroform (30 mL). The
suspension was refluxed overnight. The next day, the suspension was cooled and filtered to
obtain the crude product 5.4b (3.1 g) as a white solid (m.p. 211-214°C), which was used for the
next step without further purification. 1H NMR (CDCl3) : 7.68 - 7.61 (m, 4H), 7.35 (dd, J = 2.2,
8.3 Hz, 2H), 4.66 (s, 4H). 13C NMR (CDCl3) δ: 139.40, 137.73, 133.96, 129.62, 128.49, 124.11,
33.10.
Acetic acid 3’-acetoxymethyl-4,4’-dibromo-biphenyl-3-ylmethyl
ester (5.4c). Compound 5.4c was synthesized based on a literature
procedure.9 The crude product 5.4b (3 g) was refluxed with
potassium acetate (3 g, 30.6 mmol) in dimethylformamide (50 mL). After 1 h, the solution was
cooled, diluted with water, and extracted three times with diethyl ether. The diethyl ether
solution was extracted with brine, dried, and concentrated. The resulting material was purified by
flash chromatography, eluting with hexanes/ethyl acetate (9:1) to obtain the product 5.4c (950
mg, 2.08 mmol) as a white solid (m.p. 112-113°C) in 29% yield in two steps. 1H NMR (CDCl3)
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: 7.67 - 7.62 (m, J = 8.3 Hz, 2H), 7.57 (s, 2H), 7.40 - 7.35 (m, J = 8.0 Hz, 2H), 5.25 (s, 4H),
2.16 (s, 6H).

13

C NMR (CDCl3) δ: 170.61, 139.35, 135.87, 133.42, 128.51, 128.21, 123.09,

65.79, 20.93.
Acetic

acid

3’-acetoxymethyl-4,4’-bis-(4,4,5,5-

tetramethyl-[1,3,2]diozaborolan-2-yl)-biphenyl-3ylmethyl ester (5.4d). Compound 5.4c was synthesized
based on a literature procedure.10 Compound 5.4c (950 mg, 2.08 mmol) was dissolved in dioxane
(10.4 mL) and the solution was bubbled for 15 minutes with argon. Potassium acetate (0.98 g,
9.98 mmol), bis(pinacolato)diboron (BPin)2 (1.16 g, 4.58 mmol), and Pd(PPh3)2Cl2 (234 mg,
0.334 mmol) were added and the suspension was stirred at 80°C for 3.5 h under argon. The
suspension was filtered and concentrated. The resulting residue was purified by flash
chromatography eluting with hexanes/ethyl acetate (19:1) to obtain the product 5.4d (970 mg,
1.76 mmol) as a yellowish oil in 85% yield. 1H NMR (CDCl3)  7.93 (d, J = 7.7 Hz, 2H), 7.62 7.53 (m, 4H), 5.43 (s, 4H), 2.10 (s, 6H), 1.35 (s, 24H). 13C NMR (CDCl3) δ: 170.78, 143.25,
142.50, 
3H,3’H-[5,5’]Bi[benzo[c][1,2]oxaborolyl]-1,1’-diol

(5.4).

Compound 5.4d was oxidized based on a literature procedure.11
Compound 5.4d (420 mg, 0.76 mmol) was placed in THF (8.4 mL) and water (2.1 mL), and
sodium periodate (980 mg, 4.6 mmol) was added. The suspension was stirred overnight. 2 M
Hydrochloric acid (0.168 mL) was added and the mixture was stirred for another 24 hours.
Methanol (35 mL) was added and the mixture was filtered. The filtrate was diluted with ethyl
acetate, dried, concentrated to give the crude product 5.4e, which was used for the next reaction
without further purification. The crude product 5.4e was stirred with potassium carbonate (1.79
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g, 13 mmol) in methanol for 2 hours. The suspension was acidified with 5% HCl until the
solution became clear. The solution was diluted with water and extracted with ethyl acetate,
dried, and concentrated. The resulting solid was triturated in methanol and then hexanes to obtain
the product 5.4 (75 mg, 0.28 mmol) as a white solid (m.p. 339°C dec.) in 37% yield in two steps.
1

H NMR (DMSO) : 9.21 (s, 2H), 7.81 (d, J = 7.4 Hz, 2H), 7.72 - 7.63 (m, 4H), 5.04 (s, 4H). 13C

NMR (DMSO) δ: 155.33, 143.03, 131.51, 126.50, 120.38, 70.44.
General gel formation assay
PVA (0.1-1.7 mM) or DNA (0.5-5 mM), buffer solution (5-50 mM), and water were added into
an eppendorf tube and vortexed briefly. The boronic acid (0.1-30 mM) was added and the
solution was immediately vortexed and left at room temperature overnight. If gel had not formed
by the next day, solutions were sonicated, heated, placed at 0°C, or mixed to promote gel
formation. After each manipulation, the reaction was examined for gel formation or thickening.
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